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Preface vii
●● Preface
Are you a health professional who wishes to improve the quality 
of your practice using systematic reviews? Are you embarking 
on a career in public health, epidemiology or health technology 
assessment? Are you a clinical teacher interested in discovering 
the likely educational effects of the courses you deliver? Are you 
interested in health from the social science perspective? Are you 
about to start your first review? If so, this book is for you. 
The first edition of this book exceeded all expectations. It 
was commended in the Basis of Medicine category in the BMA 
Medical Book competition 2003. Commentators found it a clear, 
useful guide to a potentially off-putting topic that built the 
confidence of non-statisticians. The British Journal of Surgery 
called it a ‘gem’. It recognized that it stood head and shoulders 
above other texts on account of its brevity and clarity of prose. It 
advised readers that if they ever read or wrote systematic reviews, 
they should read this book first. It was praised for conveying an 
enthusiasm that made the reader want to conduct a review of 
their own. Its well-organized materials, logical structured flow and 
useful worked examples led to a recommendation to all libraries 
of educational and research institutions concerned with health 
sciences. It was directed at novice reviewers, but it was cited over 
a hundred times, indicating that even seasoned researchers took 
quite an interest in its contents. With the passage of time a second 
edition became imperative. Like the first, this edition describes 
the main principles behind systematic reviews of healthcare 
research and provides guidance on how reviews can be appraised, 
conducted and applied in practice. 
As our current healthcare practice and policy increasingly relies 
on clear and comprehensive summaries of information collated 
through systematic literature reviews, it is necessary for us to 
understand how reviews and practice guidelines are produced. You 
may not be trained in health research methods, but this book will 
enable you to grasp the principles behind reviewing literature. In 
this way you will be able to critically appraise published systematic 
reviews and guidelines, and evaluate their inferences and 
recommendations for application in your practice.
Published reviews and guidelines are not always adequate or 
sufficient for our needs. Have you ever wondered how you could 
conduct your own review? The resources required for undertaking 
reviews are increasingly becoming available in a clinical setting. 
The appointment of clinical librarians, internet access to many 
journals, ease of obtaining interlibrary loans and the availability 
of user-friendly software make it possible for systematic reviews 
to be conducted by healthcare practitioners. This book highlights 
the core information necessary for planning and preparing 
reviews. It focuses on a clinical readership and new reviewers, 
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not on experienced epidemiologists, social scientists, medical 
educationalists and statisticians. Using this book you will be able 
to initiate your own review. 
What is new in this edition of the book? We have widened the 
scope to go beyond evaluation of effectiveness of interventions 
in healthcare. We demonstrate how reviews can be usefully 
applied to evaluate qualitative and educational research. We 
have thoroughly overhauled the section and examples on how 
to interpret the findings of a review, leading to judicious and 
credible recommendations for clinical practice. We have added a 
substantial number of new case studies, providing more worked 
illustration of key concepts.
For too many years there has been a mystery surrounding 
systematic reviews and reviewers. How did they select certain 
studies and reject others? What did they do to collate results? How 
did a bunch of insignificant findings suddenly become significant? 
You are about to embark on a journey that will demystify these 
intrigues. Enjoy reading.
KS Khan,
R Kunz,
J Kleijnen,
G Antes
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We have put this book together because we feel that health 
professionals have much to gain from reviews and guidelines and, 
at the same time, reviews and guidelines have much to gain from 
them. With this book we hope healthcare practitioners will feel 
empowered to use reviews effectively and to initiate their own 
reviews. 
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Introduction  1
●● Introduction
We hardly ever come across a healthcare journal that does not 
publish reviews. All disciplines related to medicine, including 
social science and medical education, rely heavily on reviews for 
guiding practice and scholarship. What makes them ubiquitous? 
Reviews provide summaries of evidence contained in a number of 
individual studies on a specific topic. Research that is relevant to 
our practice is scattered all over the literature and sometimes it 
is published in languages foreign to us. By going through a single 
review article in our own language we can get a quick overview 
of a wide range of evidence on a particular topic. Therefore, we 
like reviews. They provide us with a way of keeping up-to-date 
without the trouble of having to go through the individual studies 
relevant to our practice. With an ever-increasing number of things 
to do in our professional lives and not enough time to do them, 
who wouldn’t find reviews handy? In all honesty, even if we had 
the time and means to identify and appraise relevant studies, 
many of us would still prefer reviews.  
Now a word of warning – the manner in which traditional 
reviews search for studies, collate evidence and generate 
inferences is often suspect. In the worst cases, personal interests 
of the author may drive the whole of the review process and its 
conclusions. After all, many of the reviews we read are invited 
commentaries; they are not properly conducted pieces of research. 
So, how can we be certain that reviews are not misleading us? 
This is why systematic reviews have come to replace traditional 
reviews. 
Robust systematic reviews of healthcare literature are proper 
pieces of research. They identify relevant studies, appraise their 
quality and summarize their results using scientific methodology. 
In this way they differ from traditional reviews and off-the-
cuff commentaries produced by ‘experts’. More importantly, the 
recommendations of systematic reviews, instead of reflecting 
personal views of ‘experts’, are based on balanced inferences 
generated from the collated evidence.
This book describes the principles behind systematically 
reviewing the literature on healthcare and related subjects. Using 
this book, readers should be able to confidently appraise a review 
for its quality, as well as initiate one of their own. 
Critically appraising systematic 
reviews
More and more healthcare policy is being based on clear and 
comprehensive summaries of information collated through 
systematic reviews of the relevant literature. So, in the current day 
and age, evidence-based practice requires more than just critical 
A systematic 
review is a 
research article that 
identifies relevant 
studies, appraises 
their quality 
and summarizes 
their results 
using a scientific 
methodology.
The term meta-
analysis is not 
synonymous with a 
systematic review. 
It is only a part of 
the review. It is a 
statistical technique 
for combining 
the results of a 
number of individual 
studies to produce 
a summary result. 
Some publications 
called meta-analysis 
are not systematic 
reviews.
From here onwards, 
whenever this 
book uses the 
term review, 
it will mean a 
systematic review, 
using these terms 
interchangeably. 
Reviews should 
never be done in 
any other way. 
Meta-synthesis 
is the synthesis of 
existing qualitative 
research findings on 
a specific research 
question. This does 
not involve meta-
analysis. 
Evidence-based 
medicine (EBM) 
is the judicious 
use of current 
best evidence in 
making decisions 
about healthcare. 
Systematic reviews 
provide strong 
evidence to 
underpin EBM.
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appraisal of individual studies. Practice guidelines are a prime 
example of how systematic reviews have come to occupy a pivotal 
role in our professional lives.
Systematic reviews may represent a quantum leap in review 
methodology. However, we should not have blind faith. Reviews 
and guidelines, just like individual studies, can be of a variable 
quality. There are numerous examples of poor reviews published 
in top healthcare journals and of inferior guidelines produced 
by professional bodies. Hence, there is a potential for misleading 
inferences even among apparently robust reviews and guidelines. 
Therefore, it is necessary for us, as healthcare practitioners, to 
acquire a deeper understanding of the principles behind systematic 
reviews. Although we may only have a basic knowledge in health 
research methods and consider the task of appraising reviews 
onerous, with this book, readers will be able to grasp the process 
and pitfalls of systematically reviewing literature, and discriminate 
between robust and not-so-robust reviews and guidelines more 
easily.
We can identify existing reviews to support our practice by 
searching the resources shown in Box 0.1. Once relevant reviews 
have been identified, the quality of their methods should be 
appraised, their evidence should be examined and their findings 
should be assessed for application in practice. Examples of how to 
use findings from existing reviews are shown in the case studies in 
Section B of this book. When drawing on reviews to support our 
practice, we will occasionally become painfully aware that relevant 
reviews either do not exist or they supply inadequate information. 
When you can’t find a review that meets your needs, why not 
initiate a new one?
Guidelines are 
systematically 
developed 
statements to assist 
practitioners and 
patients in making 
decisions about 
specific clinical 
situations. They 
often, but not 
always, use evidence 
from systematic 
reviews.
What is involved in 
the identification, 
appraisal and 
application of 
evidence 
summarized in 
reviews?
Framing questions
|
Identifying relevant 
reviews
|
Assessing quality of the 
review and its evidence
|
Summarizing the 
evidence
|
Interpreting the 
findings
Box 0.1 Selected sources of systematic reviews and guidelines
The Cochrane Library* (www.thecochranelibrary.com) has several databases of 
published and ongoing systematic reviews:
●● The Cochrane Database of Systematic Reviews (CDSR)
Contains the full text of regularly updated systematic reviews of healthcare 
interventions carried out by the Cochrane Collaboration, plus protocols for reviews 
currently in preparation.
●● Database of Abstracts of Reviews of Effects (DARE)+
Critical appraisals of systematic reviews found in sources other than CDSR. These 
reviews are identified by regular searching of bibliographic databases, hand 
searching of key major medical journals, and scanning grey literature. 
●● Health Technology Assessment (HTA) Database+
Abstracts of completed technology assessments and ongoing projects being conducted 
by members of the International Network of Agencies for Health Technology 
Assessment (INAHTA) and other healthcare technology agencies. Most of these include 
systematic reviews.
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●● Collaborative Review Groups (CRGs)
Found under ‘about the Cochrane Collaboration’ in the Cochrane Library. It contains 
a list of the total output of each one of 95 CRGs and provides an alternative method 
of searching the Cochrane Library.
There are more systematic reviews around than one might think. For example, in the 
2nd issue of the 2011 Cochrane Library alone there were 6671 complete reviews and 
protocols combined in April 2011, 14602 abstracts of quality assessed reviews in DARE 
and 9965 abstracts of technology assessments in the HTA database.
General electronic databases: (also see Box 2.3)
●● MEDLINE – PubMed Clinical Queries using the Systematic Reviews feature available 
at www.ncbi.nlm.nih.gov/entrez/query/static/clinical.html. At the time of writing 
there were 126 190 citations included in the PubMed Systematic Reviews subset 
strategy.
●● CINAHL, EMBASE, PsycLIT and others may be searched for reviews by adapting one of the 
search filters (a combination of text words, indexing terms and subject headings that 
captures relevant articles) available from the Centre for Reviews and Dissemination 
search strategies available at http://www.york.ac.uk/inst/crd/identifying_research_
evidence.htm
Selected internet sites:
●● CMA Infobase – Clinical Practice Guidelines – www.mdm.ca/cpgsnew/cpgs/index.asp
●● Guidelines and Guidelines in Practice – www.eguidelines.co.uk
●● GIN Guidelines International Network – www.g-i-n.org:
●● HTA Programme of the National Institute for Health Research (NIHR) –  
www.ncchta.org/project/htapubs.asp
●● NHS Evidence – http://www.evidence.nhs.uk/nhs-evidence-content/journals-and-
databases
●● National Institute for Health and Clinical Excellence (NICE) – www.nice.org.uk/
●● OMNI – www.omni.ac.uk (use advanced search and specify Practice Guidelines in 
Resource Type)
●● International Prospective Register of Systematic Reviews (PROSPERO) 
http://www.crd.york.ac.uk/PROSPERO/
●● ScHARR-Lock’s Guide to the evidence –  
www.shef.ac.uk/uni/academic/R-Z/scharr/ir/scebm.html 
●● SIGN guidelines – http://www.sign.ac.uk/index.html
●● Turning Research Into Practice (TRIP) – www.tripdatabase.com
Selected print publications:
●● Clinical Evidence – www.clinicalevidence.org
*See Case study 1 for an example search of the Cochrane Library
+Also available free at http://www.york.ac.uk/inst/crd
Web sites are constantly changing. The internet addresses provided in this book were obtained 
from searches in June 2011.
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Conducting a systematic review
Internet access to literature searching, the ability to obtain articles 
either electronically or through interlibrary loans, user-friendly 
software for meta-analysis, etc. all make this kind of reviewing 
possible. As these resources are increasingly available in a clinical 
setting, undertaking systematic reviews has become a realistic 
option for healthcare practitioners. But why should practitioners 
undertake reviews? 
There is no shortage of reasons for undertaking one’s own 
review. One may wish to conduct reviews for supporting evidence-
based practice, personal professional development, informing 
clinical policy, publishing in a peer-reviewed journal, writing an 
introduction to a research thesis, or preparing a presentation at a 
conference, a technical report or an invited commentary.
However, there should be no need to reinvent the wheel. 
Existing reviews and guidelines should be used to their full 
potential. Up-to-date good quality reviews may already contain all 
the information we need. 
When reviews and guidelines on a specific topic do not exist, are 
not up-to-date or are of a poor quality, our options are:
●● ask ‘experts’ for advice
●● appraise available primary studies 
●● conduct a systematic review.
We realize that ‘expert’ opinions may not be evidence-based and 
they may be unacceptable to others – for every ‘expert’ there 
is an equal and opposite ‘expert’. We know that appraisal of 
individual studies will not provide information on the complete 
picture. Isn’t this the point where we want to start a new review? 
Many Cochrane reviews commence in this way and when they 
are published everyone can benefit from them. Conducting a new 
systematic review will take a lot of effort, but not everything that 
is worthwhile is easy. 
When undertaking research projects, advanced courses or 
educational assignments, we (or at least our supervisors) should be 
aware that non-systematic reviews are increasingly less acceptable. 
Where do we go next? We should do our own systematic review. 
As academics in the health professions (without advanced 
epidemiology and statistics training), we may be used to publishing 
editorials, opinions and commentaries. We are now under pressure 
from journal editors to be more systematic in our approach. Why 
not try a systematic review for the next commentary? We may 
feel inhibited as the knowledge or skills required for initiating such 
reviews may not be within our grasp. Help is in our hands. This 
book provides the core information necessary for planning and 
initiating reviews of healthcare literature. 
This book focuses primarily on a clinical readership and 
first-time reviewers, not on epidemiologists, social scientists, 
educationalists and statisticians. This book will enable readers 
Cochrane Reviews 
are systematic 
reviews of primary 
research in human 
health care and 
health policy. 
They investigate 
the effects of 
interventions 
(literally meaning 
to intervene to 
modify an outcome) 
for prevention, 
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to initiate reviews without relying on professional reviewers 
and will also give advice about further reading and how to seek 
professional input in difficult areas. Considering the nature of work 
involved in the various Steps of a review, it is advisable to find one 
or more other reviewers to join in. First-time reviewers might want 
to attend a local workshop or course on systematic reviews. The 
Cochrane Collaboration organizes many of these – why not ask the 
local Cochrane Centre about their next training event?
How this book is structured
This book will help readers to understand the principles of 
systematic reviews. In the discourse that follows there is a step-
by-step explanation of the review process. There are just five 
steps. This book provides guidance for each step of a review with 
examples from published reviews. Many examples are followed 
through the different steps so that we will be able to see the 
link between the steps. In addition, application of the theory is 
illustrated through case studies. Each case consists of a scenario 
requiring evidence from reviews, a demonstration of some review 
methods and a proposed resolution of the scenario. Insight into 
critical appraisal and conducting a systematic review can be 
gained by working through the various Steps, examples and case 
studies.
If we have made up our mind to initiate a review, we should 
first produce a brief outline (or a protocol) of the project, giving 
some background information and a specification of the problem 
to be addressed along with the methodology to be used in the 
review. Throughout the review work, the protocol will remind us 
where we are coming from and what direction we want to go in, 
avoiding distractions and keeping us on track. It will also provide 
a document that could be peer reviewed before the review work is 
commenced. Some people suggest that a review protocol should 
be posted on a website to facilitate a wide peer review, but input 
from visitors to the site may be variable. Realistically, we have a 
much better chance of getting a professional to comment on the 
protocol if we ask a colleague experienced in reviewing or if we 
register our review with a relevant Review Group of the Cochrane 
or the Best Evidence Medical Education (BEME) Collaboration.
This book will be a useful companion in protocol development 
as well as throughout the five steps in the review process:
●● First, the problems to be addressed have to be specified in the 
form of well-structured questions (Step 1). This is a key step, as all 
other aspects of the review follow directly from the questions.
●● Second, thorough literature searches have to be conducted to 
identify potentially relevant studies which can shed light on 
the questions (Step 2). This is an essential feature that makes a 
review systematic.
●● Third, the quality of the selected studies is assessed (Step 3).
Step 1 
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Identifying relevant 
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findings
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●● Fourth, the evidence concerning study characteristics and 
results is summarized (Step 4). When feasible and appropriate, 
statistical meta-analysis helps in collating results.
●● Finally, inferences and recommendations for practice are 
generated by interpreting and exploring the clinical relevance of 
the fi ndings (Step 5).
The key points about appraisal and conduct of reviews are 
summarized at the end of each Step in Section A of this book. The 
case studies in Section B illustrate the application of the review 
theory that is covered in the fi ve Steps. Readers may prefer to 
assimilate the review theory before turning to the case studies 
or they may read them in conjunction with the information 
contained in the fi rst section. A ‘suggested reading’ list provides 
references to direct readers to other texts for theoretical and 
methodological issues that are beyond the core material covered 
in this book.
The guidance in this book is pitched at a level suitable for users 
of systematic reviews and for novice reviewers. It should not be 
seen as providing a ‘set menu’ for appraising and undertaking 
systematic reviews. What it offers is a range of ‘à la carte’ 
guidance, which can be applied fl exibly depending on the question 
and context. 
This book will 
focus mainly on 
reviews of research, 
examining the effects 
of interventions 
or exposures on 
outcomes.
 Key points about this book
●● This book will enable readers to confi dently appraise published reviews for their 
quality, as well as to initiate their own reviews.
●● It describes the main principles behind systematically reviewing literature on the 
effects of healthcare, focusing on a readership of healthcare professionals. 
●● It includes a step-by-step explanation of how to appraise and conduct reviews 
along with illustrative examples and case studies. 
●● Key points about critical appraisal and conduct of a review are summarized at the 
end of each Step.
Section A: Steps of a systematic review
This section provides a step-by-step 
explanation of the processes involved when 
carrying out a review. There are just fi ve 
Steps. For each Step, basic principles of a 
review are explained, using examples from 
published reviews. Many examples are 
followed through the different steps so that 
readers will be able to see the link between 
the various stages.
Step 1:   Framing questions for a review
▼
Step 2:   Identifying relevant literature
▼
Step 3:   Assessing the quality of the 
literature
▼
Step 4:   Summarizing the evidence
▼
Step 5:   Interpreting the fi ndings
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●● Step 1: Framing 
questions for a review
Systematic reviews are carried out to generate answers to focused 
questions about healthcare and related issues. The key to a 
successful review project lies in the reviewer’s ability to be precise 
and specific when stating the problems to be addressed in the 
review. This is a critical part of the review because, as will become 
apparent in subsequent Steps, all other aspects of the review flow 
directly from the original questions. In this Step, we will consider 
the question formulation process in detail and briefly look at the 
thinking required to examine the potential impact of variations in 
the different components of a review question.
1.1  An approach to formulating 
questions
Formulating questions is not as easy as it may sound. A structured 
approach to framing questions, which uses four components or 
facets, may be used. These components include the populations, 
interventions (or exposures), and outcomes related to the problem 
posed in the review, and the designs of studies that are suitable 
for addressing it. We can see the relationship between the various 
question components in the comparative study in Box 1.1. 
After reading Box 1.1, the formulation of questions will probably 
seem like a daunting task to new reviewers. We may begin to have 
second thoughts, but we should not give up – help is at hand. This 
chapter of the book will take us through the question formulation 
process so that our review can have just the right start. It is well-
recognized that even quite experienced clinicians don’t always find 
it easy to frame questions for evidence-based practice, so new 
reviewers can also expect to have a rough ride during the initial 
stages of their reviews. It will take some effort, but its value will 
be realized soon, as the rest of the review will flow directly and 
efficiently from the questions. 
Most serious reviewers devote a substantial amount of time 
and effort in getting the questions right before embarking on 
a review. They do this because they want to avoid having to 
change questions later on during the review. We should make no 
exceptions. If there is any difficulty in figuring out the components 
of questions, we should first write them down in free form. We 
can then reconstruct the free form question into a structured 
format as exemplified in Box 1.2.
We should think of a population as a description of the group of 
participants or patients about whom evidence is being sought in 
the review. Imagine interventions as the actions or the alternatives 
being considered for the population. Outcomes are measures of 
Question 
components
●⦁ The populations 
●⦁ The interventions 
●⦁ The outcomes 
●⦁ The study designs 
Free form 
question: It 
describes the query 
for which one seeks 
an answer through 
a review in simple 
language (however 
vague).  
Structured 
question: Reviewers 
convert free form 
questions into a 
clear and explicit 
format using a 
structured approach 
(see Box 1.2). 
This makes the 
query potentially 
answerable through 
existing relevant 
studies. 
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Box 1.1 Framing structured questions for systematic reviews
Question components
●● The populations   Succinct description of a group of participants or 
patients, their clinical problem and the healthcare 
setting.
●● The interventions (or exposures)  The main action(s) being considered, e.g. 
treatments, processes of care, social intervention, 
educational intervention, risk factors, tests, etc.
●● The outcomes  The clinical changes in health state (morbidity, 
mortality) and other related changes, e.g. health 
resource use. 
●● The study design  The appropriate ways to recruit participants 
or patients in a research study, give them 
interventions and measure their outcomes.
Relationship between the question components in a comparative 
study
A comparative study assesses the effect of an intervention using comparison groups. 
For example, it may allocate participants or patients (with or without randomization) 
from a relevant population to alternative groups of interventions (or exposures) and 
follow them up to determine the effect of the interventions (or exposures) on outcome.
See related study designs in Box 1.4
The population
A clinically suitable group of
participants or patients
The interventions
Comparison of groups with
and without the intervention
or exposure of interest
The outcomes
Changes in health status
due to interventions
Study sample
Allocation of
participants to groups
Estimate of effect
(e.g. relative risk = EER/CER)
Control group
(e.g. usual care)
Experimental group
(e.g. a new intervention)
Control event rate
CER = c/(c+d)
Experimental event rate
EER = a/(a+b)
Outcome
present
a
Outcome
absent
b
Outcome
present
c
Outcome
absent
d
Follow-upFollow-up
The effects
A measure of association
between interventions and
outcomes
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Box 1.2 Some example questions
An example question about clinical effectiveness
Free form question: Which of the many available antimicrobial products improve 
healing in patients with chronic wounds? 
Structured question
●● The population In adults with various forms of chronic wounds in an 
ambulatory setting ….
●● The interventions …. would systemic or topical antimicrobial preparations ….
●● The outcomes …. improve wound healing?
●● The study design A comparative study that allocates subjects with chronic 
wounds to alternative therapeutic interventions of interest 
and determines the effect of the interventions on wound 
healing (e.g. randomized controlled trial).
See Case study 3 for a related review
An example question about aetiology
Free form question: Is exposure to benzodiazepines in pregnancy associated with 
malformations in the newborn baby?
Structured question
●● The population In pregnant women ….
●● The exposures …. does exposure to benzodiazepines during early  
pregnancy ….
●● The outcomes …. cause malformations in the newborn baby?
●● The study designs ●● A study that recruits women in early pregnancy, assesses 
their exposure to benzodiazepines, follows them up and 
examines their newborn babies to compare the rates of 
malformations among women with exposure and those 
without (cohort study).
●● A study that retrospectively compares exposure to 
benzodiazepines in early pregnancy among women who 
have given birth to a child with malformation with those 
women who gave birth to a healthy child (case-control 
study).
See Box 5.2 for a related meta-analysis
An example question about test accuracy
Free form question: Among postmenopausal women with abnormal vaginal bleeding, 
does pelvic ultrasound scan exclude uterine cancer accurately? 
Structured question
●● The population In postmenopausal women, within a community setting, 
with vaginal bleeding ….
●● The test …. does a uterine ultrasound scan test accurately predict ….
●● The reference standard …. histological diagnosis of uterine cancer?
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what the population wants to achieve from the interventions, 
e.g. avoiding illness or death. Finally, we should think of how a 
worthwhile study could be designed to examine the effect of 
the interventions. For example, by comparing outcomes between 
groups of a population with and without the intervention, the 
effect may be assessed in terms of illness avoided by use of an 
intervention. 
The point about question formulation is that a structured 
approach should be used. The structure outlined in Box 1.1 should 
never become a ‘straight jacket’ and it may be modified to meet the 
needs of our free form question, depending on where our interest 
in healthcare lies. For example, in epidemiology the questions 
may be about aetiology. We can easily substitute the component 
interventions with exposure and frame the questions in terms of 
how outcomes might be different in populations exposed or not 
exposed to certain agents or risk factors (Box 1.2). For questions 
Section A of 
this book will 
focus mainly on 
questions relating to 
quantitative effects 
of interventions 
(therapy, prevention, 
social care, etc.) 
or exposures 
(environmental 
agents, risk factors, 
etc.) in the context of 
comparative study 
designs.
Section B of this 
book will also cover 
systematic reviews 
of qualitative and 
educational research.
●● The study design A study that recruits women from a relevant population, 
uses the test (scan) and a reference standard investigation 
to confirm or refute the presence of cancer (histology), 
and determines the accuracy with which the test identifies 
cancer (see Box C4.3).
See Case study 4 for a related review
An example question about qualitative research
Free form question: How does the experience of endometriosis impact on women’s 
lives? 
Structured question
●● The population In women with a confirmed diagnosis of endometriosis….
●● The intervention …. how does observation or treatment….
●● The outcomes …. affect pain, social relationships and self-image?
●● The study design A study that narrates subjective experiences (see Box C5.3).
See Case study 5 for a related review
An example question about an educational intervention
Free form question: How does use of portfolios affect student learning in 
undergraduate (medical and nursing) education? 
Structured question
●● The population Among undergraduate nursing or medical students ….
●● The intervention …. does a ‘portfolio’, defined as a collection of evidence 
of student learning, a learning journal or diary, or a 
combination of these two elements ….
●● The outcomes …. improve knowledge and skills?
●● The study design A study that evaluates the educational effects of portfolios.
See Case study 6 for a related review
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about the accuracy of screening or diagnostic tests we might 
substitute the component intervention with test, and outcome with 
reference standard against which the accuracy of the test will be 
measured (Box 1.2). In this way the proposed structure is versatile 
and adaptable for a wide range of question types.
1.2  Variations in populations, 
interventions and outcomes
Once the way in which questions are structured is understood (Box 
1.1), we should be able to see that systematic reviews are analyses 
of existing studies within a given set of populations, interventions 
and outcomes. We may have started with some scepticism about 
framing our question in this way; however, with the realization 
that different populations, interventions and outcomes exist 
within our free form question, we are likely to end up with many 
more than one question. If we have not, we should look hard 
to see if there is some variation within each of our question 
components. This is critical – even in a straightforward question 
about antimicrobials for chronic wounds (Box 1.2), it should be 
clear that there are many types of chronic wounds (populations), 
antimicrobials (interventions) and ways of measuring wound 
healing (outcomes) (Box 1.3).
It is important to seriously consider how populations, 
interventions and outcomes might vary among existing studies. 
Such differences are important in defining study selection criteria 
(Step 2) and planning the tabulation of findings (Steps 4 and 5). 
They are also relevant in understanding the reasons for variation 
in effects of interventions from study to study (Step 4) and in 
exploring the strength of the evidence to gauge applicability of 
the findings (Step 5). Thus, conclusions of individual studies and 
reviews may vary depending on differences in the characteristics 
of their populations, the nature or delivery of their interventions 
and the types of outcomes. These issues are examined in detail 
later on in the book. Here we briefly examine their implications 
when framing questions.
1.2.1  Variations in populations
Population characteristics may vary between studies with respect 
to patients’ age and sex, severity of illness, presence of co-existing 
illnesses, etc. For instance, when the effect of home visits is 
studied among elderly people (Box 1.3), the intervention is effective 
among young–old rather than old–old people (Box 4.5). 
1.2.2  Variations in interventions
The intervention features such as the care setting, compliance 
or intensity, additional routine care, etc. may also be associated 
with variable effects. For example, among elderly people, home 
visits are more effective if multidimensional assessments are used 
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and follow-up is frequent (Box 4.5). Defining the comparator is a 
critical element. If we wish to compare drug A versus drug B, we 
should be clear about this. The literature may only provide studies 
comparing drug A versus placebo and drug B versus placebo. This 
will amount to an indirect comparison, a deviation from our focus 
on the effectiveness of drug A assessed directly against drug B. 
1.2.3  Variations in outcomes
We need to identify all clinically relevant outcomes, which will help 
in examining the success or failure of the interventions. During 
our review it may become apparent that existing studies have not 
directly measured outcomes we felt were critical and important. 
Identification of these deficiencies in existing studies is important 
by itself for transparency in reviews. 
A relevant outcome is one that directly measures issues of 
importance to the population. Often these data cannot be easily 
acquired, and there may be a tendency, both among reviewers 
and readers, to become interested in intermediate, surrogate 
or proxy outcome measurements. For example, when we are 
really interested in discovering the effect of fluoride therapy in 
preventing fractures, we might be tempted to investigate bone 
mineral content as a surrogate outcome, as it would be easier to 
obtain information about this. How misleading such an approach 
can be is demonstrated in a randomized controlled trial (N Engl 
J Med 1999; 322: 802–9); bone density increased significantly 
(10–35% at different skeletal sites as compared to placebo) 
among the participants treated with fluorides; however, there was 
a nearly three-fold increase in non-vertebral fractures (control 
24 vs fluorides 72, p = 0.01), which was unexpected. This makes 
it evident that conclusions from research based on surrogate 
outcomes are likely to be weak when it comes to making decisions 
in practice. As we delineate in Step 5, the strength and weakness 
of evidence should be evaluated separately for each outcome, even 
when data come from the same studies. Therefore it is crucial that 
outcomes are set out in detail at the outset in a review.
When considering the outcomes for a review question, we 
should think about what we mean by health. Is it just the absence 
of illness or disease? This section of the book mainly focuses on 
quantitative morbidity or mortality outcomes. In the next section 
we also demonstrate how reviews collate evidence on outcomes 
used in qualitative and educational research (Case studies 5 and 
6). It has become fashionable to consider the question of how to 
achieve optimal outcomes with the smallest input of resources. 
This allows us to discover whether the investment in interventions 
is likely to be worthwhile. In this situation outcomes need to 
focus on the costs of providing healthcare in addition to clinical 
outcomes (Box 1.3). We will not cover these value-for-money 
issues much beyond framing the questions.
Surrogate 
outcome 
measurements 
substitute for 
direct outcome 
measures. They 
include physiological 
variables or 
measures of 
subclinical disease. 
To be valid, the 
surrogate must 
be statistically 
correlated with the 
clinically relevant 
outcome.
Clinically relevant 
outcomes directly 
measure what 
is important to 
patients in terms of 
how they feel, what 
their function is, 
and whether they 
survive. 
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Box 1.3 Framing questions for reviews: Variations in 
population, interventions, outcomes and study designs
Three example questions about clinical effectiveness
Free form question: Which of the many available antimicrobial products improve 
healing in patients with chronic wounds? 
Structured question (expanded from Box 1.2)
●● The 
population 
Adults with various 
forms of chronic 
wounds: 
●● Diabetic ulcers
●● Venous ulcers
●● Pressure ulcers
●● The 
interventions 
Antimicrobial 
preparations:
versus
Comparator:
●● Systemic preparations
●● Topical preparations
versus
●● Other preparations
●● The outcomes Various measures to 
quantify improvement 
in a critical outcome 
‘wound healing’:
●● Outcome measured directly: Complete 
healing, amputation due to wound 
complications
●● Outcome measured indirectly: Number of 
dressings/week, wound area remaining, 
healing scores, and reduction in 
histologically documented inflammation
●● The study 
design
Experimental and 
observational studies: 
(see Box 1.4)
●● Randomized controlled trials
●● Experimental studies without 
randomization
●● Cohort studies with concurrent controls
See case study 3 for a related review
Free form question: Do home visits improve the health of elderly people?
Structured question
●● The 
population 
Elderly people in 
various age groups:
●● Young-old
●● Middle age-old
●● Old-old
●● The 
interventions 
Home visits:
versus
Comparator:
●● Intensive assessments
●● Frequent assessments
versus
●● Usual care
●● The 
outcomes
Various measures to 
quantify health and 
health resource use:
●● Critical outcome measured directly: 
Mortality
●● Critical outcome measured directly: 
Functional status
●● Important outcome measured directly: 
Nursing home admissions
●● The study 
design
Experimental studies:
(see Box 1.4)
●● Randomized controlled trials
●● Experimental studies without 
randomization
See Box 4.5 for a related meta-analysis
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Free form question: Do antibiotics improve children’s outcome in otitis media?
Structured question
●● The 
population 
Children with otitis 
media:
●● Various age groups
●● The 
interventions 
Antibiotics:
versus
Comparator:
●● Different preparations
versus
●● Placebo or no treatment
●● The 
outcomes
Various measures to 
quantify health:
●● Critical outcome measured directly: 
Perforation
●● Important outcome measured directly: 
Pain
●● Important outcome measured directly: 
Adverse effects
●● The study 
design
Experimental studies:
(see Box 1.4)
●● Randomized controlled trials
●● Experimental studies without 
randomization
See Boxes 5.2 and 5.3 for a related review
An example question about clinical and cost-effectiveness
Free form question: To what extent is the risk of post-operative infection reduced by 
antimicrobial prophylaxis in patients undergoing hip replacement and is it worth the 
costs?
Structured question
●● The 
population 
Patients undergoing hip 
replacement:
●● Various types of procedures
●● The 
interventions 
Antimicrobial 
prophylaxis:
versus
Comparator:
●● Various types of antibiotics
versus
●● Placebo
●● No antibiotics
●● The 
outcomes
Clinical:
Economic:
●● Post-operative infection
●● Cost per infection prevented
●● The study 
design
Clinical:
Economic:
●● Experimental studies (see Box 1.4)
●● Cost-effectiveness analyses
See Box 3.4 for a  related review
An example question about comparing beneficial and harmful 
outcomes
Free form question: Which rennin-system inhibitor is better in treating hypertension 
and is it worth the costs?
Structured question
●● The 
population 
Patients with 
hypertension:
●● Various co-morbidities
●● The 
interventions
Angiotensin receptor 
blockers:
versus
●● Various types  
versus
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1.3  Variations in study designs
Let us turn our attention to study design, the fourth component 
of a review question (Box 1.1). For a given set of populations, 
interventions and outcomes, reviews will provide summaries of 
existing studies that used different research designs (Box 1.2). Why 
is design so important? Design of a study determines the validity 
of the observed effects, i.e. our confidence that the results of a 
study are likely to approximate to the ‘truth’ for the participants 
or patients studied depends on the soundness of its design. In this 
way design serves as a marker of study quality. Its importance 
cannot be emphasized enough. Ultimately the strength of a 
review’s inferences depends on the integrity of the designs of the 
available studies. 
Some reviewers consider certain study designs to be superior 
because they feel that the design has an inherent value in itself. 
For example, they may focus exclusively on randomized studies 
when conducting reviews. Such a view ignores the fact that 
addressing different types of questions may require the use of 
different study designs. As an example, a question about accuracy 
of a test would require a study design that prospectively (without 
randomization) recruits all eligible patients, employs the test and 
the reference standard investigation to confirm or refute the 
presence of disease, and determines the accuracy with which the 
test correctly identifies disease (as in Case study 4). Assessment 
of long-term or rare outcomes, particularly when examining 
the safety of interventions (as in Case study 2), would be more 
suited to an observational design, not an experimental study. For 
example, cohort and case-control studies, not randomized trials, 
would evaluate the effect of exposure to benzodiazepines in 
pregnancy on rare malformations in the newborn baby (Box 5.2). 
The quality of a 
study depends on the 
degree to which its 
design, conduct and 
analysis minimizes 
biases.
Valid results are said 
to be unbiased. Bias 
either exaggerates 
or underestimates 
the ‘true’ effect of 
an intervention or 
exposure.
Angiotensin converting 
enzyme inhibitors:
(avoiding comparison 
with placebo)
●● Various types
●● The 
outcomes
Clinical: ●● Critical beneficial outcome measured 
directly: Mortality and major 
cardiovascular events
●● Important beneficial outcome measured 
indirectly: Renal failure measured by 
serum creatinine
●● Important beneficial outcome measured 
directly: Successful monotherapy
●● Important adverse outcomes measured 
directly: Cough and withdrawals
●● The study 
design
Mixture of designs: 
(see Box 1.4)
●● Experimental studies for beneficial effects
●● Observational studies for adverse effects
See Boxes C7.1 and C8.1 for a related review
18 Systematic Reviews to Support Evidence-based Medicine
Even for questions concerning effectiveness of interventions, 
where randomized trials are generally preferred, it might be 
difficult to justify a restriction to using randomized studies only. 
This may be particularly true when such studies are unethical. 
Sometimes there is just a dearth of randomized studies. For 
example, in the review on antimicrobials for chronic wounds 
(Case study 3), despite a comprehensive search, only four clearly 
randomized studies could be found, so other designs had to be 
included. On the other hand, in Case study 2, where the review 
considered safety of water fluoridation, no randomized studies 
had been published, so it became necessary to consider various 
other designs. Effects of educational interventions are often 
studied using a range of designs (Case study 6). For evaluation of 
harmful outcomes that are rare, observational design is frequently 
included in reviews (Case study 8). Sometimes a review may 
consider a number of separate but related questions. For example, 
if a review is to include an assessment of efficiency in addition 
to effectiveness, then study designs for economic evaluation will 
also be required (Box 1.3). Thus, it might be necessary to consider 
different designs simultaneously in some review questions. 
This multiplicity of designs has implications for study quality 
assessment (Step 3) and synthesis (Step 4).
Insistence on randomized studies, ignoring other types of 
evidence, might paralyse reviewers as such reviews might never 
find any studies. Often because of ethical or technical reasons the 
best possible evidence can only be obtained from observational 
studies. When faced with having to make decisions for practice, 
using the best available evidence is likely to be better than not 
using any evidence at all. We will need to explore the nature 
of our questions (effectiveness, aetiology, efficiency, accuracy, 
prognosis, etc) and the different ways of addressing the specific 
issues before us, i.e. populations, interventions and outcomes. 
Then we should select the study designs that are likely to 
provide the most valid answers and develop a hierarchy of study 
designs suitable for our review. This approach will help us define 
inclusion and exclusion criteria for selecting studies of a minimum 
acceptable quality (Step 2). Once studies have been included in a 
review, a detailed assessment of their quality (Step 3) and results 
(Step 4) will be required to gauge the strength of the evidence 
(Step 5).
Each question type has a design hierarchy of its own. In this 
section of the book we focus mainly on questions relating to 
health effects of interventions and exposures. These questions 
usually focus on how one intervention or exposure compares 
with another. A hierarchy of designs for studies addressing such 
issues is shown in Box 1.4. The most sound study design in this 
context is one that randomly allocates (concealing the assignment 
code) participants from a relevant population to the alternative 
interventions of interest. This design serves to remove selection 
Effectiveness is the 
extent to which an 
intervention 
(therapy, prevention, 
diagnosis, screening, 
education, social 
care, etc.) produces 
beneficial outcomes 
under ordinary 
day-to-day 
circumstances.
Efficiency (cost-
effectiveness) is the 
extent to which the 
balance between 
input (costs) and 
output (outcomes) 
of interventions 
represents value for 
money. 
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Box 1.4 A hierarchy of study designs for questions about 
effectiveness of healthcare interventions
Description of the design
Experimental study
A comparative study* in which the use of different interventions among participants 
is allocated by the researcher.
●● Randomized controlled trial (with concealed allocation)
Random allocation of participants to an intervention and a control (e.g. placebo 
or usual care) group, with follow-up to examine differences in outcomes between 
the two groups. Randomization (with concealment of allocation sequence from 
caregivers) avoids bias because both known and unknown determinants of 
outcome, apart from the intervention, are usually equally distributed between the 
two groups of participants.
●● Experimental study without randomization (sometimes erroneously called quasi-
experimental or quasi-randomized or pseudo-randomized studies)
A study in which the allocation of participants to different interventions is managed 
by the researcher but the method of allocation falls short of genuine randomization, 
e.g. alternate or even–odd allocation. Such methods fail to conceal the allocation 
sequence from caregivers.
Observational study with control group
A comparative study* in which the use of different interventions among participants is 
not allocated by the researcher (it is merely observed).
●● Cohort study
Follow-up of participants who receive an intervention (that is not allocated by the 
researcher) to examine the difference in outcomes compared to a control group, e.g. 
participants receiving no care. 
●● Case-control studies
Comparison of intervention rates between participants with the outcome (cases) and 
those without the outcome (controls).
Observational study without control groups
●● Cross-sectional study
Examination of the relationship between outcomes and other variables of interest 
(including interventions) as they exist in a relevant population at one particular time.
●● Before-and-after study
Comparison of outcomes in study participants before and after an intervention. 
●● Case series
Description of a number of cases of an intervention and their outcomes.
Case reports
●● Pathophysiological studies or bench research
●● Expert opinion or consensus
*  A comparative study assesses the effect of an intervention using comparison groups. 
See Box 1.1 for an example flow chart of such a study
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bias and when conducted well, such studies rank at the top of the 
study design hierarchy for effectiveness evidence. Studies where 
the allocation of participants or patients falls short of genuine 
randomization and allocation concealment have an inherent 
risk of bias, and in the evaluation of strength of evidence they 
are assigned a low level initially (Step 5). Reviewers’ inability to 
recognize valid designs can have serious implications for evidence-
based practice. For example, relying on expert opinion when 
reviewing literature could mislead practice recommendations, 
e.g. erroneously withholding thrombolytic therapy in myocardial 
infarction. In this field experts have lagged a decade behind strong 
evidence of effect of this intervention on mortality (JAMA 1992; 
268: 240-8). 
As indicated above, for many reviews experimental studies 
will not exist (Case study 2) or they might be scarce (Case study 
3). Hence, reviews may have to be conducted using studies of 
an inferior design or using studies with a mixture of designs. 
If our review has several study designs, it would be prudent to 
carefully plan quality assessments (Step 3), stratify study synthesis 
by design and quality (Step 4) and interpret findings cautiously 
(Step 5). Reviewers who do not take a cautious approach to the 
design issue can easily produce erroneous conclusions, to the 
detriment of patients. For example, initial recommendations that 
postmenopausal women use hormone replacement therapy to 
reduce cardiovascular risk came from observational studies with 
inconsistent results. Recognition of the limitations of the evidence 
would have tempered the recommendations, avoiding the need to 
reverse recommendations when randomized evidence showed that 
hormone replacement therapy fails to reduce cardiovascular risk 
and may even increase it (Ann Intern Med 2002; 137: 273-84).
1.4  Modification of questions 
during a review
It is important that review questions are formulated a priori, that 
is, before the review work is actually commenced. Otherwise the 
review process may be unduly driven by presuming particular 
findings. In order to get the questions correct at the beginning, it 
may be worth involving experienced reviewers and practitioners in 
the process. This is just one of several reasons why it is considered 
unwise to prepare a review alone.
Questions will initially be developed without detailed knowledge 
of much of the relevant literature. Therefore, we should not 
be surprised if it becomes evident during the review that some 
questions need to be modified in light of the accumulated 
research. The commandment ‘thou shall pose questions for a 
review a priori’ should not be applied too rigidly. We should 
allow exploration of unexpected issues into the review process; 
as a greater understanding of the problem is developed during 
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the course of the review, it would be foolish not to do so. If the 
ongoing work identifies a need for answering questions which 
had not been foreseen, it would be quite reasonable to raise new 
questions or to modify existing questions. Such modifications 
are justifiable if they are based on the realization of alternative 
ways of defining the populations, interventions, outcomes or study 
designs, which were not considered earlier. 
Revision of questions will inevitably have some implications for 
the review work. The protocol would have to be revised. Literature 
searches (Step 2), which are usually conducted before questions 
are refined, may also need refinement and they might have to 
be run again in the light of the changes to the questions. Study 
selection criteria will have to be altered. For example, in the 
review of safety of water fluoridation in Case study 2, the original 
questions were modified in the light of information gathered 
about the extent and range of quality of available evidence during 
the initial part of the review. This led to changes in study selection 
criteria, which are provided in detail in the published report of the 
review (www.york.ac.uk/inst/crd/fluorid.htm). Reviewers should 
not be economical with the truth about question formulation and 
refinement. It is essential to be explicit about the modifications 
and indicate which questions were posed a priori and which were 
generated during the review work. 
Summary of Step 1: Framing 
questions for a review
Key points about appraising review articles
●● Examine the abstract and the introduction to see if the review is 
based on predefined questions.
●● Examine the methods and other sections to check if questions 
were modified during the review process.
●● Can we be sure that the questions have not been unduly 
influenced by the knowledge of results of the studies?
Key points about conducting reviews
●● The problems to be addressed by the review should be specified 
in the form of clear, unambiguous questions before beginning 
the review work. 
●● Questions should be structured, e.g. in terms of population, 
interventions, outcomes and study designs relevant to the issues 
being addressed in the review. 
●● Characteristics of the populations, differences in interventions, 
variation in outcomes and variety in study designs may influence 
the results of a review. The impact of these factors should be 
carefully considered at this stage.
●● Once the review questions have been set, modifications to the 
protocol should only be allowed after careful consideration. 
Sometimes, alternative ways of defining the populations, 
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interventions, outcomes or study designs become apparent after 
commencing the review. In this situation it would be reasonable 
to alter the original questions, but these modifications should 
not be driven by the knowledge of results of the studies. 
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●● Step 2: Identifying 
relevant literature
Being thorough when identifying the relevant literature is crucial 
for a systematic review. It is driven by the desire to capture as 
many relevant studies as possible. In published reviews, literature 
searches are often summarized too simplistically to allow others 
to replicate them. A good search can vary between simple and 
relatively complex, depending on the review topic. Not all searches 
are beyond the reach of novice reviewers.
A comprehensive literature search includes multistage and 
iterative processes. First we will need to generate lists of citations 
from relevant resources (e.g. electronic bibliographic databases, 
reference lists of known primary and review articles, and relevant 
journals). Second, we will need to screen these citations for 
relevance to our review questions with a view to obtaining the 
full manuscripts of all potentially relevant studies. Third, we will 
need to sift through these manuscripts to make the final inclusion/
exclusion decisions based on explicit study selection criteria. Some 
of the studies will provide reference lists from which we will find 
more potentially relevant citations, and the cycle of obtaining 
manuscripts and examining them for relevance will go one more 
round. These processes will eventually lead to a set of studies 
on which the review will be based. In the report of our review, 
a flowchart of the study identification process will be required 
(Box 2.1). The basic principles behind the identification of relevant 
literature covering various aspects of this flowchart are covered in 
this Step. 
2.1  Generating a list of potentially 
relevant citations 
Both the precision and the validity of the findings of reviews 
are directly related to the comprehensiveness of the literature 
identification processes. The aim of the initial searches, both 
electronic and manual, is to generate as comprehensive a list of 
citations as possible to address the questions being posed in the 
review. Thus, the search strategy (search terms and the resources 
to be searched) will depend on the components of the questions. 
If we have formulated the questions well, we have already made 
a head start. In practical terms, developing a search strategy may 
take several iterations, so we should be prepared for the hard 
work. However, using a systematic approach (similar to the one 
outlined below) can quickly lead us to a reasonably effective 
strategy. 
The steps involved in electronically generating lists of potentially 
relevant citations include selection of relevant databases, 
Precision of effect 
in a review refers 
to its uncertainty. 
Poor searches 
may contribute 
to uncertainty by 
identifying only 
a fraction of the 
available studies, 
which leads to wide 
confidence intervals 
around the summary 
effects. Imprecision 
refers to uncertainty 
arising due to play 
of chance, but not 
due to bias.
Validity of a 
review refers 
to the methods 
used to minimize 
bias. Bias will 
either exaggerate 
or underestimate 
the ‘true’ effect 
being sought in 
a review. Poor 
searches contribute 
to bias as they 
may preferentially 
identify studies with 
particularly positive 
or particularly 
negative effects.
Step 1 
Framing questions
Ø
Step 2 
Identifying relevant 
literature
Ø
Step 3 
Assessing quality of 
the literature
Ø
Step 4 
Summarizing the 
evidence
Ø
Step 5 
Interpreting the 
findings
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formulation of an appropriate combination of search terms and 
retrieval of citations from the searches. Searches undertaken at the 
beginning of the review may have to be updated at a later date 
depending on the length of time taken to complete the review.
2.1.1  Selection of relevant databases to 
search
There exists no such database that covers all publications from 
all healthcare journals. Serious reviewers usually search many 
databases. How should we decide about database coverage? This 
depends very much on the topic of the review. Why not compare 
and contrast the types of databases searched in Case study 2 
(Box C2.1) with those searched in Case study 3 (Box C3.1): the 
differences are mainly due to differences in the nature of the 
review topics. There are many useful databases and we may wish 
to ask our local librarian or consult one of the guides to databases. 
Some of the commonly used databases are shown in Box 2.2.
Most reviews would include searches in general databases such 
as Medline and Embase, which cover many of the same journals. 
Medline is produced by the US National Library of Medicine and 
has a North American emphasis. Embase has a greater European 
Box 2.1 A flowchart describing the process of identifying 
relevant literature
Retrieve hard copies of all potentially relevant citations
identified through the above searches plus contact with
experts, sifting through reference lists and other sources
(n = #)
Exclude irrelevant studies
after detailed assessment of
full text
(n = #)
Exclude irrelevant citations
after screening all titles and
abstracts
(n = #)
Include studies in systematic review
(n = #)
Identify potentially relevant citations
from liberal searching of electronic databases and
hand searching of other appropriate resources
(n = #)
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Box 2.2 Important databases of research in healthcare
Selected general databases
MEDLINE (available freely via PubMed at www.ncbi.nlm.nih.gov/PubMed)
Bibliographic records (with and without abstracts) of biomedical literature 
from 1966 onwards.  
EMBASE (www.embase.com)
Records of biomedical literature from 1974 onwards. 
Science Citation Index  (thomsonreuters.com/products_services/science/
science_products/scholarly_research_analysis/research_discovery/web_of_
science)
Relevant studies found through electronic or manual searches can be used to 
identify further relevant citations by electronically locating other citations on 
the same topic through citation search on Science Citation Index.
Selected databases with a specific focus
PsycInfo (http://psycinfo.apa.org/psycinfo/)
Records of literature on psychology and related behavioural and social 
sciences from 1967.
CENTRAL (The Cochrane Central Register of Controlled Trials - 
www.thecochranelibrary.com)
Records of clinical trials in healthcare identified through the work of the 
Cochrane Collaboration, including large numbers of citations from MEDLINE 
and EMBASE as well as citations not covered by these databases. In the 3rd 
issue of the 2009 Cochrane Library there were approximately 500 000 trials 
in CENTRAL.
CINAHL (Cumulative Index to Nursing and Allied Health Literature - 
www.cinahl.com)
Records of literature on all aspects of nursing and allied health disciplines.
NHS EED (NHS Economic Evaluation Database - www.crd.york.ac.uk/crdweb)
Structured abstracts of economic evaluations of healthcare interventions 
identified by regular searching of bibliographic databases, hand searching of key 
major medical journals.
MIDIRS (www.midirs.org) 
A broad reference resource available to obstetricians, midwives and consumers.
Conference Papers Index (http://ca2.csa.com/factsheets/cpi-set-c.php)
Records of conference presentations.
Research Registers (for research in progress) 
Guide to selected registers – www.york.ac.uk/inst/crd/htadbase.htm
UK Clinical Research Network: Portfolio Database – http://public.ukcrn.org.uk/
search
MetaRegister of Current Controlled Trials – http://controlled-trials.com
www.nci.nih.gov/clinical_trials
SIGLE (System for Information on Grey Literature – www.stneasy.fiz-
karlsruhe.de) 
Bibliographic database covering European non-conventional (so-called grey) 
literature in the field of pure and applied natural sciences and other areas.
See Boxes C2.1, C3.2, C5.1 and C6.1 for some other databases searched in the case 
studies.
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emphasis in terms of the journals it covers and has a high 
pharmacological content. Local medical libraries or professional 
bodies may provide free access to both Medline and Embase. To 
complicate matters, there are a number of different commercial 
software interfaces for electronic databases, e.g. Ovid, Silverplatter, 
Knowledgefinder, etc. Their mode of searching is flexible and 
user-friendly, but they are more costly than the PubMed interface 
to Medline which is freely available on the Internet. The PubMed 
interface has an additional searching feature via its ‘Related 
Articles’ function, which allows capture of additional citations on 
the basis of their similarity to known relevant citations. 
2.1.2  Search term combination for 
electronic database searches
In simple terms, building a suitable combination of search terms 
involves combining free text words and controlled terms (MeSH or 
MeSH-like terms) which represent the various components of the 
review question. 
We should begin by examining the populations, interventions, 
outcomes and study designs relevant to our review, as shown 
in Box 2.3. For each one of these components we will need to 
compile a list of words that authors might have used in their 
studies. We may identify a range of synonyms with spelling 
variations by examining the relevant studies we already know of. 
These will provide the free text words for our search. We will also 
need to compile a list of controlled terms that database indexers 
might have used when recording the citations. There are many 
ways to identify relevant MeSH or MeSH-like terms. For example, 
we may look at the key words suggested for indexing in known 
relevant studies (frequently found at the end of the abstract) and 
check how they are actually indexed in the databases we want 
to search. We need to keep in mind that indexers don’t always 
follow authors’ suggestions. Each database has its own thesaurus 
or index structure and we may want to refer to this for additional 
MeSH terms. This task is made easier in databases that offer the 
opportunity to map free text words we have selected to MeSH 
in their index lists. However we select our search terms, we must 
ensure that an adequate number of free text words and controlled 
terms are included to represent each component of the question. 
This will enhance the sensitivity of our search, increasing our 
ability to capture a large proportion of the relevant studies.
The next stage is to combine the words and terms we have 
selected to capture the various components of the question. 
This is achieved by Boolean logic which commonly uses the 
operators AND, OR and NOT to create sets of citations from the 
search terms. For example, combining coke OR cola will retrieve 
all citations where either one or both of these terms are found. 
On the other hand, combining coke AND cola will only retrieve 
citations where both of these terms are found. Combining coke 
MeSH or medical 
subject headings 
are controlled 
terms used in the 
MEDLINE database 
to index citations. 
Other bibliographic 
databases use MeSH-
like terms.
Boolean logic 
refers to the logical 
relationship among 
search terms. 
Boolean operators 
AND, OR and NOT 
are used during 
literature searches to 
include or exclude 
certain citations from 
electronic databases. 
An example of their 
use in PubMed is 
shown below:
Coke    Cola
547 + 5 + 406
 
PubMed 
Citations
Coke = 552
Cola = 411
Coke AND Cola = 5
Coke OR Cola = 958
Coke NOT Cola = 547
Sensitivity of 
a search is the 
proportion of 
relevant studies 
identified by a search 
strategy expressed 
as a percentage of 
all relevant studies 
on a given topic. It 
is a measure of the 
comprehensiveness 
of a search method. 
Do not confuse with 
sensitivity of a test.
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Box 2.3 How to develop a search term combination for 
searching electronic bibliographic databases
An example of a search term combination for Ovid MEDLINE 
database
Free form question: In women undergoing surgical termination of pregnancy, does 
antibiotic prophylaxis reduce the risk of post-operative infection?
Structured question (not all components may be needed for searching)
●● The population Pregnant women undergoing surgical abortion
●● The interventions c Antibiotics used as prophylaxis 
  c  Comparator: placebo or no intervention (not used in search 
term combination)
●● The outcome Post-operative infection
●● The study design Experimental studies (not used in search term combination)
Question components and relevant 
search terms
Type of 
terms
Boolean operator
Free MeSH
The population: Pregnant women undergoing surgical abortion
1 (terminat$ adj3 pregnan$).tw x
OR (captures population)
2 (unwant$ adj3 pregnan$).tw x
3 abortion$.tw x
4 exp abortion induced/ x
5 exp pregnancy unwanted/ x
6 or/1–5
The interventions: Antibiotics used as prophylaxis
7 exp infection control/ x
OR (captures interventions)
8 exp anti-infective agents/ x
9 exp antibiotics/ x
10 antibiotic$.tw x
11 (antibiotic adj3 prophyla$).tw x
12 (antimicrobial$ or anti-microbial$).tw x
13 or/7–12
The outcome: Post-operative infection
14 exp bacterial infections/ x
15 exp postoperative complications/ x
16 sepsis/ x
17 exp abortion septic/ x
18 exp endometritis/ x
19 exp adnexitis/ x
20 (postoperative adj3 (infect$ or 
contaminat$ or complicat$ or 
pyrexi$)).tw
x OR (captures outcome)
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Question components and relevant 
search terms
Type of 
terms
Boolean operator
Free MeSH
21 (sepsis or septic).tw x
22 (bacteria$ adj3 (contaminat$ or 
infect$)).tw
x
23 (post-abort$ adj3 (infect$ or 
complicat$ or contaminat$)).tw
x
24 endometritis.tw x
25 pelvic inflammatory disease.tw x
26 (septic adj3 abort$).tw x
27 or/14–26
28  and/6,13,27 AND (combines all components)
Commands and symbols for Ovid Medline
$ Truncation, e.g. pregnan$ will pick up pregnant, pregnancy and pregnancies 
adj  Proximity and adjacency searching, e.g. terminat$ adj pregnan$ means that these 
terms appear next to each other, terminat$ adj3 pregnan$ means that there may 
be three other words in between them
.tw  Textword search, e.g. abortion$.tw, will search for textwords in title or abstract
/  Medical subject heading (MeSH) search, e.g. abortion induced/, will search for 
MeSH in indexing terms
exp Explodes the MeSH, e.g. exp abortion induced/ will search for this MeSH as well 
as the lower order MeSH terms included under the MeSH abortion induced in 
tree structure, such as abortion eugenic, abortion legal, abortion therapeutic, 
pregnancy reduction multifetal
See related selection criteria in Box 2.5 
Based on RCOG Clinical Governance Advice No. 3 (www.rcog.org.uk/mainpages.
asp?PageID=318)
NOT cola will retrieve citations that contain the term coke only, 
thereby excluding all citations with the term cola. Needless to say, 
NOT should be used with great caution. In general, one would use 
OR to combine all the words and terms capturing a component of 
the question. This will give a large citation set for each component 
that we searched for. We can now combine these with AND to 
produce a set which contains citations relevant to all the various 
components of the question. 
Box 2.3 only shows the search term combinations for the 
Medline database. Any search term combinations developed 
for MEDLINE would need to be adapted to the peculiarities of 
each of the other databases to be searched. This may require 
professional support. It can be guaranteed that this will not be 
easy, particularly because different databases use different terms 
and index structures. But we should not lose sight of our objective, 
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which is to produce a valid answer for the questions raised for 
the review. There is substantial evidence that limiting the search 
to only a few databases tends to bias the review. The more broad 
based our search, the more likely it is that our review will produce 
a precise and valid answer.
2.1.3  Searching for study designs
One important component of the review question is study design, 
which can be used to improve our search strategy. For example, to 
identify published and unpublished clinical trials we may search 
specialist collections such as the Cochrane Central Register of 
Controlled Trials (CENTRAL) and research registers of ongoing trials 
(http://controlled-trials.com). These are usually the first databases 
to be searched in reviews of randomized studies. However, for 
other study designs such collections are rare. 
General databases have subject indexing for some study designs 
but this alone may not be adequate for searching. Therefore search 
term combinations which capture studies of a particular design 
(also known as search filters) have been developed by information 
specialists. It is tempting to search general databases using such 
design filters, e.g. those available on PubMed Clinical Queries 
(www.ncbi.nlm.nih.gov/corehtml/query/static/clinical.shtml) or 
on other health technology assessment websites, e.g. www.york.
ac.uk/inst/crd/intertasc/. Some filters are designed to perform 
quick searches to support day-to-day evidence-based practice. 
They will make our search more precise but inevitably this will be 
at the expense of sensitivity. This means that a high proportion of 
citations retrieved by filtered searches will be relevant, but many 
relevant citations will be missed because they are not indexed 
in a way that the filter can pick up. This is a major drawback 
because systematic reviews should be based on searches that 
are as thorough as possible. There is one exception – for reviews 
of randomized trials where indexing of design-related terms is 
more reasonable, carefully adapted versions of existing filters for 
therapy questions may be used (see Case study 3). Case study 5 
demonstrates the use of a qualitative research design filter (Box 
C5.1) and Case study 8 illustrates the use of an observational study 
design filter to capture literature on adverse effects.
2.1.4  Reference lists and other sources 
(e.g. journals, grey literature, 
conference proceedings) 
Inaccurate or incomplete indexing of articles and journals in 
electronic bibliographic databases requires the examination of 
other sources of citations. Reference lists from identified studies 
and related reviews provide a rich source of potentially relevant 
citations. Index Medicus and Excerpta Medica can be manually 
searched if it is desirable to identify studies prior to the start 
Study design filter  
employs a search 
term combination to 
capture citations of 
studies of a particular 
design.
Precision of a 
search is the 
proportion of 
relevant studies 
identified by a 
search strategy. 
This is expressed as 
a percentage of all 
studies (relevant and 
irrelevant) identified 
by that strategy. 
It is a measure 
of the ability of a 
search to exclude 
irrelevant studies. 
Do not confuse with 
precision of effect.
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dates of the electronic databases (as in Case study 2). The latest 
issues of the key journals may also be searched to identify very 
recent studies which have not yet been included on the electronic 
databases or cited by others. It can take some time for studies 
published in some journals indexed in Medline to finally appear in 
this database. 
Many studies published in technical reports, discussion papers 
or other formats are not included in major databases and journals, 
but some of these may be indexed on databases such as SIGLE 
(System for Information on Grey Literature), the National Technical 
Information Service (www.ntis.gov), and the British National 
Bibliography for Report Literature (www.bl.uk/). The libraries of 
specialist research organizations and professional societies may 
provide another useful source of this grey literature. Dissertations 
and theses can also be routes into obtaining otherwise 
unpublished research and these are recorded in databases such as 
Dissertation Abstracts and CINAHL (Cumulative Index to Nursing 
and Allied Health Literature). Conference proceedings can provide 
information on research in progress as well as completed research. 
You can access this information through the Index of Scientific 
and Technical Proceedings, the Conference Papers Index and in the 
catalogues of large research libraries. 
2.1.5  Identifying ongoing research
The most unbiased study retrieval can only be guaranteed in those 
few areas where prospective comprehensive research registers 
are maintained. These research registers may provide information 
on completed or ongoing studies. Box 2.2 shows some electronic 
resources to search for ongoing studies. Many pharmaceutical 
companies hold their study results in private databases, which may 
occasionally be released on request (as in Case study 1). 
2.1.6  Searching the internet
This is how research is increasingly being published and accessed. 
Many of the electronic databases described above are available 
through the internet. The ‘world wide web’ can also be used to 
identify researchers and manufacturers as well as completed 
and ongoing studies. Given the enormity of the web, any serious 
attempt to search it would be a major undertaking, with tens 
of thousands of web pages to browse. A structured approach 
would have to be developed, e.g. using meta-search engines (e.g. 
Dogpile – www.dogpile.com, Google – www.google.com, etc.), 
or search engines with a healthcare focus (e.g. Turning Research 
Into Practice – www.tripdatabase.com/, Intute – www.intute.
ac.uk/, etc.). Sometimes it is much more efficient to look for 
evidence that already has been pre-selected by experts. The BMJ 
Group and McMaster University’s Health Information Research 
Unit provide access to current best evidence from research, 
tailored to one’s own healthcare interests, to support evidence-
Bias in study 
retrieval will either 
exaggerate or 
underestimate 
the ‘true’ effect 
being sought in 
a review. Poor 
searches contribute 
to bias as they 
may preferentially 
identify studies with 
particularly positive 
or particularly 
negative effects.
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based clinical decisions. Citations (from over 130 premier clinical 
journals) are pre-rated for quality by research staff, then rated 
for clinical relevance and interest by at least three members of a 
worldwide panel of practising physicians. http://plus.mcmaster.ca/
EvidenceUpdates/Default.aspx
2.1.7  Seeking professional input 
After reading through this section you might feel that literature 
identification is beyond your current searching skills and you 
will need professional input. Many professional reviewers receive 
support from information specialists to carry out their searches. 
Your local librarian may be able to help – they might be able to 
direct you to an information service that conducts systematic 
literature searches. Registering your review with a relevant Review 
Group of the Cochrane Collaboration might allow you access to 
professional searches. Many of the Review Groups have developed 
comprehensive search strategies in their topics and maintain 
specialized registers.
2.2  Citation retrieval and 
management 
In order to effectively manage the process of literature 
identification, citations obtained from the searches will have to 
be imported into a computer program for reference management 
(e.g. Reference Manager, ProCite, EndNote). Construction of a 
master citation database for a review will involve collating all the 
citations from various sources. Built-in functions of the citation 
management software allow exact and inexact duplicates (where 
titles, authors or journal names of the same articles are cited 
or stated in different manners) to be easily detected. Additional 
functions of the software can add labels or tags to the citations, 
by creation of user defined fields, allowing for enhanced sorting 
and documentation of the selection process. Searches of some of 
the sources (e.g. CENTRAL) may not be importable directly into 
the master citation database. Citations from these sources will 
have to be scrutinized and managed using simple word-processing 
software. In addition, searches of non-electronic sources (e.g. 
reference lists of known articles) may be managed manually. 
Eventually many citations will have to be manually entered into 
the master citation database of the review. 
2.3  Selecting relevant studies
The aim of the study selection process is to use the citation lists 
to identify those articles that definitely address the questions 
being posed in the review. This is part of the multi-stage process 
described in Box 2.1. The process consists of defining the study 
selection criteria, screening the citations to obtain the full reports 
The Cochrane 
Collaboration is 
an international 
collaboration 
that aims to help 
with informed 
decision making on 
healthcare topics 
by preparing, 
maintaining and 
ensuring accessibility 
of systematic 
reviews of 
interventions (www.
cochrane.org).
Selecting relevant 
citations
●⦁ Develop selection 
criteria
●⦁ Select relevant 
citations
●⦁ Obtain full papers 
and select those 
relevant
●⦁ Do not use 
language 
restrictions
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of all studies that are likely to meet the selection criteria, and 
sifting through these manuscripts to make the final inclusion/
exclusion decisions.
2.3.1  Study selection criteria
These should follow on logically from the review question. Box 2.4 
shows example sets of selection criteria defined in terms of the 
populations, interventions, outcome and study designs of interest. 
Ultimately, only studies that meet all of the inclusion criteria (and 
none of the exclusion criteria) will be included in the review. To 
avoid bias in the selection process, the criteria (both inclusion and 
exclusion) should be defined a priori. 
When defining selection criteria, we should ask ourselves:
●● Is it sensible to group various populations together? 
●● Is it sensible to combine various interventions together? 
●● What outcomes are clinically relevant? 
●● What study designs should be included/excluded?
Often reviewers are led by what is likely to be reported rather 
than by what is clinically important, but it is preferable to select 
studies with clinical importance rather than surrogate outcomes 
(Step 1). The decision taken about study selection, whatever it is, 
will have consequences for the rest of the review. It is up to us 
as the reviewers to decide on how broad or narrow the selection 
criteria should be. Criteria that are too broadly defined may make 
it difficult to synthesize studies; criteria that are too narrowly 
defined may reduce the applicability of the findings of our 
review. A balanced approach can enhance the applicability of our 
findings. For example, using liberal inclusion criteria concerning 
the populations may allow investigation of questions concerning 
the variation in effects among different population subgroups (see 
Box 4.5).
Ideally studies of the most robust design should be included. 
However, practically, the criteria concerning study design may be 
influenced by knowing the type and amount of available literature 
to some extent after initiating the review. If the selection criteria 
are modified in the light of the information gathered from the 
initial searches, the modifications should be justified and explicitly 
reported. When studies of robust designs have not been carried 
out (Case study 2) or if they are scarce (Case study 3), the inclusion 
criterion specifying the study design may have to consider studies 
of methodologically poorer quality. This approach may be used 
in reviews where the goal is to summarize the currently available 
evidence for decision making, as in Case studies 2, 3 and 6. If a 
review has several study designs, this will have implications on 
study quality assessments (Step 3), study synthesis (Step 4) and 
interpretation of findings (which should be cautious) based mainly 
on methodologically superior studies (Step 5).
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Box 2.4 Some examples of study selection criteria
Free form question: In women undergoing surgical termination of pregnancy, does 
antibiotic prophylaxis reduce the risk of post-operative infection? (see structured 
question in Box 2.3)
Question component Inclusion criteria Exclusion criteria
●● The population Pregnant women undergoing 
surgical abortion
Other operations
●● The interventions Antibiotics compared to placebo 
or no prophylaxis; comparison 
of different antibiotics
Lack of comparison
●● The outcome Post-operative infection con-
firmed by appropriate microbio-
logical techniques
Infection not confirmed 
●● The study design Experimental studies Observational studies
Free form question: Is it safe to provide population-wide drinking water fluoridation 
to prevent caries?
Question component Inclusion criteria Exclusion criteria
●● The population Population receiving drinking 
water sourced through a public 
water supply
Unsourced water supply
●● The interventions Fluoridation of drinking water, 
naturally occurring or artificially 
added, compared to non-fluori-
dated water
Lack of comparison
●● The outcome Cancer, bone fractures and 
fluorosis
Other outcomes
●● The study design - Experimental studies
-  Observational studies (cohort, 
case-control, cross-sectional, 
and before-and-after)
- Case series
- Case reports
See Case study 2 for a related review
Free form question: Which of the many available antimicrobial products improve 
healing in patients with chronic wounds? (see structured question in Box 1.3)
Question component Inclusion criteria Exclusion criteria
●● The population Adults with chronic wounds Other wounds
●● The interventions Systemic and topical 
antimicrobial preparations 
compared to placebo or no 
antimicrobial; comparison of 
different antibiotics
Lack of comparison
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2.3.2  Screening of citations
Initially, the selection criteria should be applied liberally to the 
citation lists generated from searching relevant literature sources. 
Citations often contain only limited information, so any titles (and 
abstracts) which seem potentially relevant should provisionally 
be included for consideration on the basis of the full text articles. 
However, many citations will clearly be irrelevant and these can 
be excluded at this stage. Two reviewers should carry out citation 
screening independently and the full manuscripts of all citations 
considered relevant by any of the reviewers should be obtained. 
The yield of this process will vary from one review to another.
2.3.3  Obtaining full manuscripts
From a visit to our nearest medical library we will be able to find 
out the lists and dates of journals that we can obtain locally. 
However, first it is worth checking on the internet for freely 
available journals (www.freemedicaljournals.com) and then 
download the papers electronically. Your institution or library may 
also subscribe to electronic journals not freely available. In this 
way, many recent publications may be quickly obtained. The next 
Step will be to obtain articles not available through our library or 
on the internet. This could be time consuming and help from the 
local librarian or from a librarian at a professional body will be 
invaluable. On occasion it may be necessary to write to the authors 
directly to obtain the papers. 
2.3.4  Study selection
The final inclusion/exclusion decisions should be made after 
examining the full texts of all the potentially relevant citations. We 
should carefully assess the information contained in these to see 
whether the criteria have been met or not. Many of the doubtful 
citations initially included may be confidently excluded at this 
stage. It will be useful to construct a list of excluded studies at this 
point, detailing the reason for each exclusion. This will not take 
much time and providing this list as part of our review increases 
the quality of our report. When submitting a manuscript of a 
Question component Inclusion criteria Exclusion criteria
●● The outcome Wound healing Wound healing not assessed 
●● The study design - Randomized controlled trials
-  Experimental studies without 
randomization
-  Cohort studies with 
concurrent controls
-  Studies with historical 
controls
- Case control studies
See Case study 3 for a related review
See Box 1.4 for a brief description of various study designs
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review for publication in a printed journal, it may not be possible 
to include this section due to restrictions on space. However, these 
details can be provided in an electronic version of the journal or 
they could be made available from our offices on request.
Two independent reviewers should undertake assessments 
of citations and manuscripts for selection because even when 
explicit inclusion criteria are prespecified, the decisions concerning 
inclusion/exclusion can be relatively subjective. For example, 
when applying the study design criteria for selection, reviewers 
may disagree about including or excluding a study due to unclear 
reporting in the paper. The selection criteria can be initially piloted 
in a subset of studies where duplicate assessments allow reviewers 
to assess whether they can be applied in a consistent fashion. If 
the agreement between the reviewers is poor in the pilot phase, 
revision of the selection criteria may be required. Once these 
issues have been clarified, any subsequent disagreements are 
usually simple oversights, which are easily resolved by consensus. 
Occasionally arbitration by a third reviewer may be required. 
Beware of reviews which have only one author; it is likely that 
errors will have been made in selecting studies.
2.3.5  Selecting studies with duplicate 
publication
Reviewers often encounter multiple publications of the same 
study. Sometimes these will be exact duplications, but at other 
times they might be serial publications with the more recent 
papers reporting increasing numbers of participants or lengths 
of follow-up. Inclusion of duplicated data would inevitably bias 
the data synthesis in the review, particularly because studies with 
more positive results are more likely to be duplicated. However, the 
examination of multiple reports of the same study may provide 
useful information about its quality and other characteristics not 
captured by a single report. Therefore, all such reports should be 
examined. However, the data should only be counted once using 
the largest, most complete report with the longest follow-up.
2.4  Publication and related biases
Identification of all the relevant studies depends on their 
accessibility. Some studies may be less accessible due to:
●● a lack of statistical significance in their results
●● the type and language of their reports
●● the timing of their publication
●● their indexing in databases.
Studies in which interventions are not found to be effective, are 
less likely to be published or they are published in less accessible 
formats. Publication bias may also involve studies that report 
certain positive effects that go against strong prevailing beliefs. 
Publication bias 
is said to arise 
when the likelihood 
of publication of 
studies and thus 
their accessibility to 
reviewers is related 
to the significance 
of their results 
regardless of their 
quality.
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Systematic reviews that fail to identify such studies will inevitably 
exaggerate or underestimate the effect of an intervention and 
this is when publication bias arises. Thus the use of a systematic 
approach to track down less accessible studies is crucial for 
avoiding bias in systematic reviews. Hopefully in the future, with 
prospective registration of primary studies, there will be less 
concern about overlooking studies. Until this happens, it will be 
necessary to search hard to protect reviews against publication bias. 
In Step 4 we see how the risk of publication and related biases can 
be investigated in a review using a funnel plot analysis (Box 4.8). 
2.4.1  Searching multiple databases 
There is evidence that limiting the search to only a few databases 
tends to bias the review. We need to cast as wide a net as possible 
to capture as many citations as possible. Case studies 2 and 3 
demonstrate the great lengths serious reviewers can go to when 
searching for citations. Similarly, if our review is to be taken 
seriously, we will have to search multiple (overlapping) sources of 
citations. 
2.4.2  Language restrictions in study 
selection
There is no good reason for excluding articles published in 
languages that we cannot read or understand. There is increasing 
evidence that studies with positive findings are more likely to 
be published in English language journals. Studies with negative 
findings from non-English speaking countries are frequently 
published in local language journals. Therefore positive studies 
are more likely to be accessed if searches are limited to the 
English language, thereby introducing bias. In addition, language 
restrictions may decrease the precision of the summary effect 
in our meta-analysis. For these reasons it may be helpful to find 
some interpretation facilities. If our review is registered with a 
relevant Cochrane Review Group, there might be help available for 
dealing with foreign language papers. Otherwise we may have to 
tackle this issue by obtaining access to translation facilities or by 
asking other people to extract the necessary data for us. Sorry, but 
there is no easy way out.
Summary of Step 2: Identifying 
relevant literature
Key points about appraising review articles
●● Examine the methods section to see if the searches appear to be 
comprehensive:
 - check if search term combinations follow from the question
 - list the resources (e.g. databases) searched to identify primary 
studies 
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 - have any relevant resources been left out? 
 - were any restrictions applied by dates, language, etc? 
●● Were the selection criteria set a priori? How reliably were they 
applied?
●● Have analyses been conducted to examine for the risk of 
publication and related biases? (see Step 4)
●● How likely is it that relevant studies might have been missed? 
And what is the potential impact on the conclusions of the 
review?
Key points about conducting reviews
●● The search for studies should be extensive and the selection 
process should minimize bias.
●● The search term combination should follow from the question 
and it should be designed to cast a wide net for capturing 
as many potentially relevant citations as possible. Multiple 
resources (both computerized and printed) should be searched. 
Searches undertaken at the beginning may have to be updated 
towards the end of the review, depending on the length of time 
taken to review.
●● A systematic approach to citation management should be used 
to manage the review efficiently.
●● Study selection criteria should flow directly from the review 
questions; they should be set a priori and should be piloted to 
check that they can be reliably applied. 
●● When sifting through the citations, selection criteria should be 
applied liberally to retrieve full manuscripts of all potentially 
relevant citations. 
●● Final inclusion/exclusion decisions should be made after 
examination of the full manuscripts. Reasons for inclusion and 
exclusion should be recorded.
●● Language restriction should not be applied in searching or in 
study selection.
●● Duplicate independent assessments of citations and manuscripts 
should be performed to reduce the risk of errors of judgement 
in the study selection. 
●● If feasible, an analysis should be undertaken to explore for the 
risk of publication and related biases (see Step 4).
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●● Step 3: Assessing the 
quality of the literature
It cannot be emphasized enough that the quality of the studies 
included in a systematic review is the ‘Achilles’ heel’ behind its 
conclusions. Therefore we should consider study quality at every 
Step in a review. The quality of a study may be defined as the 
degree to which it employs measures to minimize bias and error 
in its design, conduct and analysis. We have briefly considered the 
importance of study design as a general marker of study quality 
when framing questions (Step 1) and selecting studies (Step 2). 
This approach helps to crudely define the weakest acceptable study 
design, thereby guaranteeing a minimum level of quality.
Once studies of a minimum acceptable quality (based on 
design) have been selected, an in-depth critical appraisal will allow 
us to assess the quality of the evidence in a more refined way. 
Step 3 explains how to develop and use checklists for detailed 
assessments of selected studies for their quality. These refined 
and detailed quality assessments will be used later in evidence 
synthesis (Step 4) and interpretation (Step 5). In this way, the 
checklists will help judge the strength of the evidence collated 
in a review. In this Step we will focus on quality assessment of 
studies on effectiveness of interventions. The case studies section 
of this book gives details of quality assessment of studies on safety 
of interventions (Case study 2), accuracy of tests (Case study 4), 
qualitative research (Case study 5), educational effectiveness (Case 
study 6) and adverse effects of drugs (Case study 8).
3.1  Development of study quality 
assessment checklists
Quality assessment will usually be based on an appraisal of 
individual aspects of a study’s design, conduct and analysis 
(often called quality items) – evidence of deficiencies may 
raise the possibility of bias. We can find quality items in one of 
the many published guides on critical appraisal of healthcare 
literature (see users’ guides to evidence-based practice at www.
cche.net/usersguides/main.asp). These guides are usually written 
for supporting evidence-based practice and provide advice on 
appraisal of individual studies according to the nature of the 
clinical query, which we delineate when framing our question 
(Step 1). The items in these guides can be used as a basis for 
developing a checklist to perform an in-depth appraisal of the 
quality of each study included in a review.
There are many published quality assessment checklists for use 
in systematic reviews; but beware, most have not been developed 
with scientific rigour. A whole range of quality items is emphasized 
Systematic error 
(or bias) leads to 
effects departing 
systematically, either 
lower or higher, 
from the ’true’ 
effect. 
Random error is 
due to the play of 
chance and leads 
to effects being 
imprecise (wide 
confidence intervals). 
Bias either 
exaggerates or 
underestimates 
the ‘true’ effect of 
an intervention or 
exposure.
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Ø
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Ø
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Ø
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in the various checklists but some items may not be related to 
bias. By assigning numerical values to items, some checklists create 
a scale in an attempt to provide an overall quantitative quality 
score for each study. Many checklists neatly classify studies into 
low or high quality subgroups based on their compliance with the 
quality items. If we took a leap of faith and randomly selected one 
of these published quality checklists for our review, we might find 
ourselves in trouble. On closer examination we might find that not 
all items in the checklist were relevant to our review, and some 
relevant items were not part of the checklist. For instance, blind 
outcome assessment is emphasized in most checklists. Blinding 
might be of marginal importance for an unambiguous outcome 
such as mortality, but it is fundamental in the assessment of 
subjective outcomes such as pain. The numerical values assigned to 
the items for scoring quality may not be suitable for every review; 
the same is true of the arbitrariness in the criteria recommended 
for the low–high dichotomy. It is even possible that variation in 
Box 3.1 Study quality assessment in a systematic review
1) Define the question and the selection criteria:
●● Consider the nature of the questions being posed
●● Consider the types of relevant study designs 
●● Determine a quality threshold (study design threshold) which defines the weakest 
acceptable design for selection (Step 2)
2) Develop or select a quality checklist
Identify a suitable existing checklist for your review topic. If one does not exist, develop 
a new quality checklist considering relevant quality items grouped as follows:
●● Generic items related to relevant study designs depending on the nature of the review 
question (usually obtained from published critical appraisal guides or existing quality 
checklists) 
●● Specific items related to the populations, interventions and outcomes of the review 
question
3) Examine the reliability of checklist use:
●● Assess the reliability of the checklist in a pilot phase before applying it to all the 
selected studies
4) Incorporate the quality assessments into the systematic review
We may use the quality assessment for all or some of the following:
●● To describe the quality of studies included in a review
●● To explore quality differences as an explanation for the variation in effects from 
study to study (Step 4)
●● To make decisions regarding pooling the effects observed in included studies (Step 4) 
●● To aid in determining the strength of inferences (Step 5)
●● To make recommendations about how future studies could be performed better
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the choice of checklist might produce different quality assessments 
for the same studies. Getting worried? Who would not.
With this background, it should be clear that the published 
guides on critical appraisal of studies for evidence-based practice 
or on study quality assessment for systematic reviews are mostly 
of a generic nature. Ultimately, it is our responsibility to adapt 
them to our review by considering the issues specific to our 
questions. If we are lucky, existing reviews on the same topic 
may have already developed a suitable quality checklist. In this 
situation re-invention would be pointless and using an existing 
checklist would also enhance comparability with other reviews 
on our topic. On the other hand, if there are no suitable existing 
checklists, we will have to develop one. We will need to identify 
the individual items for assessing quality carefully and judiciously. 
How can we recognize which items are important for our review? 
Studies relevant to the review question may be susceptible to 
specific biases related to the way in which they are conducted and 
the data they analysed. Therefore, we will have to be prepared to 
modify a relevant generic quality checklist, including appropriate 
additional items and deleting irrelevant ones. Following the 
approach shown in Box 3.1, the examples in Boxes 3.3 and 3.4, 
and the demonstrations in the case studies, we should be able to 
develop a reasonable quality assessment checklist for our review. 
3.1.1  Key biases in research addressed 
by generic quality assessment items 
There are many generic biases that reviewers need to consider 
when developing quality assessment checklists. Bias has been 
defined as a tendency in research to produce results that depart 
systematically from the ‘true’ results. There are several types 
of biases. Here we shall consider four key biases which impact 
on the (internal) validity of a study. These are selection bias, 
performance bias, measurement bias and attrition bias (Box 3.2). 
Ideally, researchers should try to avoid these biases altogether in 
primary studies, but we know that they don’t. Therefore a very 
good understanding of these issues must be developed in order to 
be able to discover biases during study quality assessment in our 
review. Our efforts may be made difficult or even impossible due 
to the poverty of reporting in some studies.
A simple study design for an effectiveness study is shown in Box 
3.2. An important requirement for valid results in these studies is 
that the comparison groups should be similar at the beginning. 
This is because when there is imbalance of relevant prognostic 
features between groups, it becomes difficult for differences 
in outcomes to be confidently attributed to the intervention. 
Technically speaking, this is due to confounding. It is at the time 
of allocating participants to groups that selection bias arises and 
it is important to check if appropriate measures were designed 
and implemented to prevent or minimize it. Experimental studies 
An index of study 
quality assessment 
checklists in this 
book:
Box   Study subject
C2.2  Safety of 
interventions 
C3.3  Effectiveness 
of 
interventions
C4.3  Accuracy of 
tests
C5.2  Qualitative 
research 
C6.3  Medical 
education 
research
Bias either 
exaggerates or 
underestimates 
the ‘true’ effect of 
an intervention or 
exposure.
The (internal) 
validity of a study 
refers to the degree 
which its results are 
likely to be free of 
bias.
Confounding 
is a situation in 
comparative studies 
where the effect 
of an intervention 
on an outcome is 
distorted due to 
the association 
of the population 
and  the outcome 
with another 
factor, which can 
prevent or cause 
the outcome 
independent of the 
intervention.
42 Systematic Reviews to Support Evidence-based Medicine
using random allocation of participants (with concealment of 
allocation sequence) produce comparison groups that are expected 
to be balanced for known, unknown and unmeasured prognostic 
variables. This is the main reason why there has been an emphasis 
in reviews to focus on randomized trials. 
Following the allocation of participants to groups, performance 
bias may arise due to unintended interventions or co-interventions 
(e.g. other treatments which are not part of the research). We need 
to assess if the care plans were standardized and if the researchers 
and the participants were kept blind to the group allocation. 
We also need to examine if there was a risk of measurement 
bias, particularly if the outcomes assessed were subjective, and 
if the participants and researchers involved in ascertaining the 
outcomes were not blind to group allocation. In this way blinding 
is important for preventing both performance and measurement 
bias. 
For preventing attrition bias, an intention-to-treat (ITT) analysis 
is needed, and it requires data for all patients. Participants’ 
outcomes are analysed according to their initial group allocation, 
regardless of whether they fully complied with the intervention, 
changed their intervention group during the study or dropped 
out of the study before its completion. If the selected studies do 
not perform their analysis in this way, we may be able to do the 
calculation ourselves, provided a complete description (numbers 
and reasons) of the withdrawals is available, including information 
on both the people who dropped out and those lost to follow-
up. If participants withdraw from the study and their outcome 
is unknown, there is no satisfactory way to perform the analysis. 
The options available include carrying forward the last outcome 
assessment or imputing the best or worst outcome for the missing 
observations in a sensitivity analysis. Thus, if too many participants 
are lost to follow-up, the analysis may produce biased effects.
In an intention-to-
treat (ITT) analysis, 
subjects are analysed 
according to 
their initial group 
allocation, regardless 
of whether they 
fully complied with 
the intervention, 
changed their 
intervention group 
after initial allocation 
or left the study 
early. 
Withdrawals are 
participants or 
patients who do not 
fully comply with the 
intervention, cross 
over and receive 
an alternative 
intervention, choose 
to drop out or are 
lost to follow-up. 
Intention-to-
treat analysis with 
an appropriate 
sensitivity analysis 
is required to deal 
with withdrawals.
Box 3.2 Key biases and their relationship to the design and 
the quality of a study
A study design to assess the effectiveness of interventions
Simple description 
A study that allocates (with or without randomization) subjects from a relevant 
population to alternative interventions and follows them up to determine the 
effectiveness with which interventions improve the outcome.
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Study flow chart with key biases
Selection bias
generation of random
allocation sequence
concealment of allocation
Performance bias
standardization of care plan
blinding of care providers
and participants or patients
Measurement bias
binding of outcome
assessors and participants
Study sample
Allocation of
participants to groups
(randomization)
Estimate of effect
Control group
(e.g. usual care)
Experimental group
(e.g. new intervention)
Outcome
present
Outcome
absent
Outcome
present
Outcome
absent
Follow-upFollow-up
Attrition bias
description of withdrawals
intention-to-treat analysis
Key biases and their implications for study quality assessment
Type of bias Relevant generic quality items
Selection bias
Systematic differences between 
comparison groups in prognosis or 
responsiveness to treatment.
●● Generation of random sequence for 
allocating (large number of) participants 
to groups
●● Concealment of allocation from care 
providers and participants (this can be 
done in unblinded studies)
Performance bias
Systematic differences in care provided 
apart from the intervention being 
evaluated.
●● Standardization of care protocol 
●● Blinding of clinicians and participants
Measurement bias
Systematic differences between 
comparison groups in how outcomes are 
ascertained.
●● Blinding of participants and outcome 
assessors
Attrition bias
Systematic differences between 
comparison groups in withdrawals from 
the study.  
●● Intention-to-treat analysis (or a 
complete description of withdrawals to 
allow such an analysis)
See Box 3.4 for generic quality items based on these biases
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Box 3.3 shows how key generic biases can be considered along 
with biases arising from issues specific to a review concerning the 
effectiveness of a treatment for infertility. In this example, good 
quality research requires that couples have a complete set of 
investigations for infertility before the interventions are provided, 
and that they are followed up for long enough to allow detection 
of pregnancy. In this way it would be possible to assess if the 
treatment led to pregnancies more often than the control without 
the biasing influences of poor diagnostic work-up for infertility 
and inadequate length of follow-up. These issues are considered 
along with the generic key biases to produce a checklist for study 
quality assessment (see Boxes 3.3 and 3.5). 
As indicated earlier, the biases related to selection, performance, 
measurement and attrition are some of the key biases, and they 
pertain mainly to questions about effectiveness. If our question is 
about accuracy of tests (Case study 4) or cost-effectiveness (Box 
3.4) or some other aspect of healthcare, we will have to consider 
the biases relevant to these research types for our quality checklist.
Sensitivity analysis 
involves repetition 
of an analysis 
under different 
assumptions 
to examine the 
impact of these 
assumptions on the 
results. In a primary 
study where there 
are withdrawals, 
a sensitivity analysis 
may involve 
repeating the 
analysis, imputing 
the best or worst 
outcome for the 
missing observations 
or carrying forward 
the last outcome 
assessment. 
Box 3.3 Example of developing a study quality assessment 
checklist in an effectiveness review
1) Define the clinical question and the selection criteria
Free form question: Among infertile couples with subfertility due to a male factor, 
does anti-oestrogen treatment increase pregnancy rates? (see structured question in 
Box 3.5)
2) Define the selection criteria
●● Nature of question  Assessment of clinical effectiveness
●● Study design Comparative studies (see Box 1.4)
●● Study design threshold  Inclusion criterion: experimental studies
 Exclusion criterion: observational studies
3) Develop the study quality checklist
a) Generic quality items for the checklist (see Box 3.4)
Generation of a random sequence for allocating the patients to the 
interventions
●● Adequate 
 - computer-generated random numbers or random number tables 
●● Inadequate 
 - use of alternation, case record numbers, birth dates or week days
●● Unclear or unstated
Concealment of allocation
●● Adequate 
 - centralized real-time or pharmacy-controlled randomization in unblinded studies, 
or serially numbered identical containers in blinded studies 
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 - other approaches with robust methods to prevent foreknowledge of the 
allocation sequence to clinicians and patients
●● Inadequate 
 - use of alternation, case record numbers, birth dates or week days, open random 
numbers lists, or serially numbered envelopes (even sealed opaque envelopes can 
be subject to manipulation)
●● Unclear or unstated
Blinding
●● Adequate 
 - care provider and study patients 
●● Inadequate 
 - care provider or study patients 
●● Unclear or unstated
Description of withdrawals (to allow an intention-to-treat [ITT] analysis)
●● Adequate 
 - inclusion of all those who dropped out/were lost to follow-up in the analysis
 - numbers and reasons provided for each group
 - description allows analysis following the ITT principle 
●● Inadequate 
 - only numbers (not reasons) provided for each group
 - description does not allow an analysis following the ITT principle 
●● Unclear or unstated
b) Specific quality items related to the clinical features of the review question
The population  Complete diagnostic work-up for infertility
The interventions  No relevant items
The outcome One year follow-up duration to detect pregnancy
4) Incorporate the quality assessments into the review
Some examples of the above quality assessment are as follows:
●● To describe the quality of studies included in the review (see Box 3.5)
●● To aid in determining the strength of inferences (see Box 4.7)
3.2  Study quality assessments in 
reviews with a mixture of designs
In the past there has been a strong emphasis for reviews to focus 
on a single study design of the highest quality, i.e. randomized 
controlled trials (Box 1.4). However, reviewers soon realized that 
for many important questions, studies of high quality designs were 
often not available (Case study 2) or they were scarce (Case study 
3). This is either because no one undertook such studies in the 
past or if they did try, it was not practicable or ethical to conduct 
them. When there is a dearth of studies with a high quality design, 
it is not uncommon for reviews to include a mixture of designs to 
summarize the available evidence. This approach carries problems 
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Box 3.4 Example of developing a study quality assessment 
checklist in a review with multiple questions
1) Define the question and the selection criteria
Free form question: To what extent is the risk of post-operative infection reduced by 
antimicrobial prophylaxis, in patients undergoing hip replacement and is it worth the 
costs? (see structured question in Box 1.3)
●● Nature of question  Assessment of clinical effectiveness
 Assessment of cost-effectiveness (or efficiency)
 - cost-effectiveness can be assessed by (a) review of all 
available full economic evaluations, (b) a review of 
effectiveness studies in conjunction with any available 
cost sources, and (c) a secondary economic evaluation 
using the evidence from the effectiveness review to 
build an economic decision model. In this example, we 
consider quality assessment for option (a).
●● Study design Effectiveness: Experimental studies 
 Cost-effectiveness: Full economic evaluations
●● Study design threshold  Effectiveness: (see Box 1.4)
 - inclusion criterion: Experimental studies
 - exclusion criterion: Observational studies 
 Cost-effectiveness: (see glossary)
 - inclusion criterion: Cost-effectiveness analyses 
 - exclusion criterion: Partial economic evaluations
2) Develop the study quality checklist
Some generic quality items for checklists
●● Clinical effectiveness review
 - random allocation of patients to groups
 - concealment of allocation sequence
 - pre-specified criteria for eligibility of patients
 - similarity of groups at baseline regarding prognostic factors
 - blinding of care providers, patients and outcome assessors
 - an intention-to-treat analysis
●● Cost-effectiveness review
 - a comprehensive description of alternative interventions
 - identification of all important and relevant costs and outcomes for the 
interventions
 - use of established evidence of clinical effectiveness, i.e. intervention known to 
improve outcome
 - costs and outcomes measured accurately and valued credibly
 - costs and outcomes adjusted for differential timing
 - an incremental analysis of costs and outcomes
 - sensitivity analyses for uncertainty in costs and outcomes
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Box 3.5 Example of tabulation and graphic presentation of 
study quality assessment
Free form question: Among infertile couples with subfertility due to a male factor, 
does anti-oestrogen treatment increase pregnancy rates?
Structured question
●● The population Couples with subfertility due to a male factor (low sperm count)
●● The interventions   Anti-oestrogen treatment (clomiphene citrate or tamoxifen) for 
the male partner
  Comparator: placebo, no treatment, or vitamin C
●● The outcomes Pregnancy (critical)
●● The study design Experimental studies
Tabulation of study quality
Information about quality items can be placed in columns with the studies in rows 
(sorted according to year of publication).
Author Year Randomization Blinding Descripton of
withdrawals
Population
complete
work-up
Outcome
1-year long
follow-up
Rank order
of quality*Sequence
generation
Concealment
Roonberg
Abel
Wang
Torok
Micic
AinMelk
Sokol
WHO
Karuse
1980
1982
1983
1985
1985
1987
1988
1992
1992
Unstated
Unclear
Unclear
Unclear
Unclear
Unclear
Adequate
Adequate
Unclear
Unstated
Unclear
Unclear
Unclear
Unclear
Unclear
Adquate
Adequate
Unclear
Unclear
Inadequate
Inadequate
Unclear
Inadequate
Unclear
Adequate
Adequate
Inadequate
Adequate
Adequate
Unclear
Unclear
Unclear
Unclear
Unclear
Adequate
Unclear
Adequate
Unclear
Adequate
Inadequate
Inadequate
Inadequate
Adequate
Adequate
Inadequate
Inadequate
Inadequate
Adequate
Adequate
Inadequate
Inadequate
Adequate
Inadequate
Inadequate
3
4
6
5
9
8
1
2
7
* see text for an explanation
Bar chart of study quality
Information on quality presented as 100% stacked bars. Data in the stacks represents 
the number of studies meeting the quality criteria
2
2
2 3
7
7
4
6
41
6
3
3
4
0% 25% 50% 75% 100%
Yes Unclearly reported No
Compliance with quality items
Generic quality items
Adequate random sequence generation  
Adequate allocation concealment  
Blinding  
Description of withdrawals  
Specific quality items
Complete diagnostic work-up  
Adequate follow-up duration to detect pregnancies  
Based on Arch Intern Med 1996; 156(6): 661–6.
See Box 4.7 for use of study quality assessment in exploring heterogenity.
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in evidence synthesis (Step 4) and interpretation (Step 5). However, 
reviews including studies with multiple designs need not be 
confusing, particularly if due attention can be given to the quality 
assessment issues. 
When using the approach described in Box 3.1 we might find 
that in some reviews, where the question demands studies of 
various designs to be included, the quality assessment will not be 
so straightforward. A mixture of studies with different designs may 
become part of a review because more than one design is needed 
to address the same question or because more than one question 
is to be addressed. Case study 3 presents an example where studies 
of both experimental (randomized and non-randomized) and 
observational (cohort study with concurrent controls) designs are 
included in a review to address a question about effectiveness. 
Here it is possible to develop and use a single checklist for quality 
assessment (Boxes C3.3 and C3.4). Some reviewers prefer to use 
separate checklists for different designs and this is the most 
reasonable approach in some situations; for example, when a 
review addresses two separate but related questions, e.g. about 
clinical effectiveness and efficiency of an intervention. This is like 
having two reviews in one. Here different quality assessments will 
have to be developed for the different study designs relevant to 
the two questions, as shown in Box 3.4. 
3.3  Reliability of the study quality 
checklist in a review 
The evaluation of quality items is very often affected by vague 
and ambiguous reporting in the selected studies. In order to avoid 
subjectivity and errors when extracting information about quality, 
the review protocol should provide a clear description of how to 
assess quality. This would mean designing data extraction forms 
with clear and consistent coding of responses. Ideally the forms 
should be piloted using several reviewers and a sample of studies 
to assess the reliability of the quality assessment process. Pilot 
testing might identify confusion about the extraction and coding 
instructions, which would then need to be clarified – a more 
explicit system of coding would improve inter-reviewer agreement. 
In the past, people have suggested blinding the reviewers to the 
names of the authors, institutions, journals and year of publication 
when assessing quality. This should avoid bias as judgements about 
quality may be unduly influenced by these factors. Therefore some 
reviewers go to great lengths to have such identifying information 
masked before examining the manuscripts. However, the 
cumbersome and time-consuming procedures required to produce 
blinded papers have not been shown to impact on the conclusions 
of reviews and unmasked independent quality assessment by more 
than one reviewer should be sufficient. By now it should be quite 
clear that it is unwise to undertake a review without co-authors.
Efficiency (cost-
effectiveness) is the 
extent to which the 
balance between 
input (costs) and 
outputs (outcomes) 
of interventions 
represents value for 
money. 
Effectiveness is 
the extent to which 
an intervention 
(therapy, prevention, 
diagnosis, screening, 
education, 
social care, etc.) 
produces beneficial 
outcomes under 
ordinary day-to-day 
circumstances.
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3.4  Using study quality assessments 
in a review 
Having developed our checklist and extracted the relevant data 
on quality assessment, we are ready to integrate this information 
in our review (Box 3.1). How would we describe the quality of 
the studies? There are many imaginative ways of presenting 
information about how the studies included in a review have 
complied with the quality items. Examples of quality description 
are shown in the case studies. We may start by describing how 
many studies meet the various quality criteria and support this 
with graphs, e.g. using stacked bar charts (Box 3.5). However, 
tabulation of the information on quality items for each one of the 
included studies is the clearest way to describe quality (Box 3.5). 
One difficult issue in quality assessment is that of ranking 
studies according to their quality. A simple way is to rank studies 
according to the proportion of total items they comply with. 
When studies satisfy the same proportion of quality items, but are 
deficient in different areas, there is a problem. Here the deficient 
areas should guide us about the rank: studies with deficiencies in 
areas with a greater potential for bias (e.g. lack of concealment of 
allocation) should be ranked lower than those with deficiencies in 
areas with a smaller risk (e.g. deficiencies in allocation sequence 
generation). Weighting of items has been proposed but there 
are no agreed weighting schemes that apply universally. This is 
because the importance of quality items varies from topic to topic. 
For example, blinding is highly crucial in studies with subjective 
outcomes, but not so much in those with objective outcomes. 
Reviewers have to use their judgement when ranking studies 
according to quality in the context of their topic. For example, in 
a review concerning effectiveness of a treatment for infertility 
(Box 3.5), two studies (Sokol and WHO) comply with five out 
of six quality items. Sokol is ‘unclear’ about its description of 
withdrawals and WHO has not followed participants up for one 
year (in fact they only followed up to 8 months). If we feel that 
adequacy of follow-up is more important than lack of clarity 
about the description of withdrawals, then we can rank Sokol 
higher than WHO. This subjectivity cannot be removed from 
reviewing, so it is important that judgements are made before 
the results of the studies are known. This example should also 
make it clear that there are limits to how detailed judgements 
can be. Often it is impossible to have a sensible ranking of studies 
according to quality and one may have to settle for a more crude 
categorization, e.g. high versus low quality studies, as in Case 
study 2. Having performed quality assessments in a sensible (and 
unbiased) manner, one can confidently proceed to data synthesis 
(Step 4), interpretation of results and generation of inferences 
(Step 5) where variation in the quality of the selected studies may 
have important implications. We see examples of how strength of 
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evidence is linked to study quality assessment in Box 5.3 and Case 
studies 7 and 8. 
Summary of Step 3: Assessing 
quality of the literature
Key points about appraising review articles
●● Examine the methods section to see if a study quality 
assessment has been undertaken.
●● Has quality been used as a criterion for study selection? (Step 2)
●● Has a more detailed assessment of the selected studies been 
carried out? Are the quality items appropriate for the question? 
Check the results section and the tables to see how much 
variation in quality there is between studies.
●● Is the variation in quality an explanation for heterogeneity? Is 
meta-analysis appropriate given the quality? (Step 4)
●● Is the strength of the collated evidence linked to quality? 
(Step 5)
Key points for conducting reviews
●● Obsession with quality is the ‘Achilles’ heel’ of all research 
studies and reviews. Study quality assessment plays a role in 
every Step of a review.
●● Question formulation (Step 1) and study selection criteria 
(Step 2) should have study design components in them to 
determine the minimum acceptable level of study quality.
●● For a more refined quality assessment of selected studies, 
checklists should be developed which consider the generic issues 
relevant to the study design aspects of the review question. 
These items may be derived from existing critical appraisal 
guides and design-based quality checklists.
●● It is important to consider issues relevant to the populations, 
interventions and outcomes specific to the question. Considering 
these specific issues, the existing generic items may be modified 
or deleted and new relevant items may be added to the quality 
checklists.
●● These detailed quality assessments will be used for describing 
the selected studies, exploring an explanation for heterogeneity 
(Step 4), making informed decisions regarding suitability of 
meta-analysis (Step 4), assessing the strength of the collated 
evidence (Step 5) and making recommendations for future 
research.
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●● Step 4: Summarizing 
the evidence
Collating the findings of studies included in a review requires 
more than just tabulation and meta-analysis of their results. 
It requires a deeper exploration and an in-depth analysis, for 
which the findings need to be presented in a clear way. We need 
to evaluate whether the observed effects of interventions are 
consistent among the included studies, and if not, why not? We 
need to assess if a statistical combination of individual effects 
(meta-analysis) is feasible and appropriate. These analyses allow 
us to generate meaningful conclusions from the reviews. This Step 
covers the basics of producing evidence summaries in systematic 
reviews, limiting the discussion to questions about the effects of 
interventions or exposures on binary outcomes. Once the principles 
are understood, they can be applied with appropriate tailoring to 
other question types (see Case studies 4, 5 and 6).
4.1  Description of data contained in 
the included studies
To begin with, a descriptive summary of the findings of studies 
included in a review is required. In simple terms, the objective 
of this initial exercise is to present (in a meaningful way) 
the information about studies’ characteristics (populations, 
interventions and outcomes), their design and quality, and their 
effects. There is no need to use any advanced statistics at this 
stage. We may use tables, figures and simple computations, 
such as proportions, relative risks, etc, which allow us to glance 
at the evidence and to glean the differences between studies. 
This is a crucial part of evidence synthesis; it will help us gain a 
deeper understanding of the evidence and should prevent errors 
in interpretation. It will also enhance the transparency of our 
analysis. 
When faced with large amounts of data to be summarized, 
tabulation can be a daunting task. The process of carrying out the 
tabulations should follow from the review question. The nature 
and complexity of the table depends a great deal on how many 
studies are included and how much data needs to be displayed 
from each. The decisions about the structure of the tables should 
be guided by what we considered to be important issues at 
the time of question formulation and what, in our judgement, 
could produce a variation in effects (as outlined in Step 1). So, 
for example, information may be tabulated with studies in rows 
grouped according to a characteristic of the population. Then 
information on interventions, outcomes and effects for each 
study could be summarized succinctly (Box 4.1). Information on 
Effect is a measure 
of association 
between an 
intervention or 
exposure and an 
outcome. The 
term individual 
effects means 
effects observed in 
individual studies 
included in a 
review. Summary 
effect means the 
effect generated by 
pooling individual 
effects in a meta-
analysis. 
Step 1 
Framing questions
Ø
Step 2 
Identifying relevant 
literature
Ø
Step 3 
Assessing quality of 
the literature
Ø
Step 4 
Summarizing the 
evidence
Ø
Step 5 
Interpreting the 
findings
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outcomes should make clear the importance attached to each 
outcome separately.
Sometimes tables will end up with too many columns to fit 
on one page. In this situation it is often helpful to breakdown 
the tabulation into several tables. We may produce one detailed 
table of population characteristics and relevant prognostic factors; 
another table may include details of interventions and yet another 
for details of outcomes. The features of study designs and other 
Box 4.1 Tabulating information from studies included in a 
systematic review
Suggested steps
1. Place features related to populations, interventions and outcomes in columns.
2. Consider what subgroups of populations there are among included studies.
3. Consider what subtypes of interventions there are.
4. Consider the outcomes and their importance.
5. Consider if studies need to be subclassified according to study designs and quality.
6. Populate the cells in the table with information from studies along rows in 
subgroups.
7. Sort studies according to a feature that helps to understand their results (e.g. 
a characteristic of a population or intervention, rank order of quality, year of 
publication, etc).
An example of tabulation of studies in a review of antimicrobials for chronic 
wounds 
This is only a brief tabulation. Detailed tables can be found in the report of the review 
available at www.hta.nhsweb.nhs.uk/htapubs.htm
Population subgroups Interventions Outcome 
Control group
(standard/placebo)
Systemic treatments
Topical treatments
Systemic treatments
Topical treatments
Systemic treatments
Topical treatments
Systemic treatments
Topical treatments
Diabetic ulcer
Venous ulcer
Pressure ulcers
Ulcers of mixed aetiology
2. Think! What
2. subgroups of
2. populations are
2. there?
4. Populate
2. studies and
2. their findings
2. along rows in
2. subgroups of
2. populations
2. and
2. interventions
1. Place population,
2. interventions, outcomes
2. and effects in columns
2. next to each other
Experimental group Observation
period
Outcome
measure
Effect estimate
(95% CI)
3. Think! What categories 
2. of interventions and
2. outcomes are there? 
2. What is the importance 
2. of the outcome?
Based on Case study 3 (see Box C3.5)
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aspects of study quality may be presented in a separate table or 
a figure (Box 3.5). Preparation of tables is often laborious and 
time consuming, but without them we cannot understand the 
results of the included studies. Once the hard work is done, a quick 
scan through these tables should allow us, and more importantly 
others, to judge how studies differ in terms of populations, 
interventions, outcomes and quality. 
At this stage, we should also compute and tabulate the effects 
found in each one of the studies along with their confidence 
intervals (Box 4.2). This will help us examine the direction and 
magnitude of effect among the individual studies. By direction of 
effect we mean either benefit or harm. By magnitude we mean how 
much benefit or how much harm. Box 4.3 shows how to evaluate 
direction and magnitude of effect graphically in a Forest plot.
A simple tabulation of numerical results, like the one shown 
in Case study 3 (Box C3.5), is not easy to assimilate at a glance. 
Therefore, it is worth examining effects graphically (Box 4.3). These 
graphic summaries would help us make qualitative judgements 
about the effects of interventions, particularly about the direction, 
magnitude and precision of individual effects. Occasionally, this 
may produce a surprise: a conclusion about effectiveness may 
be reached solely from qualitative examination of the observed 
effects without the need for statistical analysis, particularly if 
there are numerous studies with consistent and large effects. In 
this situation a quantitative synthesis (meta-analysis) may not add 
anything to our inferences. However, often the effects will not be 
precise enough because of a small sample size in individual studies. 
The graphic display will give us a good idea about effectiveness 
but this will not be sufficient to generate inferences. Here, meta-
analysis will be useful, as it will improve the precision of the effect 
by statistically combining the results from individual studies – but 
first we need to assess if the effects vary from study to study 
(heterogeneity) and if it is sensible to undertake a meta-analysis. 
One aim of data description is to assess the extent of the 
evidence in order to plan statistical analyses. We should have 
planned our analyses for heterogeneity and meta-analysis in 
advance, and armed with information from the tables we should 
be able to assess their feasibility. We will be able to see if data on 
clinically important outcomes are available for the interventions we 
wanted to compare. We may become aware of additional issues 
of importance, which were not known at the planning stage. If 
we decide to pursue these issues, we should be honest about 
reporting them as post-hoc analyses and we should be conscious 
of the problems of spurious significance associated with them. 
Our enquiry might be limited due to lack of data or due to missing 
information on important issues. It might be useful to contact 
the authors of individual studies before proceeding further; 
alternatively we could plan a sensitivity analysis to take account of 
the uncertainties due to missing or unclear information.
The direction of 
effect indicates 
a beneficial or a 
harmful effect. 
The point estimate 
of effect tells us 
about direction and 
magnitude of effect. 
The precision 
of effect relates 
to the degree of 
uncertainty in the 
estimation of effect 
that is due to the 
play of chance. The 
confidence interval 
tells us about 
precision. 
Point estimate of 
effect is its observed 
value in a study. 
Confidence 
interval is the 
imprecision in the 
point estimate, i.e. 
the range around 
it within which 
the ‘true’ value of 
the effect can be 
expected to lie with 
a given degree of 
certainty (e.g. 95%).
Confidence interval
Point estimate
Sensitivity analysis 
involves repetition 
of an analysis 
under different 
assumptions 
to examine the 
impact of these 
assumptions on the 
results. 
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Box 4.2 Estimation of effects observed in individual studies 
included in a systematic review
Measures of effect
An effect is a statistic, which provides a measure of the strength of relationship 
between an intervention and an outcome, e.g. relative risk (RR), odds ratio (OR) or 
risk difference (RD) for binary data; mean difference or standardized mean difference 
for continuous data; and hazard ratio for survival data (see glossary). Statistical 
significance tells us nothing about the magnitude of the effect. Effect measures help 
us to make judgements about the magnitude and clinical importance of the effects. 
The term individual effects means effects observed in individual studies included in a 
review. Summary effect means the effect generated by pooling individual effects in a 
meta-analysis.
Computing effect measures for binary outcomes in individual 
studies
Computing point estimates of effects is relatively simple, as shown below. With several 
studies to compute effects for, and to estimate confidence intervals for, every effect 
makes manual calculation tedious. We would suggest you use a statistical software 
package. We have generally used RevMan, the Cochrane Collaboration’s review 
management software, to compute and present results in this book (www.cochrane.org/
cochrane/revman.htm).
Study sample
Allocation of
participants to groups
Experimental group
(e.g. a new intervention)
Experimental event rate, (EER) = a/(a+b)
Experimental odds = a/b
Control event rate, (CER) = c/(c+d)
Control odds = c/d
Control group
(e.g. usual care)
Follow-up Follow-up
Outcome present
a
Outcome absent
b
Outcome present
c
Outcome absent
d
Estimation of effect
Relative risk, (RR) = EER/CER = [a/(a+b)]/[c/(c+d)]
Odds ratio, (OR) = (a/b)/(c/d)
Risk difference, (RD) = EER – CER = [a/(a+b)] – [c/(c+d)]
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Choosing an effect for binary outcomes
The choice depends on the ease of interpretation and statistical properties of the 
effect measure. Clinicians prefer relative risk (RR) and number needed to treat (NNT) 
– which is the inverse of risk difference (RD) – because they are intuitive. Some 
statisticians prefer OR because it is not sensitive to the reversibility of the event 
classification and it is more suitable for statistical manipulation and modelling. RR 
and OR are relative measures of effect and, compared to RD, they tend to be more 
consistent in systematic reviews when studies have considerable variation in control 
event rate. The summary NNT (and summary RD) values generated from meta-analyses 
can be challenging as their meaningful clinical application depends on the knowledge 
of baseline rates in the populations where the results are to be applied (see Step 5). 
We will often be faced with OR in the medical literature. From these we can generate 
NNTs for interpretation as shown in Box 5.4.
Box 4.3 Summarizing the effects observed in studies 
included in a systematic review
Forest plot
This is a commonly used, easy to understand, graphical display of individual effects 
observed in studies included in a systematic review (along with the summary effect 
if meta-analysis is used, as in Box 4.4). For each study, a box representing the 
point estimate of effect lies in the middle of a horizontal line which represents the 
confidence interval of the effect. When using relative risk (RR) or odds ratio (OR) 
as the effect measure, the effects are usually plotted on a log-scale. This produces 
symmetrical confidence intervals around the point estimates. A vertical line drawn at 
an RR or OR value of 1.0 represents ‘no effect’. For desirable outcomes (e.g. pregnancy 
among infertile couples) RR or OR value > 1.0 indicates that the experimental 
intervention is effective in improving that outcome compared to the control 
intervention. However, most reviews report undesirable outcomes (e.g. death) and then 
RR or OR values < 1.0 indicate an advantage for the experimental group. When using 
mean difference the value 0 indicates ‘no effect’. A confidence interval overlapping the 
vertical line of ‘no effect’ represents lack of a statistically significant effect. 
Description of effects and their uncertainty in a systematic review
Free form question: Among infertile couples with subfertility due to a male factor, 
does anti-oestrogen treatment increase pregnancy rates? (see structured question in 
Box 3.5)
The effects observed among nine studies
Effects summarized as RR and OR, sorted by year of publication. Effect values > 1.0 
indicate an advantage for the treatment group compared to control, i.e. pregnancy 
rates improve with anti-oestrogen treatment.
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4.2  Investigating differences in 
effects between studies
There are usually some differences between studies in the key 
characteristics of their populations, interventions and outcomes 
(clinical heterogeneity), and their study designs and quality 
(methodological heterogeneity). These are discovered during 
tabulation of information from the studies. These variations in 
study characteristics and quality are likely to have some infl uence 
on the observed effects. Investigation of heterogeneity is about 
this variation of effects between studies and its reasons. 
We may begin exploring for the possibility of heterogeneity of 
effects between studies by studying the tables we produced earlier. 
However, we will probably get a better idea about heterogeneity 
by visually examining the Forest plot for variations in effects (Box 
4.3). In general, if the point estimates of effects lie on one side 
of the ‘line of no effect’, then the interventions can be expected 
to produce the same qualitative effect, either benefi t or harm. If 
the point estimates are located on both sides of the ‘line of no 
effect’, then they could produce benefi cial and harmful effects (as 
Heterogeneity 
is the variation of 
effects between 
studies. It may 
arise because of 
differences in key 
characteristics of 
their populations, 
interventions and 
outcomes (clinical 
heterogeneity), 
or their study 
designs and quality 
(methodological 
heterogeneity).
Question 
components
The population: 
A clinically suitable 
sample of patients
The interventions: 
Comparison 
of groups with 
and without the 
intervention 
The outcomes: 
Changes in health 
status due to 
interventions
The study design: 
Ways of conducting 
research to assess 
the effect of 
interventions
OR [ 96% CI]
1.08 [0.06, 19.05]
1.33 [0.41, 4.32]
4.66 [0.22, 98.48]
13.79 [0.77, 248.32]
2.20 [0.63, 7.74]
5.69 [0,25, 128.50]
0.12 [0.01, 1.43]
0.80 [0.30, 2.12]
1.88 [0.41, 8.48]
Odds Ratio
Forest Plot
.001 .02  1 50 1000
Point estimate of effect
Effects
sorted by
year of
publication*
Lower limit of confidence interval
Upper limit of confidence interval
Log scale
Line of ‘no effect’
Ronnberg
Abel
Wang
Micic
Torok
AinMelk
Sokol
WHO
Karuse
1.07 [0.07, 15.54]
1.28 [0.46, 3.50]
3.79 [0.23, 62.48]
12.11 [0.71, 206.42]
1.80 [0.69, 4.67]
5.00 [0.26, 96.59]
0.20 [0.03, 1.52]
0.82 [0.34, 1.98]
1.76 [0.45, 6.84]
1980
1982
1983
1985
1985
1987
1988
1992
1992
1/15
6/47
0/7
0/45
5/27
0/16
4/9
10/96
3/39
1/14
7/43
4/18
7/56
9/27
2/16
1/11
8/94
5/37
.001 .02 1 50 1000
Relative Risk
Forest plot
Control group
n/N RR [95% CI] Year
Treatment group
n/NStudy
Based on Arch Intern Med 1996; 156: 661–666
Review manager software used to compute effects and produce graphics (http://www.
cochrane.org/cochrane/revman.htm). It is developed by the Cochrane Collaboration 
and is available as a free download. Technical support is provided only for Cochrane 
reviewers
*See Box 4.7 for a Forest plot with studies sorted according to rank order of quality
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in Box 4.3). Clearly this should raise suspicion about heterogeneity. 
We should also see if the confidence intervals of the effects 
overlap each other. If they do, as in Box 4.3, then it is more likely 
that any differences in the point estimates of effects are merely 
due to chance or indicate only limited heterogeneity, which is 
unavoidable. 
Formal statistical tests for heterogeneity examine if the 
observed variability in effects is compatible with that expected 
to occur by chance alone. The chi-square test for heterogeneity 
among the effects shown in Box 4.3 has a p-value of 0.36 – well 
above the conventional threshold of p < 0.05. These tests tend 
to have low power so they might miss important between-study 
differences in effects. It has therefore been suggested that a less 
stringent threshold of p < 0.1 should be used to statistically assess 
heterogeneity. The formal assessment with the p-value has a 
serious drawback. The underlying chi-square statistic which leads 
to the p-value, let’s call it Q, has no intuitive meaning. Q increases 
as the number of included studies, k, increases. To have a more 
appropriate tool for the assessment of heterogeneity, I2 = (Q - 
(k-1))/Q has been introduced. I2 is interpreted as the proportion 
of the existing variability due to heterogeneity between studies. 
I2 ranges between 0% and 100%; 0% indicates no observed 
heterogeneity, and larger values show increasing heterogeneity. 
Values of 25%, 50% and 75% may be taken to represent low, 
moderate and high levels of heterogeneity. With I2 dependence on 
the number of included studies is avoided. However, I2 still hinges 
on the precision of the studies, or in other words, on the size of 
the studies. This limits the use of I2 when comparing values across 
meta-analyses with different study sizes.
Assessment of heterogeneity is a challenge in synthesis of 
studies. There remain many disputes between methodologists 
about interpretation of heterogeneity statistics and details of 
these are beyond the scope of this book. A reasonable approach 
would be to evaluate both informal, non-statistical assessment of 
heterogeneity (e.g. with the Forest plot) and the I2 statistic without 
reliance on p-values alone. Whenever we suspect substantial 
heterogeneity, we should seek an explanation, whether or not 
heterogeneity is statistically confirmed. We will turn to exploring 
reasons for heterogeneity shortly, but first we take a look at the 
basics of meta-analysis.
4.3  Meta-analysis (quantitative 
synthesis) of effects observed in 
studies
As indicated earlier, individual studies may be far too small 
to produce precise effects and so meta-analysis can improve 
precision by combining them statistically. First we must determine 
Power is the 
ability of a test 
to statistically 
demonstrate a 
difference when one 
exists. When a test 
has low power, a 
larger sample size is 
required, otherwise 
there is a risk that a 
possible difference 
might be missed. 
I2 is a statistic 
ranging from 0% 
to 100% that gives 
the percentage 
of total variation 
across studies due to 
heterogeneity. 
Meta-analysis is a 
statistical technique 
for combining the 
individual effects of 
a number of studies 
addressing the same 
question to produce 
a summary effect.
4.2  Investigating differences in 
effects between studies
There are usually some differences between studies in the key 
characteristics of their populations, interventions and outcomes 
(clinical heterogeneity), and their study designs and quality 
(methodological heterogeneity). These are discovered during 
tabulation of information from the studies. These variations in 
study characteristics and quality are likely to have some influence 
on the observed effects. Investigation of heterogeneity is about 
this variation of effects between studies and its reasons. 
We may begin exploring for the possibility of heterogeneity of 
effects between studies by studying the tables we produced earlier. 
However, we will probably get a better idea about heterogeneity 
by visually examining the Forest plot for variations in effects (Box 
4.3). In general, if the point estimates of effects lie on one side 
of the ‘line of no effect’, then the interventions can be expected 
to produce the same qualitative effect, either benefit or harm. If 
the point estimates are located on both sides of the ‘line of no 
effect’, then they could produce beneficial and harmful effects (as 
Heterogeneity 
is the variation of 
effects between 
studies. It may 
arise because of 
differences in key 
characteristics of 
their populations, 
interventions and 
outcomes (clinical 
heterogeneity), 
or their study 
designs and quality 
(methodological 
heterogeneity).
Question 
components
The population: 
A clinically suitable 
sample of patients
The interventions: 
Comparison 
of groups with 
and without the 
intervention 
The outcomes: 
Changes in health 
status due to 
interventions
The study design: 
Ways of conducting 
research to assess 
the effect of 
interventions
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if meta-analysis is at all possible, and if so, whether it would be 
appropriate. By examining the tables produced for describing 
the studies we will be able to determine if the data necessary 
to perform a meta-analysis are available. Sometimes meta-
analysis will just not be feasible, for example, when there are 
important differences between the studies in terms of populations, 
interventions, outcomes and quality, it would be senseless to try 
to estimate a summary effect (as in Case study 3). A systematic 
review does not always have to have a meta-analysis! In addition, 
by examining for differences in effects between studies, we 
will be able to determine whether or not the studies are too 
heterogeneous to be sensibly combined. We should proceed 
with meta-analysis only if the studies are similar in clinical 
characteristics and methodological quality, and are homogeneous 
in effects.
In a meta-analysis, in simple terms, the effects observed across 
studies are pooled to produce a weighted average effect of all 
the studies – the summary effect. As a general principal, each 
study is weighted according to some measure of its importance, 
e.g. a method that gives more weight to more informative studies 
(often larger studies with precise effect estimates) and less weight 
to less informative studies (often smaller studies with imprecise 
effect estimates) is used. In most meta-analyses, this is achieved 
by assigning a weight to each study in inverse proportion to the 
variance, expressing precision, of its effect. Averaging effects 
across studies in this way ensures that the intervention groups 
within each study are only compared to the control groups in the 
same study. Thus, in a meta-analysis of experimental studies, the 
benefit accrued by randomization (with allocation concealment) is 
preserved when the results are pooled. An example meta-analysis 
is shown in Box 4.4. 
It is important to be familiar with the finer points concerning 
pooling individual effects in a meta-analysis because we will be 
faced with them regularly when reading or conducting reviews. 
During a meta-analysis it is essential to check how robust our 
summary effect is to the variation in statistical methods. There 
are two concepts to keep in mind: the ‘fixed effect’ and ‘random 
effects’ statistical models. 
A fixed effect model estimates the average effect assuming that 
there is a single ‘true’ underlying effect. A random effects model 
assumes that there is no single underlying value of the effect, 
but there is a distribution of effects depending on the studies’ 
characteristics. The differences between effects are considered 
to arise from between-study variation and the play of chance 
(random variability). A random effects model weights smaller 
studies proportionally higher than a fixed effect model when 
estimating a summary effect. This phenomenon may exaggerate 
the impact of publication bias and poor quality in smaller studies. 
When computing confidence intervals, random effects models 
Variance is 
statistical measure 
of variation 
measured in terms 
of deviations of 
the individual 
observations from 
the mean value. 
The inverse 
of variance of 
observed individual 
effects is often 
used to weight 
studies in statistical 
analyses used in 
systematic reviews, 
e.g. meta-analysis, 
meta-regression and 
funnel plot analysis.
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Box 4.4 Summarizing the effects using meta-analysis
Forest plot of individual and summary effects
Effects observed in individual studies are plotted along with the summary effect. For 
each study, the point estimate of effect is a box of variable size according to the weight 
of the study in the meta-analysis. The summary effect is plotted below the individual 
effects using a different graphic pattern, e.g. a filled diamond (the width of the 
diamond represents the confidence interval and the centre of the diamond represents 
the point estimate).
An example meta-analysis using fixed and random effects models
The example shown below is based on the question and the effects (relative risk, RR) 
described in Box 4.3. Compared to the fixed effect models, the random effects models 
produce wider confidence interval around the summary effect because they take into 
account between-study variability. They also preferentially weight smaller studies, 
which have more varied effects than larger studies. 
Test for heterogeneity
Size of the box
represents the 
weight assigned to 
the individual effects
Diamond shows the
summary effect
Larger study
weighted
preferentially
by fixed effects
model
Smaller studies
weighted
preferentially
by random effects
model
Note the difference 
in summary effect
between fixed and
random effects
models
.001 .02 1 50 1000
.001 .02 1 50 1000
Ronnberg
Abel
Wang
Micic
Torok
AinMelk
Sokol
WHO
Karuse
1.07 [0.07, 15.54]
1.28 [0.46, 3.50]
3.79 [0.23, 62.48]
12.11 [0.71, 206.42]
1.80 [0.69, 4.07]
5.00 [0.26, 96.59]
0.20 [0.03, 1.52]
0.82 [0.34, 1.98]
1.76 [0.45, 5.84]
1.41 [0.91, 2.18]
1.07 [0.07, 15.54]
1.28 [0.46, 3.50]
3.79 [0.23, 62.48]
12.11 [0.71, 206.42]
1.80 [0.69, 4.67]
5.00 [0.26, 96.59]
0.20 [0.03, 1.52]
0.82 [0.34, 1.98]
1.76 [0.45, 6.84]
1.32 [0.79, 2.18]
3.1
18.7
2.3
1.8
16.3
1.6
14.3
32.3
9.5
100.0
3.5
20.7
3.2
3.1
22.7
2.9
6.1
25.5
12.4
100.0
Total (95% CI)
Test for heterogeneity chi-square=8.84 df=8 p=0.36
Test for overall effect  z=1.55  p=0.12
RR
(95%Cl Fixed)
RR
(95% Cl Fixed)
RR
(95% Cl Random)
RR
(95%Cl Random)
Weight
%
Weight
%
Study
Based on Arch Intern Med 1996; 156: 661–6
Review manager software used to compute effects and produce graphics 
See Box 4.7 for subgroup meta-analysis
incorporate the variance of effects observed between the studies 
(assuming that they have a normal distribution). Hence, when 
there is heterogeneity, a random effects model produces wider 
confidence intervals of the summary effect compared with a fixed 
effect model. Therefore it can be argued that the fixed effect 
model may give undue precision to the summary effect (spuriously 
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narrow confidence interval) if there is significant unexplained 
heterogeneity between the studies. In the example meta-analysis 
shown in Box 4.4 summary effects generated with both fixed 
and random effects models are demonstrated. In practice both 
statistical models may be used to assess the robustness of the 
statistical synthesis, but if we have to make a choice we should do 
this a priori and not after we have been biased by knowledge of 
the results.
4.4  Clinical heterogeneity 
Differences in the characteristics of the studies with respect 
to populations, interventions and outcomes can provide useful 
answers regarding heterogeneity and can help in interpreting 
the clinical relevance of the findings. The exploration of these 
differences can be facilitated by constructing the summary tables 
in such a way that potential explanations for differences in effects 
can be more easily identified. During question formulation (Step 
1), we would have identified important issues that could produce 
a variation in effects (see examples in Box 1.3). Based on this 
information, we may stratify the studies into subgroups according 
to populations, interventions and outcomes sets. The differences in 
effects in the various subgroups of studies can then be explored. 
If there are many studies in our review, the differences in effects 
may also be examined statistically, as shown in Box 4.5. We can 
perform a meta-analysis of subgroups of studies and additionally 
examine if the effects are consistent within the subgroups. 
Advanced statisticians could also determine the statistical 
significance (p-value) of the difference in the effect between 
subgroups; this is beyond the scope of this book. We should be 
aware that investigations into the reasons for heterogeneity must 
be interpreted with caution. As with statistical tests for detection 
of heterogeneity, tests for evaluating its reasons also have limited 
power so they may miss a relationship. Another problem is that 
if subgroup analyses are carried out, some might be spuriously 
significant, a problem inherent in multiple analyses of any type. 
Box 4.5 Exploring clinical heterogeneity
Subgroup analysis
Free form question: Do home visits improve the health of elderly people?
Structured question 
●● The populations Elderly people in various age groups
●● The interventions  Home visits of various intensities and frequencies
  Comparator: usual care 
●● The outcomes Mortality, functional status and nursing home admissions
●● The study design Experimental studies
Step 4: Summarizing the evidence 61
Delineation of various subgroups (considering the detailed 
question structure in Box 1.3)
Subgroups 1 2 3
Age-based 
subgroups
Assessment 
intensity based 
subgroups
Follow-up 
frequency based 
subgroups
●● The populations Elderly people in 
various age groups 
Elderly people Elderly people
●● The interventions Home visits Home visits of 
various assessment 
intensities 
Home visits of 
various frequencies 
of follow-up 
Comparator: usual 
care.
Comparator: usual 
care.
Comparator: usual 
care.
●● The outcomes Mortality
(critical)
Functional status
(critical)
Nursing home 
admissions
(important)
Subgroup meta-analyses
A vertical line in the centre of the diamond indicates the point estimate of the 
summary relative risk (RR) for each subgroup of studies with particular characteristics. 
The width of the diamond represents the confidence interval of the summary RR for 
each subgroup. RR values of < 1.0 represent an advantage for the intervention group 
compared to control.
The populations
(age-based subgroups)
young–old
old–old
The interventions
(assessment intensity subgroups)
multidimensional
not multidimensional
The interventions
(frequency of follow-up subgroups)
multiple
infrequent
Young–old have reduced
mortality rather than
old–old
Multidimensional
assessments improve
functional status
Frequent follow-up
reduces nursing home
admissions
InferencesSubgroups Summary RR 
0.40 0.65 1.00 1.40
Based on JAMA 2002; 287: 1022–8
Therefore examination of the explanation for heterogeneity should 
be planned for a small number of study characteristics for which 
there is a strong suggestion of a relationship with the size of effect. 
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In addition, the choice of subgroups should be made in advance 
(Step 1). It is good to be cautious – from examining the tables we 
generated earlier we might become aware of issues and possible 
relationships we had not anticipated. The temptation would be 
to undertake further subgroup analyses that were not originally 
planned. These post-hoc analyses should be avoided. If we cannot 
resist the temptation, they should be clearly identified and their 
findings should be interpreted cautiously. They should not be 
used to guide clinical practice but they can be used to generate 
hypotheses for testing in future research.
Where substantial heterogeneity is present and clinical reasons 
for it can be found, an overall meta-analysis may be unnecessary. 
In this situation, meta-analysis should be restricted to clinically 
relevant subgroups where a variation in effect was originally 
anticipated. This approach will aid in clinical interpretation and 
application of the review’s findings as highlighted by the example 
shown in Box 4.5.
4.5  Methodological heterogeneity
We should also find out if design and quality differences among 
studies appear to be associated with variation in their effects. This 
is important not only to explore reasons for heterogeneity, but 
also to assess the strength of the evidence (Step 5). 
Hopefully, study design will have been used as one of the 
selection criteria (Step 2). This way studies of poor design would 
have been removed and the review would have focused on studies 
of a minimum acceptable quality from the outset. So why should 
there be a fuss about the quality of a review’s component studies? 
In many reviews, depending on the type and amount of available 
literature, it is inevitable that selection criteria specifying the 
study design will allow inclusion of studies of methodologically 
inferior designs (Step 2). Even when search and selection focus 
on robust study designs, there will be some variation in quality 
between studies. This happens because the devil about quality 
is in the detail: the ‘gross’ hierarchies of study designs used for 
study selection do not capture finer points about quality which are 
important for the validity of the results. 
Hopefully, we would have performed detailed study quality 
assessments and discovered the variation in quality between 
studies (Step 3). During study synthesis we should gauge if quality 
has an association with the estimation of effects as part of the 
exploration for heterogeneity and its sources. The reason for 
being concerned about study quality is that if we find different 
individual effects among studies of different quality, we can no 
longer trust the overall summary effect. If high quality studies 
produce conservative estimates of effect, our inferences would 
also have to be conservative. 
We may have got some idea about the relationship between 
Bias either 
exaggerates or 
underestimates 
the ‘true’ effect of 
an intervention or 
exposure.
The quality of a 
study depends on the 
degree to which its 
design, conduct and 
analysis minimizes 
biases.
Step 4: Summarizing the evidence 63
quality and effects by tabulating the relevant information on 
quality and effects together. In fact, where studies of different 
designs are included in a review, we should tabulate the studies 
subgrouped according to design. In this situation, if a meta-
analysis is (mistakenly) undertaken using studies of different 
designs, there is a risk that biased summary effects may be 
produced due to undue weighting of studies that are inferior 
in design. In an attempt to counter such a bias, the idea of 
weighting studies in proportion to their quality (rather than size 
or precision as described earlier) has been suggested. However, no 
agreed standards exist for producing such weights, so we should 
abandon this idea. Sometimes the only feasible approach will 
be a descriptive evidence summary, particularly if there are no 
subgroups of studies of a similar quality, but if there are, use a 
subgroup meta-analysis. 
A meta-analysis should only be contemplated within subgroups 
of studies of the same design and inferences should be based on 
the effects observed among studies of superior design. As shown 
in Box 4.6, we might find that studies of superior designs do not 
show an association between exposure and outcome when studies 
of inferior designs do. Even when a review focuses on studies of 
a single design, there may be variation in effects according to 
quality. Often the relationship between quality and effect would 
result in heterogeneity, but this is by no means the rule. If the 
studies’ effects were stacked in decreasing order of quality in a 
Forest plot, the relationship would become apparent. For example, 
an increase in effect may be observed as the quality deteriorates, 
as shown in Box 4.7. 
Box 4.6 Using study design to gauge strength of inferences
Free form question: Is exposure to benzodiazepines during pregnancy associated 
with malformations in the newborn baby? (also see Box 1.2)
Structured question
●● The population Pregnant women
●● The exposures Benzodiazepines in early pregnancy
  Comparator: no exposure
●● The outcomes Major malformations in the newborn baby
●● The study design  Observational studies with cohort and case-control designs (see 
Box 1.4)
Summary of evidence
There was statistically significant heterogeneity in the overall analysis. Overall 
summary odds ratio (OR) suggested a trend towards an association between exposure 
to benzodiazepines and the risk of major malformations in the newborn baby. We use 
OR in this analysis because among studies with case-control design it is not possible 
to compute risk and relative risk.
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Exploring the impact of study design on the effects observed in the 
review
Subgroup analysis stratified
according to study design
The association between exposure
to benzodiazepines in pregnancy
and major malformations is only
supported by the subgroup of case-
control studies (where there is
heterogeneity). These studies are
of a more inferior design than 
cohort studies. Among the sub-
group of studies with cohort 
design (where there is no 
heterogeneity) there is no
association.
Note: OR values >1.0 indicate an
association of malformations with
exposure to benzodiazepines
compared to no exposure.
01 Cohort Design
 Milkovich
 Crombie
 Hartz
 Kullander
 Laegried(1)
 Pastuszak
 Ornoy
Subtotal (95%Cl)
Test for heterogeneity chi-square=1.74  cf=6  p=0.94
Test for overall effect  z=–0.50  p=0.6
02 Case-control design
 Greenberg
 Noya
 Bracken
 Laegreid(2)
Subtotal (95%Cl)
Test for heterogeneity  chi-square=9.87  df=3  p=0.02
Test for overall effecct  z=2.63  p=0.009
Total (95%Cl)
Test for heterogeneity  chi-square=23.61  df=10  p=0.0087
Test for overall effect  z=1.47  p=0.14
1.35 [0.45, 4.07]
0.75 [0.24, 2.35]
0.90 [0.49, 1.66]
0.63 [0.16, 2.60]
1.75 [0.10, 29.93]
0.36 [0.04, 3.47]
0.97 [0.39, 2.43]
0.90 [0.61, 1.35]
1.52 [0.90, 2.58]
3.13 [0.12, 80.69]
2.61 [1.63, 4.16]
23.20 [4.29, 125.56]
3.01 [1.32, 6.84]
1.43 [0.89, 2.31]
OR
(95% Cl Random)Study
OR
(95% Cl Random)
10010 1.1.01
Naïve inference without considering study design
Exposure to benzodiazepines in pregnancy is possibly associated with major 
malformations in the newborn baby.
Inference considering study design
Exposure to benzodiazepines in pregnancy is not associated with major 
malformations in the newborn baby. 
Based on Dolovich et al. BMJ 1998; 317: 839–43
RevMan software used to compute effects and produce graphics
See Box 4.4 for summarizing effects using meta-analysis
Box 4.7 Using study quality to gauge strength of inferences
Free form question: Among infertile couples with subfertility due to a male factor, 
does anti-oestrogen treatment increase pregnancy rates? (see structured question in 
Box 3.5)
Summary of evidence (based on the review summaries in Box 4.3 and 4.4)
There was no statistically significant heterogeneity in the overall analysis. Summary 
relative risk (RR) suggested a trend towards an increase in pregnancy rate among 
couples treated with anti-oestrogens.
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We should explore the relationship between study quality and 
effects even when heterogeneity is not statistically demonstrable, 
because effects among high-quality studies may be different 
from those among low-quality studies (Box 5.3). There is some 
controversy about how to do this. Some experts consider it 
preferable to perform a subgroup analysis, stratifying the studies 
according to their compliance with individual quality items; but 
this has the disadvantage of increasing the number of subgroups 
(see Case study 4), which in turn carries the risk of spurious 
statistical significance. Alternatively, quality scores (composed with 
Exploring the impact of study quality on the effects observed in the 
review
Forest plot with effects stacked in
decreasing order of quality*
For high-quality studies there is a trend
towards harm from treatment. As the quality
of studies decreases this trend reverses and the
possibility of benefit emerges.
Subgroup analysis stratified according to
quality*
The beneficial trend in the overall meta-
analysis is supported only by low-quality
studies. High-quality studies suggest a trend
towards harm, i.e. decrease in pregnancy rates,
with treatment.
Note: RR values >1.0 indicate an advantage for 
anti-oestrogen treatment compared with control.
*See Box 3.5 for detailed quality assessment of
individual studies and rank order.
Sokol
WHO
Ronnberg
Abel
Torok
Wang
Karuse
AinMelk
Micic
0.20 [0.03, 1.52]
0.82 [0.34, 1.98]
1.07 [0.07, 15.54]
1.28 [0.46, 3.50]
1.80 [0.69, 4.67]
3.79 [0.23, 62.48]
1.76 [0.45, 6.84]
5.00 [0.26, 96.59]
12.11 [0.71, 206.42]
01 High quality studies
 Sokol
 WHO
Subtotal (95% Cl)
Chi-square 5.03 (df=1) P: 0.02  Z=–1.16 P : <0.00001
02 Low quality studies
 Ronnberg
 Abel
 Torok
 Wang
 Karuse
 AinMelk
 Micic
Subtotal (95%Cl)
Chi-square 3.81 (df=6) P: 0.70  Z=2.61 P: 0.0001
Total (95%Cl)
Chi-square 8.84 (df=8) P: 0.36  Z=11.55 P: <0.00001
0.20 [0.03, 1.52]
0.82 [0.34, 1.98]
0.63 [0.29, 1.37]
1.07 [0.07, 15.54]
1.28 [0.46, 3.50]
1.80 [0.69, 4.67]
3.79 [0.23, 62.48]
1.76 [0.45, 6.84]
5.00 [0.26, 96.59]
12.11 [0.71, 206.42]
2.10 [1.20, 3.66]
1.41 [0.91, 2.18]
.001 .02 1 50 1000
.001 .02 1 50 1000
Study
Study
Relative Risk
RR
(95% Cl Fixed)
RR
(95% Cl Fixed)
RR [95% Cl]
Naïve inference without considering quality 
Anti-oestrogen therapy seems to have a trend towards a beneficial effect among 
infertile couples with subfertility due to a male factor.
Inference considering study quality 
Anti-oestrogen therapy has no beneficial effect among infertile couples with 
subfertility due to a male factor.
Based on Arch Intern Med 1996; 156(6): 661–666
RevMan software used to compute effects and produce graphics
See Box 3.5 for a detailed description of quality
See Box 4.3 for a Forest plot with studies sorted according to year of publication
See Box 4.4 for summarizing effects using meta-analysis
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the quality items) may be used to stratify studies, but the scoring 
systems are usually not well developed (Step 3). If there is a good 
correlation between studies with regard to compliance (and non-
compliance) with a number of quality items, it may be sensible 
to stratify studies into high- and low-quality subgroups based on 
compliance with most of the quality items (Box 4.7). This approach 
would reduce the number of subgroup analyses and minimize the 
risk of spurious findings. 
A technique for exploring heterogeneity (called meta-
regression) is becoming fashionable, so we should touch on it 
briefly, mainly with a view to helping us with critical appraisal. Put 
simply, this technique fits a multivariable linear regression model 
for examining the influence of study characteristics and quality 
on the size of individual effects observed among studies included 
in a review. In this way it searches for the unique contribution 
of different variables towards an explanation for heterogeneity. 
Meta-regression does have a down side – it suffers from the risk 
of what is described in regression analysis as ‘overfitting’. This 
arises because reviews often only have a small number of studies 
and a large number of variables are available for inclusion in the 
model. In this situation, if a regression model is used, it will lead 
to spurious findings. So beware! The most powerful way to assess 
between-study differences is based on an analysis using individual 
patient data from the included studies. However, this is only rarely 
possible.
4.6  Meta-analysis when 
heterogeneity remains unexplained
Hopefully studies included in our review will not have any obvious 
heterogeneity. If we do encounter it, hopefully our exploration for 
reasons behind the heterogeneity will bear some fruit. However, 
in many reviews there will be no explanations, neither clinical nor 
methodological. In this situation one might say that heterogeneity 
remains unexplained despite a sensible exploration. This may be 
because the number of studies in a review is not large enough 
to allow a powerful analysis to decipher the reasons behind 
differences in effects between studies. Now, do we or do we not 
perform meta-analysis? There is no simple answer. 
We should ask ourselves what is to be gained by meta-analysis. 
Can we not interpret the studies’ findings with tabulation and 
Forest plots of individual effects? The temptation would be to 
attribute the heterogeneity to chance variation between studies 
and then undertake meta-analysis using a random effects model 
as this approach accounts for the variation between studies that 
cannot be explained by other factors. If we do succumb to this 
temptation (which happens far too often), proceed with caution. 
Make sure to look for and exclude funnel asymmetry (Box 4.8), 
a factor indicative of publication and related biases. Otherwise 
Publication bias 
is said to arise 
when the likelihood 
of publication of 
studies and thus 
their accessibility to 
reviewers is related 
to the significance 
of their results 
regardless of their 
quality.
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a random effects model may produce biased summary effect 
estimates. In addition, our interpretation of the summary effect 
should be cautious as heterogeneity limits the strength of the 
evidence collated in reviews (Step 5). We must examine to see if 
the overall summary effect and the effects of the high-quality 
subgroup of studies are, by and large, consistent. Even when there 
is no apparent reason for heterogeneity, the results of high-quality 
studies may be different. In this way quality becomes a factor in 
the assessment of strength of evidence (Step 5).
4.7  Exploring for publication and 
related biases
How can we be sure that our review does not suffer from 
publication and related biases? Hopefully a systematic approach 
has been used to track down studies, whether they are published 
or not (Step 2). Hopefully, the search has particularly focused 
on capturing those studies that are less accessible, e.g. through 
searching multiple databases, and has not used language 
restrictions in study identification. Hopefully, the cast net is wide 
enough to capture all relevant studies (or at least an unbiased 
sample of the relevant literature). However thorough the literature 
search is, there cannot be any guarantees. But there can be some 
comfort (or discomfort) from formal post-hoc assessment for 
publication and related biases in a review. 
A simple, in many cases too simple, but commonly used method 
of exploring for these biases is based on the so-called ‘funnel 
plot’ analysis. To perform this analysis meaningfully numerous 
studies, including some large studies, are required. As shown in 
Box 4.8, it is a scatter plot of individual effects that are observed 
among studies included in a review against some measure of 
study information (e.g. study size, inverse of variance). If all the 
relevant studies ever carried out are included in our review, the 
scatter of data points in the plot can be expected to lie within a 
symmetric funnel shape. The funnel is inverted when the y-axis 
is taken to represent study size (or inverse of variance), as in Box 
4.8. This is because there is a wider range of effects among smaller 
studies compared to the effects observed among larger studies, 
due to less precision in smaller studies. In this situation the funnel 
therefore is symmetrical and we can have more confidence that 
publication and related biases are unlikely in our review. If the 
funnel is truncated (sometimes called banana-shaped), a group of 
studies may be missing from our review. Usually missing studies 
are small in size with different effects to those observed in the 
large studies included in our review. Such omissions are unlikely to 
be due to chance alone and they make the funnel asymmetrical. 
Publication bias is just one of a host of related reasons for funnel 
asymmetry, including location bias, English language bias, database 
bias, citation bias, multiple publication bias, poor methodological 
Variance is a 
statistical measure of 
variation, measured 
in terms of deviation 
of the individual 
observations from 
the mean value. 
The inverse 
of variance of 
observed individual 
effects is often used 
to weight studies 
in the statistical 
analyses used in 
systematic reviews, 
e.g. meta-analysis, 
meta-regression and 
funnel plot analysis.
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quality of small studies and clinical heterogeneity (e.g. small 
studies in high risk populations) to name a few. The multiplicity of 
reasons, and the difficulty in separating them from each other, has 
led to use of the term small-study-effect rather than publication 
bias. Whatever the reason, our confidence in the findings of the 
review will be limited if there is a truncation of the funnel.
A number of statistical tests are available to examine if funnel 
asymmetry is likely to be due to chance. These are outside the 
remit of this book, but some advice will be helpful for critical 
appraisal of reviews. The shapes of funnel plots vary according 
to the measures of effect and study size, and statistical tests 
for asymmetry often don’t give consistent results. So, to avoid 
overinterpretation, funnel plot analyses should only be considered 
exploratory in nature. If it is any consolation, the true extent of 
publication and related biases may never be known.
Summary of Step 4: Summarizing 
the evidence
Key points about appraising review articles
●● Examine the methods and results sections to see if 
heterogeneity of effects is evaluated.
Box 4.8 Funnel plots to explore for publication and related 
biases
Effect size
St
u
d
y 
si
ze
Effect size
St
u
d
y 
si
ze
? Missing studies
Symmetrical funnel plot
Effects in smaller studies (open
circles) have a wider scatter than the
larger studies (filled circles), and they
appear on both sides of the effects
observed in larger studies. Effects lie
within a funnel shape.
Asymmetrical funnel plot
Smaller studies with effects smaller
(open circles) than those observed in
larger studies (filled circles) seem to be
missing. The funnel is truncated.
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●● Was the exploration for heterogeneity planned in advance?
●● Is variation in clinical characteristics of the studies an 
explanation for heterogeneity?
●● Is variation in study design and quality an explanation for 
heterogeneity?
●● Is meta-analysis appropriate in the light of information 
gathered on heterogeneity and its reasons?
●● Is there a risk of publication and related biases?
Key points about conducting reviews
●● The aim of this Step is to collate and summarize the findings of 
studies included in a review.  
●● Data synthesis consists of tabulation of study characteristics, 
quality and effects as well as use of statistical methods for 
exploring differences between studies and combining their 
effects (meta-analysis) appropriately. 
●● Tabulation of evidence helps in assessing feasibility of planned 
statistical syntheses and improves overall transparency.
●● Exploration of heterogeneity and its sources should be planned 
in advance.
●● Exploration of clinical heterogeneity should be based on a small 
number of study characteristics for which there is a strong 
theoretical basis for a relationship with estimation of effect.
●● Exploration of methodological heterogeneity should consider 
factors for which there is strong theoretical or empirical basis 
for suspecting a relationship with bias. 
●● The following questions should be considered prior to 
embarking on meta-analysis: Is meta-analysis feasible given 
clinical heterogeneity? Is meta-analysis feasible given the 
variation in study quality?
●● If an overall quantitative summary is not feasible, subgroup 
meta-analysis might be feasible and could provide clinically 
useful answers. 
●● If feasible, funnel plot analysis should be undertaken to explore 
for the risk of publication and related biases.
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●● Step 5: 
Interpreting the 
findings
Deciphering the salience of a review’s 
findings is as much art as it is science. The 
ultimate purpose of a review is to inform 
decision making, and the big question at the 
end of a systematic review is ‘how can one 
go about making decisions with the collated 
evidence?’ However, the task of generating 
meaningful and practical answers from 
reviews is not always easy. We will cover 
some of the key issues that aid sensible and 
judicious interpretation of the evidence, 
avoiding both over- as well as under-interpretation.
By the time our review is nearing completion or after having 
read someone else’s review, we may think that we already know 
the meaning of the findings. But what are the main findings? 
Is the evidence strong? How much trust can we have in the 
results of the review? How can we generate inferences and 
recommendations for current clinical practice as well as for 
future research? The answers to these questions may not be as 
straightforward as one might think in the first instance. 
This step describes transparent and replicable ways to determine 
the strength of the evidence collated in a review for generating 
clinically meaningful and trustworthy bottom lines that aid in 
application of research into practice.
5.1 Strength of the evidence 
How do we gauge the strength of the evidence? This will depend 
on the strengths and weaknesses of the review. How well did it 
comply with the key points on appraising reviews at the end of 
each Step in this book:
The Grading of 
Recommendations 
Assessment, 
Development and 
Evaluation (GRADE) 
working group 
is an informal 
collaboration that 
aims to develop 
a comprehensive 
methodology 
for assessing the 
strength of the 
evidence collated in 
systematic reviews 
and for generating 
recommendations 
from evidence 
in guidelines. 
See www.
gradeworkinggroup.
org. This chapter 
and interpretation 
of findings in case 
studies draws on 
this methodology.
Question 
components
The population: A 
suitable sample of 
participants
The exposures: 
Comparison 
of groups with 
and without the 
exposure
The outcomes: 
Changes in health 
status due to 
interventions
The study design: 
Ways of conducting 
research to assess 
the effect of 
interventions
The effect: 
A measure of 
association between 
interventions and 
outcomes
Step 1 
Framing questions
Ø
Step 2 
Identifying relevant 
literature
Ø
Step 3 
Assessing quality of 
the literature
Ø
Step 4 
Summarizing the 
evidence
Ø
Step 5 
Interpreting the 
findings
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●● Is there evidence on critical and important outcomes for the 
population and intervention of interest described in the question?
●● Are the searches adequate?
●● Is there a risk of publication and related biases? 
●● Is the methodological quality of the included studies good enough? 
●● Are the results consistent from study to study?
●● Are there enough data for precise estimation of effect?
●● Are the observed effects of substantial clinical, not just 
statistical, significance?
We have formulated a focused and structured question. We 
have to compare how well the evidence matches against the 
components of the question. Were the study populations sicker, 
older or from a different setting? Are interventions replicable in our 
workplace? Have we thought about outcomes relevant to patients 
and classified them as critical, important and less important? (Step 
1). Are results available for critical and important outcomes? The 
principal findings should relate to these. Other findings should be 
considered secondary. 
Having undertaken a thorough literature search (Step 2), we 
have examined the results for publication bias and other related 
biases (Box 4.8). We have considered the design and quality of 
studies included in the review (Step 3; Box 3.5). We have explored 
the observed effects of the individual studies for (in)consistency 
(Step 4). We have probed whether certain population features 
such as severity of the disease or the setting (Box 4.5), intervention 
features such as treatment intensity or timing (Box 4.5) or 
methodological features such as study design or study quality 
(Boxes 4.6 and 4.7) are associated with a larger or reduced size of 
relative effect. We have inspected the confidence intervals around 
the effect estimates to evaluate (im)precision.
Having explored in-depth the above issues individually, we 
ultimately need to make a judgement about the overall strength 
of the evidence. This judgement should be arrived at in an explicit 
manner. It would be wise to stop for a moment and consider 
what we mean by the term ‘strength of evidence’: In the context 
of systematic reviews, the strength of the evidence describes 
the extent to which we can be confident that the estimate of an 
observed effect is correct for critical and important outcomes. The 
judgements on the strength of the evidence can be classified as 
being of high, moderate, low or very low level (Box 5.1).
Publication bias 
is said to arise 
when the likelihood 
of a study being 
published, and thus 
its accessibility to 
reviewers, is related 
to the significance of 
its results regardless 
of their quality.
The point estimate 
of effect is its 
observed value in a 
study. 
The confidence 
interval is the 
imprecision in the 
point estimate, i.e. 
the range around 
it within which 
the ‘true’ value of 
the effect can be 
expected to lie with 
a given degree of 
certainty (e.g. 95%).
Confidence interval
Point estimate
The direction of 
effect indicates 
a beneficial or a 
harmful effect. 
The point estimate 
of effect tells us 
about direction and 
magnitude of effect. 
The precision 
of effect relates 
to the degree of 
uncertainty in the 
estimation of effect 
that is due to the 
play of chance. The 
confidence interval 
tells us about 
precision. 
Strength of 
evidence describes 
the extent to which 
we can be confident 
that the estimate 
of an observed 
effect is correct for 
important questions. 
It takes into account 
directness of outcome 
measure, study 
design, study quality, 
heterogeneity, 
imprecision and 
publication bias (this 
is not an exhaustive 
list).
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5.1.1 Assigning a level of strength to 
evidence
We begin the process of assigning a level of strength to evidence 
by evaluating the study design (Box 1.4). As a default rule, 
evidence from experimental design is initially assigned a high level 
of strength while that from observational design is assigned a low 
level. Appraisal of key issues concerning directness of evidence in 
relation to question, publication bias, methodological quality of 
included studies, and heterogeneity and precision of results is then 
employed to lower the initially assigned level of strength by one or 
two levels. This depends, as shown in the examples below, on how 
much the critical appraisal of key issues alters the confidence in 
the observed effect. 
One has to explicitly consider how good the methodological 
quality of included studies has to be for evidence to be valid? 
How consistent should the effects be across studies to be 
homogeneous? How large should an improvement in effect be for 
it to be relevant for clinical practice? When is a confidence interval 
narrow enough to be called precise? Addressing these questions 
involves judgement, which requires a mixture of methodological 
and clinical expertise. Whatever the judgement, it should be 
explicit and transparent, so that others can make sense of the 
reasoning employed to assign levels of strength of evidence. 
Consider Case study 3 for instance, where the included studies 
are of experimental design. To begin with one may consider 
the strength of evidence to be at a high level. If the review 
on antimicrobial therapy in chronic wounds only reported the 
outcome reduction in histologically documented inflammation, 
Confidence interval
Point estimate
Strength of 
evidence describes 
the extent to which 
we can be confident 
that the estimate 
of an observed 
effect is correct for 
important questions. 
It takes into account 
directness of outcome 
measure, study 
design, study quality, 
heterogeneity, 
imprecision and 
publication bias (this 
is not an exhaustive 
list).
Box 5.1 Levels of strength of evidence collated in a review
The strength of evidence describes the extent to which we can be confident that the 
estimate of an observed effect, i.e. the measure of association between interventions 
and outcomes assessed in the review, is correct for critical and important questions.
High strength of evidence:  We are very confident that the true effect lies close 
to the observed effect.
Moderate strength of evidence:  We are moderately confident that the true effect 
is likely to be close to the observed effect, but 
there is a possibility that it could be substantially 
different.
Low strength of evidence:  Our confidence in the observed effect is limited. 
The true effect may be substantially different from 
the observed effect.
Very low strength of evidence:  We have very little confidence in the observed 
effect. The true effect is likely to be substantially 
different from the observed effect.
Heterogeneity 
is the variation of 
effects between 
studies. It may 
arise because of 
differences in key 
characteristics of 
their populations, 
interventions and 
outcomes (clinical 
heterogeneity), 
or their study 
designs and quality 
(methodological 
heterogeneity).
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most would agree there would be difficulties in translating results 
based on this surrogate into practice. This is because one would 
prefer to base practice on results from data on a clinically relevant 
outcome like complete wound healing. On reflection, rating down 
the strength of this evidence by a couple of levels to low because 
of indirectness of the outcome would seem appropriate. 
Are there situations where strength of evidence can be 
justifiably raised after initially assigning a low level? Consider 
a systematic review of observational studies on the protective 
effect of bicycle helmets, compared to not wearing such helmets 
(Cochrane Database Syst Rev 1999; Issue 4: CD001855). This 
demonstrated a strong protective effect against head injury, a 
critical outcome. The effect size measured by OR was 0.31 with 
a 95% confidence interval of 0.26–0.37. At the outset the level 
of strength of evidence is considered low due to the risk of bias 
in observational study design. The bias may inflate the protective 
effect of the helmet observed in the review. However, it is unlikely 
that the large observed effect is solely due to the bias inherent 
in the observational design. The true effect may smaller, but it is 
unlikely that there would be no protective effect in reality. This 
raised our confidence in the observed effect and we have good 
reason for rating up the level of strength of evidence from low to 
moderate. 
Take, as another example, antibiotic treatment in otitis media 
(Box 5.2). The review found a reasonably large point estimate 
of effect. The OR was 0.51 for the critical outcome perforation 
of the ear drum, indicating that the odds of perforation under 
antibiotics were reduced by half. However, the confidence interval 
around this point estimate ranged from 0.2 to 1.26, including the 
possibility of a benefit as large as a reduction in odds by 80%. 
However, at the other extreme the confidence interval crossed the 
line of no effect (OR = 1.0) and included the possibility of a 26% 
increase in the odds of perforation under antibiotics. This result 
leaves considerable uncertainty about the true effect of antibiotics 
on perforation. We may, justifiably, make a judgment that this 
imprecision in the result merits lowering the level of strength of 
the evidence by a couple of levels, from high to low.
A dose–response relationship would demonstrate that at higher 
doses the strength of association is increased. This can raise the 
level of strength of evidence from observational studies. Consider 
observational studies that consistently show that in patients on 
oral anticoagulation the risk of bleeding increases with higher INR 
values. It is needless to say that criteria for raising and relegating 
the strength level of the evidence should be applied judiciously 
and transparently. 
Odds ratio (OR) is 
an effect measure 
for binary data. It 
is the ratio of odds 
in the experimental 
group to the odds in 
the control group.
A dose–response 
relationship 
demonstrates 
that at higher 
doses the strength 
of association 
between exposure 
and outcome is 
increased.
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5.2 Tabulating findings to aid 
interpretation
To improve transparency, a summary of findings table should be 
prepared. The results and levels of strength of evidence should be 
stratified according to the outcomes. The number of studies and 
participants should be included per outcome to illustrate how 
much the body of evidence varies. The impact of antibiotic therapy 
in otitis media is investigated by nine studies with 2287 patients 
for the outcome pain on days 2–7, while only two studies with 
381 patients assessed prevention of perforation of the ear drum 
(Box 5.2). 
The strength of the evidence should be evaluated separately for 
each outcome. This is because the strength of the evidence may 
vary across outcomes, even when the evidence comes from the 
same studies. For example, in the otitis media example (Box 5.3), 
take the outcome pain at 2–7 days. The strength of the evidence 
is high because the populations, interventions and outcomes refer 
directly to the question posed and there are no limitations in the 
methodological quality of the studies. The results are consistent 
across studies, the confidence interval around the point estimate 
of effect is narrow and there is no indication of publication bias. 
Contrast this with the outcome perforation of the ear drum. There 
is a limitation in study quality, because one large trial excluded 
from the analysis all patients who had dropped out before this 
outcome could be addressed. There is imprecision around the 
observed effect. We have a low level of confidence in the impact 
of antibiotic therapy on the prevention of perforation.
5.3 Applicability of findings
By this time we must be thinking that we have reached the end. 
We already know if we can have sufficient trust in the review 
and we also have a good idea of the magnitude and range of the 
expected benefits (or harms or other outcomes). However, we 
need to do a bit more work before applicability of findings can be 
assessed. 
We have measured the effects in relative terms (e.g. relative 
risk [RR] and odds ratio [OR]) as suggested in Box 4.2. Although 
the relative effect measures are useful for assessing the strength 
of the effect (and to perform meta-analysis), to judge whether an 
intervention is worthwhile, the absolute magnitude of the benefits, 
tailored to specific population groups, is needed. This allows the 
clinical significance and the possible impact of the intervention 
to be understood. The absolute effect might be expressed as the 
risk difference (RD), which is a fraction, not a whole number (it 
is sometimes also called ‘absolute risk reduction’). The average 
human brain can only interpret natural frequencies or whole 
numbers well. The reciprocal of RD converts a fraction into a 
Risk difference 
(RD) is an effect 
measure for 
binary data. In a 
comparative study, 
it is the difference in 
event rates between 
two groups. 
Number needed 
to treat (NNT) is 
the inverse of RD in 
individual studies.
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Box 5.2 Summary of findings in a review of effectiveness of antibiotics in otitis media among children 
seen in primary care
Importance 
of outcome
Outcome
Odds ratio
[95% CI]
Baseline risk 
(risk without treatment)
Risk under 
treatment*
[95% CI]
Risk difference
[95% CI]
NNT or NNH+
[95% CI]
I
m
p
o
r
t
a
n
t
Pain 2–7 days 
9 Trials
0.57
[0.45–0.73]
Medium: 
260 per 1000
(26%)
167 per 1000
[137–204]
93 less per 1000 treated 
[56–123]
11
[8–18]
C
r
i
t
i
c
a
l
Perforation 
(assessed with otoscopy 
or examination of 
discharging ear within 7 
days follow-up)
2 Trials
0.51
[0.2–1.26]
Low:
17 per 1000 
(1.7%)
9 per 1000
[3–21]
8 less per 1000 treated
[14 fewer – 4 more]
125
[NNT: 250 – NNH: 71]
Medium:
160 per 1000 
(16%)
89 per 1000
[37–194]
71 less per 1000 treated
[123 fewer – 34 more]
14
[NNT: 29 – NNH: 8]
I
m
p
o
r
t
a
n
t
Adverse effects 
(Vomiting, diarrhoea, rash)
4 Trials 
1.94
[1.28–2.94]
Low: 
10 per 1000
(1%)
19 per 1000
[13–29]
9 more per 1000 treated
[3–19]
111
[52–333]
High: 
300 per 1000
(30%)
454 per 1000
[354–558]
154 more per 1000 
treated
[54–258]
6
[3–18]
* Risk under treatment is based on the risk without treatment and the odds ratio of the intervention calculated using GRADEpro software freely available at  
www.gradeworkinggroup.org 
+ NNT is number needed to treat; NNH is number needed to harm; see Box 5.4 for NNT computation
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Box 5.3 Assessing strength of the evidence collated in a review of effectiveness of antibiotics in otitis 
media among children seen in primary care.
Outcome and its 
importance
Study design 
Directness 
of outcome 
measure
Study quality
(risk of bias)
Inconsistency of 
results
(heterogeneity)
Imprecision of 
effects
Publication 
bias 
Strength of 
evidence
Pain 2–7 days Randomized trial Direct No limitations Consistent Precise Not detected High 
(Important)
Initially assigned a 
high strength level
Æ No change Æ No change Æ No change Æ No change Æ No change ∟
Perforation  Randomized trial  Direct Serious limitations Consistent Imprecise Not assessed Low
(Critical)
Initially assigned a 
high strength level
Æ No change Æ Relegation Æ No change Æ Relegation Æ No change ∟
Adverse 
 effects 
Randomized trial Direct No limitations Consistent Imprecise Not assessed Moderate 
(Important)
Initially assigned a 
high strength level
Æ No change Æ No Change Æ No change Æ Relegation Æ No change ∟
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whole number called the number needed to treat (NNT). When 
dealing with an adverse effect the same calculation is called 
number needed to harm (NNH). However, this simple approach 
is only useful in dealing with data from individual studies. When 
using relative summary effect estimates obtained from reviews, 
the computation of the NNT is a bit more complicated and freely 
available software helps with calculation. This is explained in Box 
5.4, but first we examine some virtues of NNTs.
Decision making in healthcare is influenced by many factors. The 
size of the effect and its statistical significance in a meta-analysis 
provide only part of the information required. For example, when we 
interpret the summary effect, having received information about our 
patient’s risk of an outcome without treatment, we might decide 
not to use it in low-risk patients as in our judgement the treatment-
associated morbidity and costs may not be worth the benefits. Thus, 
we may only use the treatment for patients at high risk. Relative 
effect measures tend to be constant across varying baseline risk, so 
they are not as informative when tailoring treatment decisions. The 
NNT, however, is sensitive to changing baseline risks and it allows 
us to individualize the benefit of interventions. The higher the NNT, 
the greater the number of patients clinicians must treat to achieve 
a beneficial effect in one. Therefore they would be less inclined to 
recommend treatment and their patients would be more inclined to 
avoid treatment. Very often, in patients at higher baseline risk (i.e. 
worse prognosis), the NNT will be lower than in patients at lower 
risk (i.e. good prognosis). The lower the NNT, the smaller the number 
of patients clinicians must treat to achieve a beneficial result in 
one person; the more inclined a clinician would be to recommend 
treatment and the more enthusiastic their patients would be to have 
treatment.
Prognosis is a 
probable course 
or outcome of a 
disease. Prognostic 
factors are 
patient or disease 
characteristics, 
which influence 
the course. 
Good prognosis 
is associated 
with a low rate 
of undesirable 
outcomes. Poor 
prognosis is 
associated with 
a high rate of 
undesirable 
outcomes.
Baseline risk is 
the risk of outcome 
in a population 
without intervention. 
It is related to 
severity of the 
underlying disease 
and prognostic 
factors. Baseline 
risk is important for 
determining who will 
benefit most from an 
intervention.
Box 5.4 Individualizing summary effects from reviews to 
clinical scenarios
Free form question: Does aspirin in early pregnancy prevent later onset of 
hypertensive disorders?
Structured question
●● The population Women in early pregnancy
●● The interventions Low dose aspirin
  Comparator: placebo or no treatment
●● The outcomes Hypertensive disorders of pregnancy
●● The study design Experimental studies (see Box 1.4)
Summary of evidence of effectiveness of aspirin (Based on BMJ 2001; 
322: 329–33)
There were 32 relevant studies. Aspirin prevented hypertensive disorders of pregnancy 
with a summary relative risk (RR) of 0.85 (95% confidence interval 0.78–0.92). (RR 
values < 1.0 indicate an advantage for aspirin treatment compared to control.)
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Exploring variation in relative effects of aspirin among various risk 
groups
Subgroup analysis
stratified according to
population risk groups
Comparison of studies with
clinically defined moderate
and high-risk groups of
pregnant women shows that
relative effectiveness of
Aspirin in preventing
hypertensive disorders is
consistent across the
subgroups.
Prognostic subgroups
Overall summary
Summary RR
Moderate risk
High risk
0.7 0.8 0.9 1.0
Individualizing aspirin prevention among various risk groups in 
early pregnancy
Numbers of women needed to be treated (NNT) with aspirin to prevent hypertension 
in pregnancy may be computed for various risk groups defined according to the 
clinical history and the results of the Doppler ultrasound test. This would aid in 
decision making as one would be quite inclined to treat Doppler-positive women and 
not so inclined to treat Doppler-negative women according to the following NNTs.
Risk group Baseline risk* NNT+
Clinical history: high risk
Doppler-positive 23.5%  29
Doppler-negative  7.8%  86
Clinical history: moderate risk
Doppler-positive 18.8%  36
Doppler-negative  2.5% 267
* Based on a review of diagnostic accuracy of Doppler test in predicting pregnancy 
hypertension (BJOG 2000; 107: 196–208)
+ Computed using the following formula:
NNT = 1/[BR ¥ (1–RR)], where BR is baseline risk and RR is 0.85
If the summary effect measure is odds ratio (OR), then the following formula is 
required:
NNT = [(1 - BR) + (OR ¥ BR)]/[BR ¥ (1 - OR) ¥ (1 - BR)]
Based on BMJ 2001; 322: 329–33.
How are NNTs generated from relative summary effects 
provided by reviews? A precondition is that the relative effects 
are in fact consistent across studies with varying baseline risks. 
Empirical evidence suggests that summary RR and ORs from 
meta-analysis using a random effects model are reasonably 
constant across various baseline risks. We can explore this 
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phenomenon in our review by subgroup meta-analysis of 
studies stratified according to the prognostic category of the 
recruited patients. When such an analysis shows consistency in 
relative effects, we may use them to generate NNTs. We will of 
course need information on our patient’s clinical condition and 
prognosis, which may require us to draw on evidence outside 
our effectiveness review. We might find that the evidence of 
the review moderated by the patient’s specific circumstances 
might lead to different applications in different patients. For 
example, considering the variation in NNTs among the risk 
groups outlined in Box 5.4, we might decide to treat Doppler-
positive women but not Doppler-negative women among the 
clinically moderate risk group.
We consider the implications of individualizing summary effects 
from reviews to clinical scenarios using our earlier example of 
antibiotic treatment in children with otitis media (Box 5.2). At an 
OR of 0.57, antibiotics (compared with no treatment) will reduce 
pain at 2–7 days among children at moderate risk of this symptom 
from 26% to 16.7%. This translates into 93 fewer children with 
pain per 1000 cases treated or an NNT of 11. This beneficial effect 
has to be balanced against the adverse effects that antibiotics 
can induce, like vomiting, diarrhoea and rash. Among children 
without antibiotics where only few suffer these symptoms (e.g. 10 
in 1000 children, 1%), antibiotics lead to adverse effects in 9 more 
children per 1000 treated cases, at an OR of 1.94. This corresponds 
to an NNH of 111. The situation is altogether different if the 
baseline risk for adverse effects is high, say 300 in 1000 children, 
30%. Here, an additional 154 children among 1000 treated cases 
will experience adverse effects. The corresponding NNH will be 
just 6. Judicious interpretation of findings of systematic reviews 
in different contexts is required to reach sound resolutions of 
scenarios.
5.4 Generating recommendations 
The usefulness of a review can be greatly enhanced by providing 
evidence-based ‘bottom line’ messages to healthcare practitioners. 
Generating graded practice recommendations from the findings 
of the studies summarized in a review helps to achieve this 
objective. This approach is commonly used in clinical practice 
guidelines. There is considerable scope for confusion when moving 
from evidence synthesis to recommendations. In this section 
we straighten out some common misconceptions and give a 
brief outline of the key factors to consider when generating 
recommendations for practice. 
Recommendations should convey a clear message and should 
be as simple as possible to follow in practice. To achieve this, 
guideline developers need to start with high quality reviews. This 
is the starting point for the development of recommendations 
An adverse effect 
is an undesirable 
and unintended 
harmful or 
unpleasant reaction 
resulting from an 
intervention.
Evidence-based 
medicine (EBM) is 
the conscientious, 
explicit and judicious 
use of current best 
evidence in making 
decisions about 
healthcare.
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for action in healthcare. What we and other practitioners really 
want to know about recommendations is how credible they are. 
By credibility most people mean the trustworthiness and the 
reliability of a message. Credibility of a recommendation depends 
only in part on the strength of evidence collated from the review. 
Guideline developers need to make additional judgments on 
issues such as those listed in Box 5.5. Credibility requires that all 
judgements involved in a recommendation are made explicit. The 
criteria outlined in Box 5.5 provide one approach to explicitness in 
Box 5.5 Key considerations when generating 
recommendations
Consideration
1. Balance between desirable  
and undesirable effects 
Large difference between desirable and 
undesirable effects increases the chances 
of a strong recommendation. A small 
difference increases the likelihood of a weak 
recommendation.
2. Overall strength of evidence 
across all critical outcomes 
(see Box 5.1)
The higher the level of strength of the 
evidence, the higher the likelihood of a strong 
recommendation.
3. Values and preferences Large variation in values and preferences, 
or great uncertainty in values and 
preferences, increase the likelihood of a weak 
recommendation.
4. Costs (resource allocation) The higher the costs of an intervention, the lower 
the likelihood of a strong recommendation.
The implications of strong and weak recommendations
Implications Strong recommendation Weak recommendation
…for patients 
Most patients in this situation 
would want the recommended 
course of action and only a 
small proportion would not.
Most people in this situation 
would want the recommended 
course of action, but many 
would not. 
… for clinicians
Most patients should receive 
the recommended course of 
action.
Different choices will be 
appropriate for different 
patients, and the clinician must 
help each patient to arrive 
at a management decision 
consistent with the patient’s 
values and preferences.
… for policy makers
The recommendation can be 
adopted as a policy in most 
situations.
Policy making will require 
substantial debate and 
involvement of many 
stakeholders. 
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classifying recommendations as strong and weak. Needless to say, 
strong and weak recommendations can be in favour of or against 
a healthcare intervention.
Recommendations are used by different groups such as 
healthcare professionals, patients and the general public, and 
local, regional or national policy makers. A strong or weak 
recommendation is likely to have different implications for each 
type of user. Healthcare professionals may interpret a strong 
recommendation as a directive advising them that almost all 
patients should receive the suggested action, and they may advise 
their patients accordingly. For patients, a strong recommendation 
may indicate that, when fully informed, most are very likely to 
make the same choice. Healthcare policy makers and funders may 
conclude from a strong recommendation that compliance with 
the suggested action could serve as a quality indicator to measure 
the performance of the organizations they commission to provide 
services. 
A weak recommendation, on the other hand, may imply for 
clinicians that patients may vary in their values and preferences 
and as a result may take different courses of actions despite the 
same evidence. In this situation, clinicians may therefore advise 
their patients to select a treatment that best suits their personal 
values. For patients, a weak recommendation may imply that a 
considerable proportion of patients would differ in their treatment 
choices. They might want to clarify their own preferences in 
this situation. Health policy makers may conclude from weak 
recommendations that compliance with suggested action will not 
be suitable as a quality indicator. In this scenario, a documented 
discussion with the patient on alternative treatment options would 
be a better standard of care criterion.
When assigning a strong or weak grade to a recommendation, 
four key factors need be taken into consideration (Box 5.5). First, 
the balance between desirable and undesirable effects of an 
intervention, between its benefits and harms. For example, the 
proven benefit of aspirin after a heart attack to prevent a re-
infarction outweighs by far the potential adverse effects and cost 
for the patient. This unambiguous benefit of aspirin following 
a myocardial infarction calls for a strong recommendation. If 
the benefit is less obvious or the harm to the patients, including 
cost and inconvenience, is more substantial, it is better that the 
guideline group gives a weak recommendation, implying that 
patients might consider alternative options and clinicians should 
dedicate some time eliciting the treatment options that are most 
in line with a patient’s preferences.
The second factor is the overall strength of the evidence that 
confirmed the beneficial effects. Strong evidence is much more 
likely to result in a strong recommendation than treatment effects 
observed in studies of low or even very low evidence. While 
high quality randomized trials have demonstrated the benefit 
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of calcium-channel blockers versus placebo in lowering events 
from coronary heart disease and from stroke, backing a strong 
recommendation, only case series have examined the utility of oral 
nifedipine for the treatment of chronic anal fissure, making strong 
recommendations much less likely.  
The third factor is the values and preferences that patients 
relate to the intervention. Consider the situation of young women 
with newly diagnosed breast cancer. When faced with the decision, 
almost all will place a higher value on the life-prolonging effects 
of aggressive chemotherapy over treatment toxicity. Therefore, this 
treatment option deserves a strong recommendation. Compare 
this to the situation where women with advanced age have 
been diagnosed with breast cancer. Their decisions on aggressive 
chemotherapy are likely to vary and a considerable minority might 
place a higher value on avoiding treatment toxicity compared to 
the life-prolonging effects of aggressive chemotherapy. In this 
situation, a weak treatment recommendation appropriately reflects 
those distinct value judgements of the women. 
The fourth factor that influences the grading of a 
recommendation refers to the resource use that results from a 
recommendation, in particular (but not exclusively) cost. Although 
all recommendations have implications for resource use, many 
groups omit an explicit consideration of this factor in their 
decision. Despite being more effective, the high cost of rasburicase 
compared to allopurinol in tumour lysis syndrome is likely to 
attenuate the grade of a recommendation, while the low cost of 
aspirin is unlikely to impair the grade of a recommendation in 
patients after myocardial infarction.
Summary of Step 5: Interpreting the 
findings
Key points about appraising review articles
●● Are data on all critical and important outcomes reported?
●● What is the level of strength of the evidence for each outcome?
●● If the evidence in the review is trustworthy, what is its meaning 
for clinical practice?
●● Are the recommendations derived judiciously?
●● The article may not provide much of the analysis required for 
recommendations, but following the advice given in this Step, 
we might be able to generate clinically meaningful inferences 
for ourselves.
Key points about conducting reviews
●● Set out the main findings for each critical and important 
outcome separately.
●● Ascertain that the key points about appraising reviews listed at 
the end of each of the four Steps so far have been met.  
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●● Assign a level of strength to the evidence for each outcome 
considering at least study design, methodological quality, 
consistency of results from study to study, precision of observed 
effect, and risk of publication and related biases.
●● Explore variations in the relative effects and their reasons, 
particularly if the relative effects vary with baseline risk level 
or severity of disease. The intervention may be effective only in 
certain clinical groups.
●● Compute the predicted absolute effects (numbers needed to 
treat, NNTs) according to disease severity. This way we will be 
able to individualize the effects observed in the review to the 
requirements of our patients.
●● Any recommendations should be graded strong or weak 
considering the balance between desirable and undesirable 
effects, the strength of evidence across all critical and important 
outcomes, patients’ values and preferences, and costs.
Section B: Case studies
The application of review theory covered in 
the preceding section is illustrated through 
the following case studies. Some readers may 
prefer to assimilate the review theory fi rst 
before turning to the case studies. Others may 
read them in conjunction with the information 
contained in the previous section. Each case 
consists of a scenario requiring evidence from 
reviews, a demonstration of some review 
methods and a proposed resolution of the 
scenario. The interpretations of the evidence 
are based on specifi c scenarios. Judicious 
interpretation of fi ndings of systematic reviews 
in other scenarios may lead to different 
resolutions. Insight into critical appraisal and 
conduct of a systematic review can be gained by 
working through the case studies.
Case study 1:  Identifying and appraising 
systematic reviews
Case study 2:  Reviewing evidence on safety of 
a public health intervention
Case study 3:  Reviewing evidence on 
effectiveness of therapy 
Case study 4:  Reviewing evidence on accuracy 
of a test
Case study 5:  Reviewing qualitative evidence 
to evaluate patient experience  
Case study 6:  Reviewing evidence on 
the effects of educational 
intervention
Case study 7:  Gauging strength of evidence to 
guide decision making
Case study 8:  To use or not to use a therapy? 
Incorporating evidence on 
adverse effects
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●● Case study 1: 
Identifying and appraising 
systematic reviews
When seeking evidence from reviews to guide our clinical practice, 
we may face some difficulty in formulating questions. This is often 
due to the tension between addressing questions with either a 
wide or a narrow focus. Practitioners think broadly about clinical 
topics before making a decision for a specific patient or problem 
but evidence is not always summarized in this way. Nowadays 
we are likely to find several reviews on a question and awareness 
about variation in their focus is important. 
This case study will demonstrate advantages and disadvantages 
of broad and narrow types of questions, and how to identify and 
appraise existing reviews. It will help us develop an approach to 
selecting relevant reviews when several reviews are available on 
a topic. It will draw on the key points about appraisal (shown at 
the end of each step in Section A) to make our reading of reviews 
more efficient. 
Scenario: Drug treatment for recent 
onset schizophrenia
You are a psychiatrist due to see a 25-year-old amateur guitar 
player who has a recent diagnosis of schizophrenia. This is a 
mental condition where the patient may suffer symptoms such as 
hallucinations (often hearing voices) and delusions (unshakeable 
beliefs that are contrary to a person’s social and cultural 
background), called ‘positive’ symptoms. There may also be emotional 
numbness, lack of motivation, muddled speech and thoughts, which 
are called ‘negative’ symptoms. You want to consider the available 
options for this patient, taking account of her preferences. Playing 
music is the joy of her life; thus you are aware of the importance 
of avoiding treatments associated with movement disorders so that 
your patient’s guitar playing is not impaired.
Being a specialist, you are well aware of the various treatment 
options. These include the classical drugs such as chlorpromazine 
and haloperidol, and a whole range of new antipsychotic drugs. 
The beneficial and harmful effects of these drugs are varied. New 
drugs are also more expensive. Given these variations, you had 
been thinking about examining the literature to check whether 
your prescribing practice was in line with the best evidence. 
This case study was developed as a learning aid in 2002. It has 
been retained in the second edition of this book in its original 
form. The results of the literature searches, therefore, are not 
current.
What is involved 
in identification, 
appraisal and 
application 
of evidence 
summarized in 
reviews?
Framing questions
Ø
Identifying relevant 
reviews
Assessing quality of 
the review and its 
evidence
Ø
Summarizing the 
evidence
Ø
Interpreting the 
finding
Free form 
question: It 
describes the query 
for which you seek 
an answer through 
a review in simple 
language (however 
vague).  
Structured 
question: Reviewers 
convert free form 
questions into a 
clear and explicit 
format using a 
structured approach 
(see Box 1.2). 
This makes the 
query potentially 
answerable through 
existing relevant 
studies.
Ø
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Step 1: Framing the question
Free form question 
For adults with recent onset schizophrenia, what is the 
effectiveness of the various drug treatments and what are their 
harmful effects?
Structured question
The populations Adults with recent onset schizophrenia (in 
this case study you are not interested in 
patients with unresponsive schizophrenia).
The interventions Antipsychotic drugs, both classical and new. 
The outcomes Beneficial: improvements on ‘positive’ and 
‘negative’ symptoms. This may involve 
psychological measurements of global or 
mental state of the patient. 
 Adverse effects: movement disorders and 
other side effects, e.g. somnolence. 
The study design Beneficial outcomes: review(s) of experimental 
studies addressing effectiveness.
 Adverse effects: review(s) of experimental and 
observational studies addressing safety.
The question formulated above is a broad one. Of the various 
components of the question, the population is quite focused, the 
interventions and outcomes are broad and so are the study designs. 
Both classical and new interventions (of which there are more 
than a dozen drug treatments), both beneficial outcomes and 
adverse effects, and both experimental and observational designs 
(Box 1.4) are to be considered. You expect to find a number of 
reviews, which have taken a narrower focus, e.g. comparing one 
drug versus another without regard for other available options. 
However, this would not be suitable for your case scenario. You 
want to choose a treatment for your patient with the optimum 
balance between beneficial and adverse effects after considering 
all available options. 
Step 2: Identifying relevant reviews
The number of reviews has increased exponentially in recent years. 
When searching for reviews to guide your practice, sometimes 
you may be faced with numerous reviews collating the findings 
of several studies on your topic of interest. Although this might 
fill you with enthusiasm, at the same time multiplicity of reviews 
presents a challenge. Identifying which reviews to read and which 
not to, may not be easy. 
The Cochrane Library search
Having framed your question you decide to search the Cochrane 
Library. It has several databases, some of which are shown in 
Effectiveness is 
the extent to which 
an intervention 
produces beneficial 
outcomes under 
ordinary day-to-day 
circumstances.
Question 
components
The population: 
A clinically suitable 
sample of patients.
The interventions: 
Comparison 
of groups with 
and without the 
intervention.
The outcomes: 
Changes in health 
status due to 
interventions.
The study design: 
Ways of conducting 
research to assess 
the effects of 
interventions.
Adverse effect 
is an undesirable 
and unintended 
harmful or 
unpleasant reaction 
resulting from an 
intervention.
Effect is a measure 
of association 
between an 
intervention and an 
outcome.
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Box 0.1. It is the best source of reviews and protocols of reviews 
about effectiveness of interventions, which are included in its 
Cochrane Database of Systematic Reviews (CDSR). It also provides 
abstracts of quality assessed systematic reviews from a wide range 
of sources in the Database of Abstracts of Reviews of Effectiveness 
(DARE), and abstracts of technology assessments from a network 
of agencies in the Health Technology Assessment (HTA) Database. 
In the fourth issue of the 2009 Cochrane Library there are:
●● 1906 complete reviews
●● 4027 protocols of reviews
●● 11 447 abstracts of quality assessed reviews
●● 7596 abstracts of technology assessments.
There are several ways to find reviews in the Cochrane Library. 
Just by typing the words ‘schizophrenia AND antipsychotics’ in 
the query box of the 2002 Cochrane Library (Issue 3) and clicking 
the search button, there were 59 hits (50 reviews and 9 protocols) 
in CDSR and 14 hits in DARE (Box C1.1). In addition, there were 
three hits in the HTA Database. CDSR had several reviews, but 
they appeared to address very focused questions, much narrower 
than the question you had formulated. However, among the 14 
DARE abstracts, the first three titles appeared to address a broad 
question similar to the one you are trying to answer. One of the 
HTA Database titles was relevant and it was the same as one of 
the three identified in DARE (Drug treatments for schizophrenia). 
For busy clinicians the most useful property of the DARE database 
is that assessment of the review’s quality has already been carried 
out by trained staff who write the structured abstracts for this 
database. This may help you to decide which reviews to read in 
detail and, more importantly, which not to (Box C1.1). 
Selecting a review to read in detail
From the titles of the DARE abstracts, it was clear to you that only 
three reviews have a broad focus compatible with your question. 
The key findings of the DARE abstracts concerning quality of 
their literature searches are provided in Box C1.1. The review in 
the BMJ searched comprehensively (though it reported unclearly 
about use of language restrictions) but it was not up-to-date. The 
other review in the Annals of Pharmacotherapy searched only one 
database; it used language restrictions in study selection and it 
was not up-to-date either. 
The remaining review turned out to be a ‘review of Cochrane 
reviews’ which are not up-to-date either (last updated in 1999). Its 
abstracts in the DARE and HTA Databases provided a web link to 
its full report (www.york.ac.uk/inst/crd/EHC/ehc56.pdf). The report 
actually warned readers that its contents were likely to be valid for 
around one year following publication, by which time significant 
new research evidence was expected to become available. It also 
said that the review will be updated as part of the work for a 
A Cochrane review 
is a systematic 
review undertaken 
following the 
methodology of 
the Cochrane 
Collaboration and 
is included in the 
Cochrane Database 
of Systematic 
reviews in the 
Cochrane Library. 
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Box C1.1 Searching the Cochrane Library for systematic 
reviews on drug treatment for schizophrenia and selecting a 
review to read in detail
The Cochrane Library* search terms
‘schizophrenia AND antipsychotics’
CDSR+ (50 reviews, 9 protocols) DARE+ (14 abstracts)
All titles:
 Atypical antipsychotics in the treatment of schizophrenia: systematic
 overview and...
 Atypical antipsychotics part I: pharmacology, pharmacokinetics,
 and efficacy
 Drug treatments for schizophrenia
 Effectiveness of second-generation antipsychotics in patients with
 treatment-resistant...
 Efficacy and extrapyramidal side-effects of the new antipsychotics...
 Efficacy and safety of neuroleptics in behavioural disorders associated
 with dementia
 Refractory schizophrenia and atypical antipsychotics
 Risperidone: efficacy and safety
 Sulpiride: an antipsychotic with selective dopaminergic antagonist ...
 Treatment of schizoaffective disorder and schizophrenia ...
 Typical and atypical antipsychotics in adolescent schizophrenia ...
 Consistency of atypical antipsychotic superiority to placebo ...
 The clinical value of risperidone and olanzapine: a meta-analysis ...
 The effects of atypical antipsychotic drugs on neurocognitive
 impairment in schizophrenia ...
Selected review titles:
 Amisulpride for schizophrenia
 Clozapine versus typical neuroleptic medication for
 schizophrenia
 Depot bromperidol decanoate for schizophrenia
 Electroconvulsive therapy for schizophrenia
 Loxapine for schizophrenia
 Molindone for schizophrenia and severe mental illness
 Newer atypical antipsychotic medication versus clozapine
 for schizophrenia
 Olanzapine for schizophrenia
 Quetiapine for schizophrenia
 Risperidone versus other atypical antipsychotic
 medication for schizophrenia
 Risperidone versus typical antipsychotic medication for
 schizophrenia
 Sertindole for schizophrenia
 Sulpiride for schizophrenia
 Ziprasidone for schizophrenia and severe mental illness 
 Zotepine for schizophrenia
Reviews with a narrow focus.
Do not read further!
The first three titles seem relevant.
Go ahead. Read Abstracts first.
Selecting a review to read in detail
Review behind DARE Abstract Quality of its search Decision to read further
Atypical antipsychotics in the 
treatment of schizophrenia: 
systematic overview and meta-
regression analysis. BMJ 2000; 
321: 1371–6.
MEDLINE, EMBASE, PsycLIT 
and the Cochrane Controlled 
Trials Register searched to 
December 1998. No description 
of language restrictions.
No, do not read further. 
Outdated.
Atypical antipsychotics 
part I: pharmacology, 
pharmacokinetics, and efficacy. 
Ann Pharmacother 1999; 33: 
73–85.
MEDLINE only searched from 
July 1986 to June 1998. Study 
selection restricted to English 
language only.
No, do not read further. 
Outdated
Drug treatments for 
schizophrenia. Effective 
Health Care Bull 1999: 5(6). 
(www.york.ac.uk/inst/crd/EHC/
ehc56.pdf)
Review of Cochrane reviews in 
the Cochrane Library 1999. 
Yes. The bulletin available 
on the internet indicates 
that an update has been 
commissioned. Obtain the 
most up-to-date review from  
www.ncchta.org/project/
htapubs.asp
* Search results from the Cochrane Library 2002, Issue 3
+  CDSR, the Cochrane Database of Systematic Reviews; DARE, the Database of 
Abstracts of Reviews of Effectiveness (see Box 0.1 for details).
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forthcoming report commissioned by the UK National Health 
Service HTA Programme. 
This information led you to check the web pages of the HTA 
programme (Box 0.1). The above project had been superseded 
by a similar one commissioned by the HTA programme and data 
had recently been published (but it was not yet included in the 
Cochrane Library’s HTA database). This review, it turned out, 
included no less than eight systematic reviews addressing benefits, 
adverse effects and cost-effectiveness of new antipsychotics, 
including amisulpride, clozapine, olanzapine, quetiapine, 
risperidone, sertindole, ziprasidone and zotepine. Given the fact 
that clozapine is a relatively old drug that was reintroduced for 
treating those with unresponsive schizophrenia, you leave it out 
of the rest of this case study. The reviews were actually based on 
updates of the Cochrane reviews that you had already identified 
in CDSR. This search emphasizes the importance of checking if 
reviews have already been done or are in progress before even 
considering preparing a new systematic review.
Step 3: Assessing quality of the 
review
Given the large size of this report, and the fact that the included 
reviews had been prepared using the same protocols, you can take 
a two-step approach to their appraisal. First, check the quality of 
the overall report, and if satisfactory, then take a closer look at 
the amount and quality of the evidence included in each of the 
reviews when interpreting the findings. 
In this report the Cochrane reviews from 1999 had been 
updated with relevant studies found in comprehensive literature 
searches of more than 20 databases, 10 conference proceedings, 
ongoing trials registers, scanning of the reference lists of retrieved 
papers and reports of studies submitted by the companies which 
produced the drugs. In addition, further searches had been carried 
out for non-randomized studies of rare or long-term harmful 
outcomes. The quality of the included evidence was assessed by 
using separate checklists for effectiveness and safety studies. The 
studies were synthesized and interpreted in an appropriate way. 
Although assessment for the risk of publication and related biases 
had been limited because of scarcity of suitable data, the searches 
had been comprehensive enough to reassure you that this report 
provided the best available information (Box C1.2). 
Step 4: Summarizing the evidence
There were 171 experimental studies and 52 observational studies 
addressing rare or long-term effects in the review. However, 
the quality of the studies was not always ideal and the number 
of head-to-head comparisons evaluating similar outcomes was 
Safety relates to 
adverse effects 
associated with 
interventions. 
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Box C1.2 Appraising the overall quality of a Health 
Technology Assessment report on systematic reviews of 
drug treatment for schizophrenia
Step 1: Framing questions
●● The report is based on predefined questions.
●● The questions were modified during the review, but justifications were provided.
●● The questions do not seem to have been unduly influenced by knowledge of the 
results of studies.
Step 2: Identifying relevant literature
●● The searches appear to be comprehensive. Over 20 databases, 10 conference 
proceedings, ongoing trials registers and the reference lists of retrieved papers have 
been searched. In addition, the companies that produce the drugs have submitted 
reports of their own studies.
●● The selection criteria were set a priori and applied by two reviewers independently.
●● It seems unlikely that relevant studies might have been missed.
Step 3: Assessing quality of the literature
●● Quality assessment has been undertaken for studies included in the review. 
●● Quality has been used as a criterion for study selection (Step 2): for effectiveness 
experimental studies were included and for safety clear inclusion criteria concerning 
study designs were formulated.
●● A more detailed quality assessment of selected studies has been carried out. The 
quality items seem to be appropriate for the question. 
●● Variation in quality has been explored as an explanation for heterogeneity and 
meta-analysis seems to have been used selectively where appropriate (Step 4).
Step 4: Summarizing the evidence
●● Heterogeneity of effects has been evaluated.
●● The exploration for heterogeneity was planned in advance in broad terms and with 
variations within the included systematic reviews.
●● Variation in studies’ clinical characteristics has been found to be an explanation for 
heterogeneity.
●● Variation in study design and quality has also been found to be an explanation for 
heterogeneity.
●● Meta-analysis seems to have been used selectively and appropriately in the light of 
information gathered on heterogeneity and its reasons.
Step 5: Interpreting the findings
●● Risk of publication and related biases has been addressed in a limited way because 
suitable data were not available for all outcomes.
●● There is no formal categorization of strength of inferences according to quality of 
evidence, but the conclusions are clearly made with consideration of the quality of 
most studies.
●● The credibility or trustworthiness of the evidence included in the review – the 
quality of included studies is limited and so is the number of relevant comparisons.
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limited. An overview of the findings of the various reviews is 
provided in Box C1.3. The new drugs most frequently assessed for 
their effectiveness and safety were olanzapine and risperidone.
Beneficial effects 
Evidence suggested that both classical and new antipsychotics had 
comparable levels of effectiveness. There were no clear differences 
in effectiveness between the various new antipsychotics. No single 
new antipsychotic agent stood out as being more effective than 
any of the others, nor did they collectively seem to be superior to 
classical drugs. 
Adverse effects 
The new antipsychotics possibly had fewer adverse effects in 
terms of movement disorders than the classical drug haloperidol. 
For example, risperidone showed a relative risk (RR) of 0.64 (95% 
CI 0.56–0.73) for ‘movement disorders’ based on seven studies. 
The new agents all seemed to have slightly different side-effects 
from haloperidol, and these may vary in importance to those with 
schizophrenia and their carers. 
Daytime sleepiness (somnolence) and drowsiness possibly 
occurred more frequently in those given clozapine or quetiapine 
than in those given classical drugs. Olanzapine, amisulpride, 
sertindole and perhaps risperidone may cause less somnolence 
than classical drugs. There was no evidence to suggest that the 
other new drugs were any more or less sedating than the classical 
drugs.
Step 5 Interpreting the findings
It is important to assess the strength of evidence when 
interpreting the findings using the key points from Step 5. The 
available evidence for the effectiveness and safety of the new 
antipsychotics compared to classical drugs was, in general, of low 
quality and it was often based on short-term studies. The basis for 
choosing between the classical and the newer drugs was not as 
strong as one would like. However, for olanzapine and risperidone 
there was the largest body of evidence and it suggested 
effectiveness comparable or better than classical drugs and similar 
to other new drugs. The evidence showed significantly less adverse 
effects such as movement disorders and somnolence. Although 
Strength of 
evidence describes 
the extent to which 
we can be confident 
that the estimate 
of an observed 
effect is correct for 
important questions. 
It takes into account 
directness of 
outcome measure, 
study design, 
study quality, 
heterogeneity, 
imprecision and 
publication bias (this 
is not an exhaustive 
list).
●● The meaning of the review’s findings for clinical practice – the review provides 
information that has limitations which make it difficult to generate durable 
inferences for practice.
Critical appraisal based on key points listed at the end of each step in Section A of 
this book
The full review report is available from www.ncchta.org/project/htapubs.asp.
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Box C1.3 Assessing the quality of evidence included in systematic reviews of drug treatment for 
schizophrenia in a Health Technology Assessment report
Total number of 
experimental studies
Effectiveness
(alleviation of schizophrenic symptoms)
Safety
(movement disorders and somnolence/drowsiness)
vs classical 
drugs
vs other 
new drugs
vs classical drugs vs other new drugs vs classical drugs vs other new drugs
Amisulpride 13  4 Marginally better on most 
outcomes
No important differences Less movement disorders Few data, no clear 
differences
Olanzapine 24 14 Mostly marginally better No important differences Less movement disorders, 
less drowsiness
No clear differences 
Quetiapine  9  1 Better on most outcomes, 
often marginally
Only one comparison 
available
Less movement disorders, 
may cause sleepiness
Very few data available
Risperidone 27 19 Better on most outcomes, 
often marginally
No important differences Less movement disorders, 
less somnolence
Similar
Sertindole  2  0 No clear differences, few 
data
No comparisons available Less movement disorders 
Ziprasidone  9  4 Few data in public domain* Studies not in public 
domain*
Less movement disorders 
than haloperidol
Data not publicly available*
Zotepine  8  3 Equal or better results Very few comparisons 
available
Less movement disorders, 
no differences for 
somnolence
Very few data available
The full review report is available from www.hta.nhsweb.nhs.uk/
*One governing body (UK National Institute for Clinical Excellence – www.nice.org.uk/cat.asp?c=32878), after considering this evidence, concluded that for patients 
with newly diagnosed schizophrenia, prescribing one of the following newer oral antipsychotic drugs should be considered: amisulpride, olanzapine, quetiapine, 
risperidone or zotepine. In drawing its conclusion, the governing body had access to confidential information which is not available in the public domain. Its 
recommendation is said to have a time limit of 3 years, after which it is likely to be reviewed again, taking into account the newly accumulated evidence.
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the quality of the evidence was variable, when subgroup analysis 
was carried out on the highest quality studies available, results 
remained unchanged. Having considered the evidence yourself, 
you were more confident to use olanzapine or risperidone unless 
there were clear contraindications. 
Resolution of scenario
Given the musical interest of your patient, you felt that a 
therapeutic choice based on avoiding movement disorders and 
somnolence made sense as it would not interfere with her guitar 
playing. You decide to commence either olanzapine or risperidone 
with careful monitoring of the beneficial and adverse effects. If 
the treatment is not effective in alleviating symptoms or if there 
are unacceptable side-effects, you will switch to the other drug.
This page intentionally left blank 
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●● Case study 2: 
Reviewing evidence on 
safety of a public health 
intervention
Reviews of safety of interventions are not as common as those 
of their effectiveness. Research on safety may relate to common 
harmful outcomes, which may be captured in the same studies 
that address effectiveness. However, most experimental studies 
focus primarily on effectiveness and secondarily on safety – 
any information on safety is often only a by-product. Harmful 
outcomes can be rare and they may develop over a long time. 
There are considerable difficulties in designing and conducting 
safety studies to capture these outcomes, as a large number of 
people need to be observed over a long period of time. In this 
situation, observational, not experimental, studies are needed. With 
this background, systematic reviews on safety have to include 
evidence from studies with a range of designs. 
This case study demonstrates how to seek and assess evidence 
on safety using a published review of a preventive public health 
intervention. This topic is important because public health 
interventions have an impact on large groups of populations and 
it has to be assured that the benefit outweighs any potential 
harm. This case study provides a demonstration of the application 
of review theory related to question formulation, literature 
identification and quality assessment of studies on safety. It was 
developed as a learning aid in 2002. For the second edition of 
this book, we searched the literature for reviews published since 
the year 2000. There were 9 reviews which evaluated whether it 
was safe to provide population-wide drinking water fluoridation. 
Findings of all new reviews were compatible with the conclusions 
of the original case study. So we decided to keep this case study 
on safety in the same form as it was presented in the first edition.
Scenario: Safety of public water 
fluoridation
You are a public health professional in a locality that has public 
water fluoridation. For many years, you and your colleagues have 
held the belief that it improves dental health. Recently your local 
authority has been under pressure from various interest groups to 
consider the safety of this public health intervention because they 
fear that it is causing cancer.
In the past, most public health decisions have been based on 
Safety relates to 
adverse effects 
associated with 
interventions. 
Effectiveness is 
the extent to which 
an intervention 
produces beneficial 
outcomes under 
ordinary day-to-day 
circumstances.
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judgement and practical feasibility; however, in recent years there 
has been an increasing demand to examine the scientific basis 
behind the issues under consideration. You have been observing 
this development with interest and now you have the chance to 
apply this approach yourself. In anticipation of the discussion 
about the safety of water fluoridation intensifying in the near 
future, you want to prepare well and use evidence from the 
literature to inform any future decisions. 
Using Medline through the freely accessible PubMed interface 
(www.ncbi.nlm.nih.gov/entrez/query.fcgi), you enter ‘drinking water 
fluoridation’ into the query box and find 588 citations that may 
potentially provide information on your issue. Although you are a 
bit shocked about this large number of studies and are wondering 
how to squeeze the necessary reading time into your already 
packed daily routine, you perform a PubMed Clinical Queries 
search (www.ncbi.nlm.nih.gov/entrez/query/static/clinical.html) 
using the same query in the Systematic Reviews feature. You find 
four citations; three are reviews and one is suitable for addressing 
your current concern: 
●● Systematic review of water fluoridation. BMJ 2000; 321: 855–9. 
(seems relevant)
●● Association of Down’s syndrome and water fluoride level: a 
systematic review of the evidence. BMC Public Health 2001; 1: 6. 
(does not seem directly relevant)
●● Exposure to high fluoride concentrations in drinking water is 
associated with decreased birth rates. J Toxicol Environ Health 
1994; 42: 109–21. (does not seem directly relevant)
●● Factors influencing the effectiveness of sealants – a meta-
analysis. Community Dent Oral Epidemiol 1993; 21: 261–8. (does 
not seem relevant)
Incidentally if you do an internet search on the same day using 
the Google search engine (www.google.com), you will have an 
overwhelming 15 100 hits, but in second position among them 
will be the full report of the systematic review on which the above 
relevant paper is based:
●● A systematic review of water fluoridation. NHS Centre for 
Reviews and Dissemination (CRD) Report 18. York, University of 
York, 2000 (available at www.york.ac.uk/inst/crd/fluorid.htm)
Your impression is that using the review is the right starting 
point as it may save an enormous amount of time compared with 
obtaining and reading the large number of individual studies. 
(The above search was undertaken in 2002.)
Free form 
question: It 
describes the query 
for which you seek 
an answer through 
a review in simple 
language (however 
vague).
Structured 
question: Reviewers 
convert free form 
questions into a 
clear and explicit 
format using a 
structured approach 
(see Box 1.2). 
This makes the 
query potentially 
answerable through 
existing relevant 
studies. 
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Step 1: Framing the question
Free form question
Is it safe to provide population-wide drinking water fluoridation to 
prevent caries? 
Structured questions
The populations Populations receiving drinking water sourced 
through a public water supply. 
The exposures Fluoridation of drinking water (naturally or 
artificially) compared with non-fluoridated 
water. 
The outcomes Cancer is the main outcome of interest for 
the debate in your health authority. You also 
decide to consider other outcomes such as 
fluorosis (mottled teeth) and fractures as 
there has been concern about the effect of 
fluorides on bones. 
The study designs Comparative studies of any design (Box 1.4) 
examining the outcomes in at least two 
population groups, one with fluoridated 
drinking water and the other without.
The original review was conducted to address five different 
questions. This case study will only focus (not least for the sake 
of brevity and simplicity) on the question of safety related to the 
outcomes described above.
Step 2: Identifying relevant 
literature
To cast as wide a net as possible to capture as many relevant 
citations as possible, a wide range of medical, political and 
environmental/scientific databases were searched to identify 
primary studies of the effects of water fluoridation (Box C2.1). 
The range of databases searched in this review is far beyond what 
is usually covered in reviews of clinical questions. The electronic 
searches are also supplemented by hand searching Index Medicus 
and Excerpta Medica for several years (back to 1945) to cover 
the time period before Medline and Embase became accessible 
electronically. The search process was further supported by use 
of the internet. Various internet search engines were used to find 
web pages that might provide references. In addition, web pages 
were set up to inform the public about the review and to enable 
individuals and organizations to submit references or reports. Not 
surprisingly, there was a degree of duplication in the captured 
citations resulting from searching a wide range of databases. After 
the removal of duplicates, 3246 citations remained, from which 
the relevant studies were selected for review.
Question 
components
The population: A 
suitable sample of 
participants.
The exposures: 
Comparison 
of groups with 
and without the 
exposure.
The outcomes: 
Changes in health 
status due to 
interventions.
The study design: 
Ways of conducting 
research to assess 
the effect of 
interventions.
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This comprehensive search of a variety of databases yielded 
far more citations than are commonly found when searching 
the literature for focused clinical questions (compare with Case 
study 3). The potential relevance of the identified citations was 
assessed – 2511 citations were found to be irrelevant. The full 
papers of the remaining 735 citations were assessed to select 
those primary studies in humans that directly related to fluoride 
in drinking water supplies, comparing at least two groups. These 
criteria excluded 481 studies, leaving 254 studies in the review. 
They came from 30 countries and were published in 14 languages 
between 1939 and 2000. Of these studies, 175 were relevant to 
the question of safety (Box C2.1). 
Step 3: Assessing study quality 
Study design threshold for study 
selection
Use of study design as a marker for ensuring a minimum level of 
quality has been described as an inclusion criterion in Step 2. This 
approach is easier to apply when seeking evidence of effectiveness 
using experimental studies. This is because randomized studies 
are often difficult (if not impossible) to conduct at a community 
level for a public health intervention such as water fluoridation. 
Thus, systematic reviews assessing safety of such interventions 
have to look beyond experimental studies, and include evidence 
from various types of study design. Considering the nature of 
the research likely to be available to address safety issues, in this 
review a simple design threshold was used as a selection criterion: 
Comparative studies of any design were included, but those 
without any comparative information were excluded (Box 2.4). 
In this way studies that provided information about the harmful 
effects of exposure to fluoridated water compared with non-
exposure were selected.
Quality assessment of safety studies
After selecting studies of an acceptable design, their in-depth 
assessment for the risk of various biases allows us to gauge the 
quality of the evidence in a more refined way. The objective of 
the included studies is to compare groups exposed to fluoridated 
drinking water with groups without such exposure, and look 
for rates of undesirable outcomes without bias. Step 3 shows 
how to develop and use study quality assessments in a review 
of effectiveness. For safety studies to have validity, they must 
ascertain exposures and outcomes in such a way that the risk 
of misclassification is minimized. They must also establish the 
association between exposures and outcomes, adjusting for the 
confounding effect of other factors. These features are likely to 
be more robustly implemented in experimental studies, but they 
Identifying 
relevant literature:
●⦁ Develop search 
term combinations 
●⦁ Search relevant 
electronic 
databases
●⦁ Search other 
relevant resources 
●⦁ Obtain full papers 
of potentially 
relevant citations
●⦁ Include/exclude 
studies using 
pre-set selection 
criteria
A comparative 
study is one where 
the effect of an 
exposure is assessed 
using comparison 
groups.
Confounding 
is a situation in 
comparative studies 
where the effect 
of an exposure 
on an outcome is 
distorted due to 
the association 
of the outcome 
with another 
factor, which can 
prevent or cause 
the outcome 
independent of 
the exposure. 
Data analysis 
may be adjusted 
for confounding 
in observational 
studies.
The validity of a 
study depends on the 
degree to which its 
design, conduct and 
analysis minimizes 
biases.
Bias either 
exaggerates or 
underestimates the 
‘true’ effect of an 
exposure.
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Box C2.1  Identification of relevant literature on safety of 
public water fluoridation
Electronic databases searched
1. Agricola
2. BIOSIS Previews (a database on life 
sciences)
3. CAB Health
4. CINAHl (Cumulative Index of Nursing 
and Allied Health literature);
5. Conference Papers Index
6. EI Compendex (Engineering Index)
7. EMBASE (Excerpta Medica Database)
8. Enviroline
9. Food Science and Technology 
Abstracts (FSTA)
10. Health Service Technology, 
Administration and Research 
(Healthstar)
11. HSR Proj
12. JICST-E Plus (Japanese Science and 
Technology)
13. latin American and Caribbean Health 
Sciences literature (lIlACS)
14. MEDlINE and OldMEDlINE
15. NTIS 
16. PASCAl
17. PSYClIT
18. Public Affairs Information Service 
(PAIS)
19. Science Citation Index and Social 
Science Citation Index
20. System for Information on Grey 
literature in Europe (SIGlE) 
21. TOXlINE
22. Water Resources Abstracts
23. Waternet
Study identification flow chart
Potentially relevant citations identified through
comprehensive electronic searching of databases, hand
searching and contact with experts
n = 3246 citations with titles and abstracts
Retrieval of hard copies of potentially relevant citations
n = 735 papers
Studies excluded after
assessment of full text
n = 481
Studies included in the
original review but
excluded from this case
n = 79
Studies on safety included in the published review
n = 175
Cancer: n = 26
Fluorosis: n = 88
Bone fractures: n = 29
Other adverse outcomes: n = 32
Citations excluded
n = 2511
The original search is part of the full report of the review available at www.york.ac.uk/
inst/crd/fluorid.htm
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typically assess a relatively small number of participants over a 
short duration of follow-up. So in such studies there is only a 
limited chance of detecting rare outcomes that often do not follow 
immediately after exposure. Hence quality assessment has to be 
planned somewhat differently to that in reviews of effectiveness 
of interventions. In this case study the quality issues related to 
safety studies are briefly examined.
Anticipating that experimental studies would be scarce, 
reviewers planned study quality assessment based on features 
that would minimize biases of the various types described above. 
They assessed ascertainment of exposures and outcomes, i.e. 
how did the investigators make sure that the study participants 
had the exposures and outcomes under question. A prospective 
design would facilitate this. This means that those exposed (and 
unexposed) to fluoridated water and those developing cancer (and 
remaining free of cancer) are more likely to be correctly identified 
in these groups if they are assessed in a prospective fashion. The 
exposure is likely to be more accurately ascertained if the study 
commenced soon after water fluoridation and the outcomes are 
likely to be more accurately ascertained if the follow-up is long 
and if it is assessed blind to exposure status.   
When examining how the effect of exposure on outcome was 
established, reviewers assessed if the comparison groups were 
similar in all respects other than their exposure to fluoridated 
water. This is because the other differences may be related to 
the outcomes of interest independent of the drinking water 
fluoridation, and this would bias the comparison. For example, 
if the people exposed to fluoridated water had other risk factors 
that make them more prone to cancer, the apparent association 
between exposure and outcome may be explained by the more 
frequent occurrence of these factors among the exposed groups 
compared with the non-exposed groups. Technically speaking, 
such studies suffer from confounding. In a (large) experimental 
study, confounding factors are expected to be approximately 
equally distributed between groups (but no such studies exist on 
water fluoridation). In observational studies their distribution may 
be unequal. Primary researchers can statistically adjust for these 
differences when estimating the effect of exposure on outcomes 
(using multivariable modelling). The larger the number of variables 
adjusted for, the more likely it is that the observed association 
between exposure and outcome will be ‘true’. 
Put simply, use of a prospective design, robust ascertainment 
of exposure and outcomes, and control for confounding are the 
generic issues one would look for in quality assessment of studies 
on safety. Assessing these methodological features in safety 
studies of water fluoridation will require development of quality 
criteria specific to this topic. For example, studies commencing 
within 1 year of water fluoridation would be able to ascertain 
exposure better than those commencing within 1–3 years, which 
Effect is a measure 
of association 
between an 
exposure and an 
outcome.
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in turn will be better than those commencing after 3 years. This 
way studies would range from satisfactorily meeting quality 
criteria, to having some deficiencies, to not meeting the criteria at 
all, and they can be assigned to one of three prespecified quality 
categories as shown in Box C2.2. 
Description of quality of the selected 
studies
Based on the degree to which studies comply with the quality 
criteria, a quality hierarchy can be developed (Box C2.2). None of 
the included studies is in the highest quality category, but this 
is because experimental studies are non-existent and control 
for confounding is not always ideal in observational studies 
(none is adjusted for three or more confounding factors in the 
analysis). Many studies lacked a prospective design, which makes 
ascertainment of exposure and assessment of outcomes difficult. 
More details of the study quality may be obtained from the review, 
but the general dearth of quality evidence in reviews of safety of 
interventions is not surprising to those experienced in this field.
The quality assessment for studies addressing the three harmful 
outcomes assigns low quality to the vast majority of the available 
evidence, only a few studies are classified as having medium 
quality, none has high quality (Box C2.2). Fortunately (because 
cancer is of major interest in this case study) studies examining 
the association between fluoridation and cancer show the highest 
quality as compared to those examining the other two harmful 
outcomes related to bones. 
Step 4: Summarizing the evidence
Summarizing the evidence from studies with a large variety of 
designs and quality is not easy as highlighted in Steps 4 and 
5. The review provides details of how the differences between 
study results were investigated and how they were summarized 
(with or without meta-analysis). This case study restricts itself to 
summarizing the findings narratively for the outcomes below:
Cancer
The association between exposure to fluoridated water and cancer 
in general was examined in 26 studies. Of these, 10 examined all-
cause cancer incidence or mortality in 22 analyses. Eleven analyses 
found a negative association (fewer cancers due to exposure), nine 
found a positive association and two found no association. Only 
two studies found statistical significance. Thus, no clear association 
between water fluoridation and increased incidence or mortality 
was apparent. While a broad number of cancer types were 
represented in the included studies, bone/joint and thyroid cancers 
were of particular concern due to fluoride uptake by these organs. 
Six studies of osteosarcoma and water fluoridation reporting 
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Box C2.2 A quality assessment checklist for studies on safety 
of public water fluoridation
Quality assessment checklist
Quality issues Quality categories
High* – Moderate Low
Prospective design Prospective Prospective or retrospective
Exposure ascertainment Study commenced within 3 
years of water fluoridation
Study commenced after 3 
years of water fluoridation
Outcome ascertainment long follow-up and blind 
assessment
Short follow-up and 
unblinded assessment
Control for confounding Adjustment for at least one 
confounding factor 
No adjustment for 
confounding factors
* High-quality studies were prospective, commencing within 1 year of water 
fluoridation, followed up people for at least 5 years, used blinding (or other robust 
methods) to ascertain outcomes and adjusted for at least three confounding factors 
(or used randomization) – no such studies existed.
Description of study quality
Information on quality presented as 100% stacked bars separately for studies evaluating 
different harmful outcomes. Data in the stacks represent the number of studies in 
moderate and low quality categories. There were no high quality studies.
18
28
871
1
8
0% 25%
Moderate Low
50%
Study quality
75% 100%
Cancer
(n = 26)
Harmful outcomes
(number of studies)
Fluorosis or mottled teeth
(n = 88)
Bone fractures
(n = 29)
variance data found no statistically significant differences. Thyroid 
cancer was considered by only two studies and these also did not 
find a statistically significant association with water fluoride levels. 
Overall, from the research evidence presented, no association 
was detected between water fluoridation and mortality from any 
cancer or from bone or thyroid cancers specifically. These findings 
were also borne out in the moderate quality subgroup of studies. 
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Fluorosis
Dental flourosis is the most frequently studied harmful outcome, 
as reflected by the largest number (88) of studies included. Meta-
regression analysis showed a strong (statistically significant) 
association between fluoride level and the prevalence of dental 
fluorosis. 
Bone fractures
Twenty nine of the included studies investigated a variety of 
fracture sites; hip fracture was included in 18 of them. There 
are no definite patterns of association for any of the fractures. 
Similarly to the cancer studies, the studies showed similar numbers 
of positive and negative associations. Hip fracture analysed as a 
subgroup also showed no association with exposure to fluoridated 
drinking water.
Step 5: Interpreting the findings
In this case scenario, you focused on safety of a community-based 
public health intervention. The generally low quality of available 
studies means that interpretation must be with appropriate 
caution. The elaborate efforts in searching an unusually large 
number of databases provide some safeguard against missing 
relevant studies and ongoing research. The strength of the 
evidence summarized in this review is likely to be low, but it is as 
good as it is going to get in the foreseeable future. 
Cancer is the outcome of most interest in the case scenario. No 
association is found between exposure to fluoridated water and 
specific cancers or all cancers. The interpretation of the results in 
this review may be limited because of the low quality of studies, 
but the findings for the cancer outcomes are also supported by the 
moderate quality studies.
Fluorosis (mottled teeth) shows a simple association and also 
a dose–response relationship with increasing exposure to water 
fluoridation. When compared with a fluoride level of 0.4 ppm 
(parts per million), a level of 1.0 ppm had an estimated number 
needed to treat (NNT) of 6 (range 4–21), sometimes called number 
needed to harm (NNH) in this context. This means that on average, 
for every six people exposed to the higher concentrations of 
fluorides, one additional person has mottled teeth. Bone fractures 
did not show an association with water fluoridation. 
Resolution of the scenario
After having spent some time reading and understanding the 
review, you are impressed by the sheer amount of literature 
relevant to the question of safety. However, you are somewhat 
disappointed about the poor quality of the available primary 
The strength of 
the evidence lies 
in the relevance of 
the outcomes, the 
methodological 
quality of the 
included studies, 
the heterogeneity of 
results, the precision 
and size of effects, 
etc, features that 
underpin the trust 
in the inferences 
generated from a 
review.
A dose-response 
relationship 
demonstrates 
that at higher 
doses the strength 
of association 
between exposure 
and outcome is 
increased.
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studies. Of course, examining safety only makes sense in a context 
where the intervention has some beneficial effect. Benefit and 
harm have to be compared to provide the basis for decision 
making. Regarding the issue of the beneficial effect of public 
water fluoridation, you are reassured by the review that your prior 
belief and that of your health authority is correct: drinking water 
fluoridation does prevent caries. You can now go on to evaluate 
the findings of the review on safety – reduction in caries by 
introducing fluoridation can be considered in context with cancer, 
fluorosis, bone fractures and other problems.
When the pressure from the interest groups raises the profile of 
the safety issue again, you will be able to reassure them that there 
is no evidence to link cancer with drinking water fluoridation. You 
will also be able to reassure them that there is no risk of fractures 
to bones. However, you will have to admit the risk of dental 
fluorosis, which appears to be dose dependent. Those concerned 
about this issue can be given advice about examining their fluoride 
intake from other means. You may also want to measure the 
fluoride concentration in your area’s water supply to openly share 
this information with the interest groups.
Being able to quantify the safety concerns of your population 
through a review, albeit from studies of moderate–low quality, 
allows your health authority, politicians and the public to consider 
the balance between beneficial and adverse effects of water 
fluoridation. For some, the prevention of caries is of primary 
importance, so they would prefer fluoridation. On the other hand, 
aesthetic reasons may play a more important role for others who 
would prefer to have caries removed occasionally rather than have 
mottled teeth. In any case, you are able to reassure all parties that 
there is currently no evidence of a risk of cancer or bone fractures 
from drinking water fluoridation.
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●● Case study 3: 
Reviewing evidence on 
effectiveness of therapy
Not all reviews can provide answers that have immediate practical 
implications. And this may be due to a dearth of relevant studies. 
But lack of evidence of effectiveness should not be interpreted as 
evidence of lack of effectiveness. 
This case study will demonstrate how to seek and assess 
evidence of therapeutic effectiveness in a review and how to act 
when faced with limited evidence. Based on a published review, 
it will provide a good demonstration of the application of review 
theory related to literature identification, study quality assessment 
and synthesis without meta-analysis. 
Scenario: Antimicrobial therapy for 
chronic wounds
You are a clinical research fellow in an academic primary 
healthcare practice. There are a large number of patients with 
chronic wounds of various aetiologies. You have taken it upon 
yourself to develop an evidence-based clinical strategy for use 
of antimicrobials in management of these patients. Your initial 
discussions with other members of the practice reveal that they 
base their management on:
●● what they had learnt many years ago during medical school
●● what they observed from the nurses on the wards during 
postgraduate training
●● what they have been told by pharmaceutical company 
representatives.
Hardly anybody could underpin their advice by good evidence. 
There are a variety of antimicrobial products and there seems to be 
no clear way forward. 
You are keen to conduct a review yourself but, sensibly, you first 
decide to see if there is one already out there in the literature. You 
search MEDLINE using PubMed Clinical Queries at www.ncbi.nlm.
nih.gov/entrez/query/static/clinical.html. You type ‘antimicrobial 
chronic wounds’ in the query box of the Systematic Reviews 
feature and click the Go button. You find the following references, 
which are two reports of a relevant review:
●● Systematic review of antimicrobial agents used for chronic 
wounds. Br J Surgery 2001; 88: 4–21. (this review is based on the 
citation below).
●● Systematic review of wound care management: (3) antimicrobial 
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agents for chronic wounds. Health Technol Assess 2000: 4; 21. 
(available at www.ncchta.org/execsumm/summ421.htm).
This case study was developed as a learning aid in 2002. An update 
search carried out for the second edition of this book revealed one 
further review:
●● Antibiotics and antiseptics for venous leg ulcers. Cochrane 
Database Syst Rev 2008; Issue 1: CD003557.
Its findings were compatible with the conclusions of the original 
case study. So we decided to keep this case study on safety in the 
same form as it was presented in the first edition. In the section 
on resolution of scenario we provide additional information from 
this new review.
Step 1: Framing the question
Free form question 
Which of the many available antimicrobial products improve 
healing in patients with chronic wounds? 
Structured question (also see Boxes 1.2 
and 1.3)
The population Adults with various forms of chronic wounds 
being cared for in an ambulatory setting. 
We narrow down the definition of chronic 
wounds to diabetic ulcer, venous ulcer, 
pressure ulcer and chronic ulcer (excluding 
pilonidal sinus – which was included in the 
related reviews – from further consideration 
in this case study).
The interventions Systemic or topical antimicrobial 
preparations (e.g. antibiotics, antifungal, 
antiviral, antiseptic agents) compared with 
usual treatment, placebo or alternative 
antimicrobial products (excluding studies 
about prevention).
The outcomes A range of assessment for wound healing, e.g. 
complete healing, change in ulcer size, rate 
of healing, time to heal, etc. Complete wound 
healing is the clinically relevant outcome 
while the rest are surrogates.
The study designs Comparative studies with or without 
randomization (selection of non-randomized 
studies restricted to those with a concurrent 
control group).
Question 
components
The population: 
A clinically suitable 
sample of patients.
The interventions: 
Comparison 
of groups with 
and without the 
intervention.
The outcomes: 
Changes in health 
status due to 
interventions.
The study design: 
Ways of conducting 
research to assess 
the effect of 
interventions.
Surrogate 
outcome 
measurements 
substitute for 
direct outcome 
measures. They 
include physiological 
variables or 
measures of 
subclinical disease. 
To be valid, the 
surrogate must 
be statistically 
correlated with the 
clinically relevant 
outcome.
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Step 2: Identifying relevant 
literature 
A comprehensive search was undertaken by the reviewers (without 
language restrictions) to identify as many relevant published and 
unpublished studies as possible. The electronic search covered 
17 databases from their inception to January 2000 (Box C3.1). 
The combination of search terms used for the Medline database 
is shown in Box C3.2. Other databases were searched using a 
modified combination of these terms. In addition, manual searches 
of five relevant journals not covered by the electronic databases, 
12 proceedings of relevant meetings and bibliographies of all 
retrieved articles were undertaken. A panel of subject experts was 
also consulted to identify studies not captured by the searches. 
Examples of going to such great lengths to hunt down relevant 
literature are not as common as one might think in the field 
of systematic reviews. The initial search provides 400 possibly 
relevant citations. After screening their titles and abstracts, 150 
papers are retrieved for examination of the full text. Despite the 
exhaustive efforts, ultimately only 22 studies (including over 1000 
patients) are found that address the question posed. 
Step 3: Assessing study quality 
Study design threshold for study 
selection 
From the outset, there was a worry that only a few studies with 
sound designs would be available. So the threshold for study 
selection had been lowered to allow observational studies with 
concurrent controls to be included along with randomized 
controlled trials and experimental studies without randomization 
(Box 1.4). Comparative studies with historical controls and case-
control studies were excluded because of the higher risk of bias 
associated with these designs (Box 2.4). Of the 22 studies selected, 
18 claimed to be experimental studies (but only four were clearly 
randomized, though with some deficiencies in concealment of 
allocation), and four were observational cohort studies with 
concurrent controls.
Description of quality of the selected 
studies
The development of a quality checklist is outlined in Box C3.2. 
The selected studies are systematically examined for key generic 
biases: Is there potential for selection bias?, for performance 
bias?, for measurement bias? or for attrition bias? (Box 3.2). At the 
same time, quality issues specific to the populations, interventions 
and outcomes of the review question were considered. In this 
review, appropriateness of inclusion and exclusion criteria and 
Identifying 
relevant literature
●⦁ Develop search 
term combinations 
●⦁ Search relevant 
electronic 
databases
●⦁ Search other 
relevant resources 
●⦁ Select citations to 
retrieve potentially 
relevant papers
●⦁ Include/exclude 
studies using 
pre-set selection 
criteria
Study design filter 
employs a search 
term combination to 
capture citations of 
studies of a particular 
design.
The quality of a 
study depends on the 
degree to which its 
design, conduct and 
analysis minimizes 
biases.
Bias either 
exaggerates or 
underestimates the 
‘true’ effect of an 
intervention.
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Box C3.1 Identification of relevant literature on 
antimicrobials for chronic wounds
Electronic databases searched*
1. BIOSIS Previews (a database on life 
sciences)
2. British Diabetic Association Database 
3. CINAHL (Cumulative Index of Nursing 
and Allied Health Literature)
4. CISCOM (Computerised Information 
Service for Complementary  
Medicine)
5. Cochrane Database of Systematic 
Reviews (CDSR)
6. Cochrane Wounds Groups developing 
database 
7. Current Research in Britain (CRIB)
8. Database of Abstracts of Reviews of 
Effectiveness (DARE)
9. DHSS (Database produced by the 
Department of Health, UK on health 
services provided by the NHS nursing 
and primary care; people with 
disabilities and elderly people) 
10. Dissertation Abstracts
11. EMBASE (Excerpta Medica Database)
12. Index to Scientific and Technological 
Proceedings 
13. ISI® Science Citation Index
14. MEDLINE (see search term 
combinations in Box C3.2)
15. National Research Register (NRR)
16. Royal College of Nursing Database
17. System for Information on Grey 
Literature in Europe (SIGLE)
Study identification flow chart
Diabetic ulcers n = 3
Venous ulcers: n = 9
Pressure ulcers: n = 4
Chronic ulcers of mixed aetiologies: n = 6
Potentially relevant citations identified through
comprehensive electronic searching of databases, hand
searching and contact with experts
n = 400 citations with titles and abstracts
Retrival of hard copies of potentially relevant citations
n = 150 papers
Studies included in systematic review
n = 22
Citations excluded
 n = 250
Studies excluded after
assessment of full text
 n = 128
* Economic evaluations were included in the original review, but as the question in this 
case study is concerned with effectiveness, we have not described them here.
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Box C3.2 Search term combination for Ovid MedlIne 
database to identify citations on antimicrobials for chronic 
wounds
The original search term combination consists of 58 sets of terms. The following table 
shows only a selection of these. The purpose is to demonstrate how to build a search 
term combination.
Question components and a selection of 
relevant terms
Type of terms Boolean operator
(see glossary)Free MeSH
The populations: patients with various forms of chronic wounds
1. decubitus ulcer/ or foot ulcer x
OR (captures population)
2. leg ulcer/ or varicose ulcer/ x 
3. skin ulcer/ x 
4. diabetic foot/ x
5. ((plantar or diabetic or heel or venous or stasis 
or arterial) adj. ulcer).tw
x
6. ((decubitus or foot or diabetic or ischaemic or 
pressure) adj. ulcer).tw
x
7. ((pressure or bed) adj. Sore$ x 
8. additional terms (see in original report of the 
review)
 
9. or/1–9
The interventions: treatments for chronic wounds
10. debridement/ or biological dressings/ or 
bandages 
x
OR (captures intervention)
11. occlusive dressings/ or clothing/ or wound 
healing/
x
12. antibiotics/ or growth substances/ or platelet-
derived growth factor/
x
13. (debridement or dressing$ or compress$ or 
cream$ or (growth adj factor$)).tw
x
14. antibiotic$ or (electric adj therapy) or laser$ or 
nutrition$ or surg$).tw
x
15. (homeopath$ or acupuncture or massage or 
reflexology or ultrasound).tw
x
16. additional terms (see in original report of the 
review)
17. or/10–17
The outcomes
No search is performed to capture outcomes
18. and/9,17 AND (combines population 
and intervention)
The study designs
19. random allocation/ or randomized controlled 
trials/
x
OR (captures study designs)
20. controlled clinical trials/ or clinical trials phase I/ 
or clinical trials phase II/
x 
21. single-blind method/ or double blind method/ x
22. ((random$ adj controlled adj trial$) or 
(prospective adj random$).tw.
x
23. additional terms (see in original report of the 
review)
24. or/19–23
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comparability of groups at baseline for severity of ulcers was 
particularly important because there were concerns about 
inadequacies of methods used for minimizing selection bias. 
Assessment of the wound healing process to determine outcomes 
is critical even when measurement bias is minimized by blinding 
outcome assessors. This is because outcome assessment could be 
qualitatively different. For example, when assessing healing, the 
outcomes could be any one of complete healing, ulcer healing 
quotient, healing index, improvement scores, etc. Complete 
healing should be regarded as the most important outcome 
due to its importance to patients. Considering both generic and 
specific issues, a quality checklist with a total of nine items can be 
developed as shown in Box C3.3. 
This checklist is applied to studies included in the review (Box 
C3.4), but the quality is often unclear due to lack of reporting. 
Where information on quality is available, many studies fall short 
of meeting the desired quality. For example, even when studies 
purport to be randomized, there are deficiencies both in sequence 
generation and in allocation concealment.
Step 4: Summarizing the evidence 
A brief descriptive summary of the studies’ characteristics 
and effects is tabulated in Box C3.5. A number of treatment 
comparisons were available but only in studies with a small 
number of patients (range 8–52 per group). Duration of follow-up 
also varied (range 2–20 weeks) and there was no consistency in 
Question components and a selection of 
relevant terms
Type of terms Boolean operator
(see glossary)Free MeSH
18 and 24 AND (combines 
population and 
intervention and study 
designs)
25. limit 25 to human
Commands and symbols for Ovid MEDlINE
$ Truncation, e.g. antibiotic$ will pick up antibiotics in general as well as different 
types of antibiotics (e.g. antibiotics, aminoglycosides; antibiotics, lactam)
adj  Proximity and adjacency searching, e.g. chronic adj wounds$ means that these 
terms appear next to each other
.tw  Textword search, e.g. skin adj ulcer.tw will search for these adjacent textwords in 
title or abstract
/  Medical subject heading (MeSH) search, e.g. diabetic foot/ will search for MeSH in 
indexing terms
The original search is part of the full report of the review available at www.ncchta.org/
execsumm/summ421.htm.
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Box C3.3 A quality assessment checklist for studies on 
effectiveness of antimicrobials for chronic wounds
The clinical question and selection criteria
●● Nature of question Assessment of effectiveness
●● Study design  Evaluation of effectiveness of therapy, focusing on how one 
treatment compares with another (see Box 1.4)
●● Study design threshold  Inclusion criteria:   Randomized controlled trials (see Box 
5.2)
    Experimental studies without 
randomization
    Cohort studies with concurrent controls 
  Exclusion criteria:  Studies with historical controls
   Case-control studies
The quality checklist
a) Generic quality items for checklist (see also Boxes 3.2 and 3.3)
●● Adequate generation of random sequence for allocating patients to 
interventions
Computer generated random numbers or random numbers tables 
●● Adequate concealment of allocation
Robust methods to prevent foreknowledge of the allocation sequence to clinicians 
and patients, e.g. centralized real-time or pharmacy-controlled randomization in 
unblinded studies, or serially numbered identical containers in blinded studies 
●● Adequate blinding 
Care provider, study patients and outcome assessors 
●● A priori sample size estimation
●● Description of withdrawals
Numbers and reasons provided for each group
●● Intention-to-treat analysis (ITT) 
Inclusion of all those who dropped out/were lost to follow-up in the analysis so that 
the calculations indeed follow the ITT principle
b) Specific quality items related to clinical features of the review 
question
●● The population
Correct inclusion/exclusion criteria
Comparison of severity of wound condition at baseline
●● The interventions 
No items 
●● The outcome
Importance of outcomes: complete healing (critical); ulcer healing quotient, healing 
index, improvement scores and microbial growth (surrogates))
See Box C3.4 for description of study quality
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Box C3.4 description of the quality of studies on 
antimicrobials for chronic wounds
4 17 1
1
10 5 7
2 20
6 6 10
10 7 5
16 6
14 6 2
7
0%
Unclearly reportedYes No
25% 50% 75% 100%
14
17 4
Adequate random sequence generation
Adequate allocation concealment
Adequate blinding
A priori sample size estimation
Intention-to-treat analysis
Description of withdrawals
Correct inclusion/exclusion criteria
Baseline comparison
Outcome: Complete wound healing
Specific quality items
Generic quality items
Compliance with quality items
Information on quality presented as 100% stacked bars
Data in the stacks represent number of studies
See Box C3.3 for related information on quality items.
measures of outcomes. This variation in what is done to whom, 
over what period and how outcomes are assessed, introduces 
clinical heterogeneity and this makes a meaningful synthesis of 
results difficult (and makes meta-analysis impossible). 
An examination of the observed effects in individual studies 
shows large values for point estimates of odds ratios (OR), but 
most effects are not statistically significant as the 95% confidence 
intervals (CI) include the possibility of no beneficial effect or 
even a harmful effect. For example, Wunderlich (1991) found 
that a silver-based product SIAX was better than various control 
regimens with an OR of 3.9 but the 95% CI is 0.7–22.1. Similarly, 
Heterogeneity 
is the variation of 
effects between 
studies. It may 
arise because of 
differences between 
studies in key 
characteristics of 
their populations, 
interventions and 
outcomes (clinical 
heterogeneity), 
and their study 
designs and quality 
(methodological 
heterogeneity).
Effect is a measure of association between an intervention and an 
outcome.
Point estimate of effect is its observed value in a study.
Confidence interval is the imprecision in the point estimate, i.e. the 
range around it within which the ‘true’ value of the effect can be 
expected to lie with a given degree of certainty (95%). This reflects 
uncertainty due to play of chance.
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Alinovi (1986) showed that healing rate was worse when standard 
care was supplemented by systemic antibiotics compared with 
standard care alone with an OR of 0.54, but 95% CI is 0.1–1.9. 
Even when effects were statistically significant, e.g. Morias (1979) 
reports OR 20.3 (95% CI 1.1–375.1), the estimation is quite 
imprecise due to small sample size. Considering the low quality of 
the studies, one could hardly be enthused to trust such a result, 
even when it is statistically significant. 
Step 5: Interpreting the findings
This review shows that research on the value of different 
antimicrobial products in wound care is scarce. Despite an 
exhaustive search effort, there are only a few relevant studies (Box 
C3.1) and their quality is relatively low (Box C3.4). A descriptive 
summary of the evidence shows that the observed effects are 
seemingly good (perhaps one reason why these studies are 
published despite their low quality), but they are imprecise, as 
insufficient numbers of patients are studied (Box C3.5). Technically 
speaking, the studies are likely to be underpowered. In this 
situation, the studies are unable to detect an effect when one 
possibly exists, so one cannot prove the lack of effectiveness of 
the interventions. None of the numerous antimicrobials currently 
in use for various types of chronic ulcers has been robustly 
assessed, i.e. with appropriate design and conduct, clinically 
relevant outcomes and large enough sample size. Thus, no 
recommendations can be made regarding superiority or lack of 
effectiveness of any of the antimicrobial agents. Needless to say, 
additional research is needed. 
Resolution of the scenario
You are taken by surprise about the slim and feeble body of 
evidence on such a common problem as chronic wounds, which 
have a significant impact on healthcare resources in your primary 
healthcare setting. For you, it is currently not possible to inform a 
clinical policy on the management of chronic wounds with robust 
evidence. 
Lack of evidence of effectiveness does not equate with evidence 
of lack of effectiveness! So you decide to form the most sensible 
policy using common sense and the consensus of your colleagues 
(this keeps everyone happy). However, you obtain agreement to 
periodically seek new evidence and update your policy when new 
robust evidence becomes available. 
To help fill the gap in evidence that you have identified through 
this review, there are some other options open to you. To help 
generate the new evidence:
●● the least you can do is submit this topic to relevant research 
funding bodies for prioritization
Power is the 
ability of a study 
to statistically 
demonstrate an 
effect when one 
exists. It is related 
to sample size. The 
larger the sample 
size, the more the 
power, and the 
lower the risk that a 
possible effect could 
be missed. 
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Box C3.5 A brief summary of the findings of studies included in a systematic review on antimicrobials 
for chronic wounds
(not all comparisons included in the original review are presented in this table)
Population subgroups
Interventions
(number of patients/ulcers in group)
Outcomes Effects
Study author & year of publication
Control group
(standard/placebo)
Experimental group Observation period Outcome measure+
Effect estimate*
(95% CI)
Diabetic ulcer Systemic treatments
Chanteleau 1996 Placebo (22) Antibiotics (22)  3 weeks Complete healing OR: 0.45 (0.1–1.6)
Lipsky 1990 Cephalexin (29) Clindamycin (27)  2 weeks Complete healing OR: 1.31 (0.4–4.0)
Topical treatments
Vandeputte (unpublished) Hydrogel (15) Chlorhexidine (14) 12 weeks Complete healing OR: 0.07 (0.007–0.7)
Venous ulcer Systemic treatments
Huovinen 1994 Ciprofloxacin (12) Trimethoprim (12) 12 weeks Complete healing OR: 2.14 (0.38–12.2)
Alinovi 1986 Standard (24) Antibiotics+ standard (24)  3 weeks Complete healing OR: 0.54 (0.1–1.9)
Topical treatments
Pierard-Franchimont 1997 Hydrocolloid (21) Povidone iodine + 
hydrocolloid (21)
 8 weeks Median healing index ES: 1.00 (–0.4–2.4)
Bishop 1992 Placebo (29) Silver sulphadiazine (30)  4 weeks Complete healing OR: 7.57 (0.8–67.4)
Cameron 1991 Non-medicated tulle gras 
(15)
Mupirocin-impregnated 
tulle gras (15)
12 weeks Complete healing OR: 1.31 (0.31–5.49)
Salim 1991 Allopurinol (51) Dimethyl sulphoxide (50) 12 weeks Complete healing OR: 2.04 (0.36–11.69)
Wunderlich 1991 Various preparations (20) Silver impregnated 
activated charcoal 
dressing (20)
 6 weeks Complete healing OR: 3.86 (0.7–22.1)
Blair 1988 Saline (30) Silver sulphadiazine (30) 12 weeks Complete healing OR: 0.43 (0.14–1.38)
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Pegum 1968 Lint (17) Polynaxylin + lint (17) Until healed Mean ulcer healing 
quotient
ES: –0.30 mm²/day 
(–2.1–1.5)
Pressure ulcers Topical treatments
Della Marchina 1997 Alternative spray (10) Antiseptic spray (9) 15 days Complete healing OR: 2.57 (0.19–34.6)
Toba 1997 Povidone iodine/sugar (11) Gentian violet 0.1% 
blended with dibutyryl 
cAMP (8)
14 weeks Mean % baseline ulcer 
area remaining
ES: 11.1 (–8.69–30.89)
Gerding 1992 A&D ointment (13) DermaMend (26)  4 weeks No. of improved scores OR: 6.57 (1.30–33.34)
Huchon 1992 Hydrocolloid (38) Povidone iodine (38)  8 weeks Improved scores OR: 0.46 (0.2–1.4)
Chronic ulcers of mixed aetiology Systemic treatments
Valtonen 1989 Disinfectant (8) Ciprofloxacin + 
disinfectant (18)
12 weeks Complete healing OR: 3.84 (0.2–83.5)
Morias 1979 Placebo (29) Levamisole (30) 20 weeks Complete healing OR: 20.33 (1.1–375.1)
Topical treatments
Worsley 1991 Hydrocolloid (12) Povidone iodine ointment 
(15)
12 weeks Complete healing 0R: 0.31 (0.05–2.08)
Beitner 1985 Saline (10) Benzoyl peroxide 20% (10)  6 weeks Mean % remaining ulcer 
area
ES: 34.10 (21.1–47.1)
Margraf 1977 Various agents (10) Silver zinc allantoine 
cream (10)
Until healed Mean days to heal ES 59.0 (34.12–83.88)
Marzin 1982 Benzoyl peroxide (20) Collagen gel (20) 12 weeks Wound area remaining No effect estimate 
reported
(p < 0.01)
+  In studies with several outcome measures the most clinically important one is presented using the following hierarchy: complete healing > ulcer 
healing quotient, healing index, improvement scores > microbial growth.
*  Odds ratio (OR) >1 and effect size (ES) > 0 indicates improved outcome with experimental treatment.  See Box 4.1 for advice on constructing 
tables.
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●● you can also design and commence a robust clinical trial 
yourself if you are so inclined and can obtain the funding to do 
this
●● the most practical approach in our view is to actively recruit 
patients in a relevant clinical trial if there is one ongoing.
An update of the review in this case study showed that there 
have been four additional studies. The methodological quality 
of all studies was only moderate due to unclear concealment of 
the treatment allocation, unclear or lack of blinding and their 
uncertain use of intention-to-treat analysis. The studies were 
generally small, three included 21 or fewer patients in each 
treatment arm, whereas the fourth study had more than 100 
patients per arm. Only one trial reported a clinically relevant 
outcome (complete healing rate), while the others measured 
surrogates, e.g. change in ulcer surface area, which may or may 
not be a valid proxy for complete healing. How could this new 
information fill the knowledge gap you identified? There was weak 
evidence that topical preparations like cadexomer iodine improved 
ulcer healing compared to standard care. No evidence supported 
the routine use of systemic antibiotics. You could inform your 
colleagues about the review, and may decide to modify the 
care protocol for patients with chronic wounds, with a weak 
recommendation favouring the use of cadexomer iodine.
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●● Case study 4: 
Reviewing evidence on 
accuracy of a test 
No document of approximately 1800 words can purport to do 
justice to systematic reviews of test accuracy literature. We make 
no attempt to profess mastery of the methodological nuances in 
this expanding and, for some, exciting field. 
In this case study, we reinforce the general principles behind 
systematic reviews by demonstrating their application in a scenario 
concerning use of evidence about accuracy of a test. It provides 
a good demonstration of study quality assessment, exploration 
of heterogeneity, quantitative synthesis and interpretation of 
findings.
Scenario: Ultrasound scan test 
for postmenopausal women with 
vaginal bleeding
You are a clinician responsible for women’s health in a primary 
care centre serving a relatively large retired population. You are 
often faced with women who present with unexpected episodes 
of vaginal bleeding after menopause. You know that in the past 
these patients used to be routinely investigated by gynaecologists 
using uterine curettage under anaesthesia. This practice is now 
considered outdated, but current local practice still involves 
referral to a specialist based in a tertiary care setting. You wonder 
if an ultrasound scan of the uterus can exclude pathology 
accurately in postmenopausal women with abnormal vaginal 
bleeding. In this way, women who test negative will not need 
referral to tertiary care. 
You search MEDLINE using PubMed Clinical Queries to see 
if there are any reviews in the literature. At www.ncbi.nlm.
nih.gov/entrez/query/static/clinical.html you type ‘ultrasound 
postmenopausal bleeding’ in the query box of the Systematic 
Reviews feature and click the Go button. You find the following 
seemingly relevant citations on this topic:
●● Evaluation of the woman with postmenopausal bleeding: Society 
of Radiologists in Ultrasound-Sponsored Consensus Conference 
statement. J Ultrasound Med 2001; 20: 1025–36. (this is not a 
review)
●● Ultrasonographic endometrial thickness for diagnosing 
endometrial pathology in women with postmenopausal 
bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002; 81: 
799–816.
Step 1 
Framing questions
Ø
Step 2 
Identifying relevant 
literature
Ø
Step 3 
Assessing quality of 
the literature
Ø
Step 4 
Summarizing the 
evidence
Ø
Step 5 
Interpreting the 
findings
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This case study was developed as a learning aid in 2002. An  
update search carried out for the second edition of this book 
revealed no further review that was incompatible with the 
conclusions of the original case study. So we decided to keep 
this case study in the same form as it was presented in the first 
edition.
Step 1: Framing the question
Free form question 
Among postmenopausal women with abnormal vaginal bleeding, 
does ultrasound scan exclude uterine cancer accurately?
Structured question
The population Postmenopausal women in the 
community with symptoms of vaginal 
bleeding.
The test Endometrial thickness measurement 
during ultrasound imaging of the pelvis 
and the uterus (see Box C4.1). You are 
mainly interested in the accuracy of the 
negative test result.
The reference standard Endometrial cancer confirmed 
histologically. There are many 
abnormalities of the endometrium 
and the uterus (benign, pre-cancer 
and cancer). Among your population, 
endometrial cancer is the most 
important one. Focusing on this 
diagnosis is not unreasonable (not least 
for the sake of simplicity in this case). 
You are mainly interested in excluding 
the diagnosis of cancer.
The study design Test accuracy study (Box C4.3), i.e. 
observational studies in which results 
of a test (endometrial ultrasound) 
are compared with the results of 
a reference standard (endometrial 
histology).
Step 2: Identifying relevant 
literature
An electronic search was carried out to capture all the relevant 
citations about ultrasound of the endometrium and then 
those citations identified that evaluate ultrasound among 
postmenopausal women with vaginal bleeding to predict the 
likelihood of endometrial cancer. MEDLINE and EMBASE databases 
Free form 
question: It 
describes the query 
for which you seek 
an answer through 
a review in simple 
language (however 
vague).
Structured 
question: Reviewers 
convert free form 
questions into a 
clear and explicit 
format using a 
structured approach 
(see Box 1.2). 
This makes the 
query potentially 
answerable through 
existing relevant 
studies. 
Question 
components
The population: 
A clinically suitable 
sample of patients
The test: The test 
whose predictive 
value is being 
assessed 
The reference 
standard: A ‘gold’ 
standard test that 
confirms or refutes 
the diagnosis
The study design: 
Ways of conducting 
research to assess 
the predictive value 
of the test
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were searched without language restrictions. The search term 
combination included MeSH, textwords and appropriate word 
variants of ‘“ultrasound OR sonography” AND “endometrium 
OR uterus”’. The resultant set of citations was limited to human 
studies. The electronic search was coupled with manual scanning 
of bibliographies of known primary and review articles to identify 
relevant papers (Box C4.2). In total 57 studies (including 9031 
patients) were included in the review. Of these, 21 studies were 
on the accuracy of endometrial thickness, at a 5 mm abnormality 
threshold, to predict the diagnosis of endometrial cancer. 
Step 3: Assessing study quality
Quality assessment of test accuracy 
studies
An accuracy study is different from an effectiveness study. It 
is designed to generate a comparison between measurements 
obtained by a test and those obtained by a reference standard. A 
reference standard is a test that confirms or refutes the presence 
or absence of disease beyond reasonable doubt. Therefore it is 
sometimes also known as the ‘gold’ standard. We shall give a 
basic explanation about the design and quality features of a test 
accuracy study (Box C4.3).
There are many possible sources of bias in accuracy studies, as 
shown in Box C4.3. Selection bias may arise if the sample is not 
suitably representative of the population. This is less likely to occur 
when using consecutive or random sampling. Poor descriptions 
of test and reference standards in terms of preparation of the 
patients, details of measurements, computation of results and 
thresholds for defining abnormality are also associated with bias. 
The reference standard should be a recognized ‘gold’ standard 
and it should be administered independently of the test. In 
Identifying 
relevant literature
●⦁ Develop search 
term combinations 
●⦁ Search relevant 
electronic 
databases
●⦁ Search other 
relevant resources 
●⦁ Obtain full papers 
of potentially 
relevant citations
●⦁ Include/exclude 
studies using 
pre-set selection 
criteria
The quality of a 
study depends on the 
degree to which its 
design, conduct and 
analysis minimizes 
biases.
Bias either 
exaggerates or 
underestimates the 
‘true’ accuracy of 
a test.
Box C4.1 Ultrasound scan of the pelvis and the uterus
In ultrasound imaging of the uterus, the endometrium (lining of the womb) is described 
in terms of thickness and regularity. Regular endometrium of less than 5 mm thickness 
is often used to define a threshold or cut-off for abnormality. An example of a normal 
test result is shown below.
122 Systematic Reviews to Support Evidence-based Medicine
Box C4.2 Identification of relevant literature on endometrial 
ultrasound
Potentially relevant citations identified through
comprehensive electronic searching of MEDLINE and
EMBASE databases
n = 551 citations with titles and abstracts
Retrieval of hard copies of potentially relevant citations
n = 145 papers
Identified through electronic search: n = 115
Identified through review of bibliographies: n = 30
Studies included in the meta-analysis used in this case
Endometrial thickness to exclude diagnosis of cancer at
5mm cut-off
n = 21
Studies included in the published review
n = 57
Citations excluded
 n = 436
Studies excluded after
assessment of full text
 n = 88
addition, observers assessing reference standards for verification 
of diagnosis should be kept blind to measurements obtained from 
the test, and vice versa. Blinding avoids bias because recordings 
made by one observer are not influenced by the knowledge of the 
measurements obtained by other observers. During the verification 
process, bias may arise if the reference standard is not applied to 
all patients, or if it is differentially applied to test-positive and 
test-negative cases. 
A detailed quality checklist is developed for assessment of test 
accuracy studies on endometrial ultrasound using the principles 
outlined in Step 3. We consider the elements of study design 
(generic items) and couple them with issues relevant to the review 
question (specific items), as shown in Box C4.3. An overview of 
the relevant generic aspects of test accuracy studies in this review 
reveals that the ultrasound test and the histological examination 
of the endometrium, which serves as the reference standard, are 
independent. So the remaining methodological issues related to 
recruitment of patients, blinding of observers and completeness of 
verification of diagnosis are examined. 
Among quality issues related specifically to the review question, 
a sufficient description of the population to demonstrate that the 
sample is representative of the disease spectrum seen in practice 
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Box C4.3 Design and quality of test accuracy studies 
evaluating endometrial ultrasound
Simple description of study design
An observational study that tests subjects from a relevant population and compares 
its results with those of a reference standard. For example, studies comparing results 
of endometrial ultrasound with those of endometrial histology in women with 
postmenopausal bleeding.
Study flow chart with key generic quality features
Study sample
Test
Test positive Test negative
Estimation of test accuracy,
e.g. likelihood ratios
Reference standard Reference standard
The reference standard
Independent of test
Conducted blind to test result
Verified fully in both test
positive and test negative
cases
The population
A clinically appropriate
consecutive or random
sample
The test
Measurement
Cut-off for abnormality
Outcome
present
False
negative
Outcome
absent
True
negative
Outcome
present
True
positive
Outcome
absent
False
positive
Development of a quality checklist
a) Generic items obtained from the published research appraisal 
guidelines on test accuracy
●● recruitment of subjects (consecutive or random sample)
●● independence between the test and the reference standard 
●● blinding of the observers conducting the reference standard to the findings of the 
test and vice versa
●● verification of diagnosis by reference standard in all tested cases.
b) Specific items related to features of this review
●● The population  Appropriate spectrum composition 
●● The test Adequate description of endometrial ultrasound measurements 
determining cut-off level for abnormality a priori
●● The reference 
standard
 Adequate endometrial samples obtained for reference standard 
histology. Hysterectomy and directed biopsy are adequate but 
blind (non-directed) biopsy may be less satisfactory.
See Box C4.4 for results of quality assessment.
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is essential, otherwise the estimates of accuracy may be biased. 
For the test, a priori setting of the 5 mm threshold is crucial, as 
post hoc determination of threshold is subject to manipulation in 
light of findings of the study. Finally, for the reference standard, 
use of adequate endometrial sampling is crucial to the validity of 
the selected studies. Adequate methods of obtaining endometrial 
samples include hysterectomy and directed biopsy.
Study design threshold for study 
selection
In this review a quality threshold in study selection was used to 
exclude all studies with case-control design. These studies would 
have selected cases with and without cancer and patients would 
be retrospectively examined if their endometrial ultrasound scans 
were abnormal. Such a design has been empirically shown to be 
associated with bias, leading to exaggeration of test accuracy. 
Description of study quality for 
selected studies
Box C4.4 indicates the quality of selected studies. For most of the 
quality items, lack of compliance with good quality features was 
due to lack of reporting. In general, there were deficiencies of one 
sort or another among all studies. The impact of these deficiencies 
on the estimation of accuracy is explored in Box C4.6.
Step 4: Summarizing the evidence
This case study describes the estimates of accuracy of individual 
studies, the examination of heterogeneity of accuracy across 
studies and the meta-analysis of individual accuracy estimates 
among studies using 5-mm thickness as the threshold for 
abnormality (other details of included studies can be obtained 
from the original report). But first we must understand how to 
choose a measure of accuracy (Box C4.5). The discussion about 
the pros and cons of various accuracy measures is a never-ending 
story in which there is no consensus among experts and it is 
outside the remit of this book. To cut a long story short, sensitivity 
and specificity are often considered to be of a limited clinical 
value. For the question posed in this case study, you are interested 
to discover the value of a negative endometrial ultrasound test (at 
a threshold of 5-mm thickness) for excluding endometrial cancer. 
This case study describes the statistical synthesis using individual 
likelihood ratios (LR) for negative test result. For meta-analysis 
it uses a bivariate model to derive summary LRs. This approach 
provides the most robust summary estimates, although description 
of its detail is outside the scope of this book.
Likelihood ratio 
(LR) is the ratio of 
the probability of a 
positive (or negative) 
test result in subjects 
with a disease to 
the probability of 
the same test result 
in subjects without 
the disease. The LR 
indicates by how 
much a given test 
result will raise or 
lower the probability 
of having the 
disease.
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Variation in test accuracy from study to 
study
The point estimate of accuracy in each study, its precision 
(confidence interval) and the possibility of heterogeneity can be 
explored by examining variability of individual LRs in a Forest plot. 
As shown in Box C4.6, there is a suspicion about heterogeneity, 
as confidence intervals do not overlap among some studies. 
Heterogeneity was confirmed by a formal statistical test. When 
heterogeneity was found, its possible sources were searched for 
using subgroup analysis examining the impact of study quality and 
characteristics (not shown here). No explanation for heterogeneity 
could be found. 
Quantitative synthesis of results
In this instance heterogeneity remains unexplained despite an 
exhaustive exploration. Now do we, or do we not, perform meta-
analysis? As discussed in Step 4, caution is required. In this review, 
authors chose to pool individual LRs using the random effects 
Heterogeneity 
is the variation of 
accuracy between 
studies. It may 
arise because of 
differences between 
studies in key 
characteristics of 
their populations, 
tests and reference 
standards (clinical 
heterogeneity), 
and their study 
designs and quality 
(methodological 
heterogeneity).
Box C4.4 Description of quality of studies on accuracy of 
endometrial ultrasound
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0% 25% 50% 75% 100%
Adequate reference standard
Adequate test description
Appropriate patient spectrum
Specific quality items
Over 90% verification of diagnosis
Blinding of results
Consecutive recruitment
Generic quality items
Compliance with quality items
Yes Unclearly reported No
Information on quality presented as 100% stacked bars
Data in the stacks represent the number of studies
See Box C4.3 for related information on the development of the quality checklist
See Box C4.6 for subgroup analysis.
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Box C4.5 Estimation of accuracy in studies evaluating tests
Measures of test accuracy
These are statistics for summarizing the accuracy of a test. For binary tests, there are 
three commonly used pairs of accuracy measures: positive and negative predictive 
values; sensitivity and specificity; and likelihood ratios. Unlike measures of effect, 
single measures of accuracy are infrequently used.
Computing accuracy for binary test results
A way of computing accuracy measures is shown below. Predictive values give the 
probability of having a disease and not having a disease among subjects with positive 
and negative test results respectively. Sensitivity and specificity give the probability 
of a positive and a negative test result among subjects with and without disease 
respectively. Likelihood ratios (LRs) describe the relative probabilities of obtaining a 
test result in subjects with and without a disease. However, with several studies to 
compute accuracy for and to estimate uncertainty of the accuracy (its confidence 
intervals), manual calculations can become tedious. We would suggest you use 
statistical software.
Study sample
Test
Test positive Test negative
Reference standardReference standard
True positive
TP
False positive
FP
Present
Disease
Absent
FP
TN
TP
FN
Accuracy estimates for positive test results
Positive predictive value = TP/(TP+FP)
Specificity = TN/(TN+FP)
Likelihood Ratio for positive test result
LR+ = [TP/(TP+FN)]/[FP/(FP+TN)]
Accuracy estimates for negative test results
Negative predictive value = TN/(TN+FN)
Sensitivity = TP/(TP+FN)
Likelihood Ratio for negative test result
LR– = [FN/(FN+TP)]/[TN/(TN+FP)]
False negative
FN
True negative
TN
Positive
Negative
Test
Choosing accuracy measures for binary tests
There is a debate about which measures are preferable and how best to pool them 
across several studies in a meta-analysis. No single approach is entirely satisfactory. 
Likelihood ratios (LRs) are more clinically meaningful because when they are used in 
conjunction with information on disease prevalence (pre-test probability), they help to 
generate post-test probabilities as shown in Box C4.7. Pooling of individual sensitivity 
(Sn) and specificity (Sp) results should take into account their interrelationship, as they 
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model (not shown in the case study). Precaution was taken to 
ensure that the summary point estimate was not biased by the 
choice of this method compared to a fixed effect model. Box 
C4.6 shows accuracy of the 21 studies evaluating the accuracy 
of endometrial ultrasound using LR–, sensitivity and specificity. 
A meta-analysis using a bivariate model produced summary 
sensitivity and specificity from which LRs were derived: LR– was 
0.025 (95% CI 0.005–0.118). Interestingly the summary LR+ for 
positive test is 2.14 (95% CI 1.75–2.61) although this information 
was not really required to help with decision making in your case 
scenario.
Bivariate model 
estimates the 
correlation between 
sensitivity and 
specificity and 
incorporates this 
in meta-analysis of 
results from test 
accuracy studies.
may not behave independently. Bivariate method and summary receiver operating 
characteristics plot allows for pooling of results from individual studies taking account 
of the relation between Sn and Sp. LRs are not suitable for pooling in meta-analysis, 
particularly when the threshold for abnormality varies from study to study. The 
preference for LRs over other accuracy measures for clinical interpretation can be met 
by deriving these from Sn and Sp as LR+ = [Sn/(100–Sp)] and LR– = [(100–Sn0/Sp].
See relevant sections of the glossary for definitions of measures and methods of 
meta-analysis.
Box C4.6 Exploring reasons for variation in accuracy among 
studies evaluating endometrial ultrasound
Forest plot
Summary of likelihood ratios for negative test results (LR–) among studies with an 
endometrial ultrasound test threshold of 5 mm thickness (sorted in alphabetical order).
Abu-Ghazzeh 0.65 [0.06, 7.30]
Briley 0.16 [0.01, 2.35]
Cacciatore 0.37 [0.03, 5.30]
De Silva 0.90 [0.40, 2.03]
Granberg 0.07 [0.00, 1.08]
Grigoriu 0.03 [0.00, 0.47]
Gu 0.22 [0.01, 3.50]
Gupta 0.52 [0.10, 2.61]
Hanggi 0.18 [0.06, 0.52]
Ivanov 0.08 [0.01, 1.18]
Karlsson 0.10 [0.02, 0.69]
Lovero 0.02 [0.00, 0.36]
Malinova 2 0.01 [0.00, 0.23]
Merz 0.08 [0.00, 1.21]
Nasri 0.10 [0.01, 1.40]
Nasri 2 0.12 [0.01, 1.69]
Perti 0.20 [0.03, 1.36]
Suchocki 0.14 [0.01, 2.31]
Taviani 0.31 [0.02, 3.96]
Weber 0.04 [0.01, 0.29]
Wolmann 0.16 [0.01, 2.19]
Total (95% Cl) 0.15 [0.08, 0.29]
.001 .02 1 50 1000
128 Systematic Reviews to Support Evidence-based Medicine
Plot of sensitivity vs specificity
Sensitivities and specificities among studies with an endometrial ultrasound test 
threshold of 5 mm thickness are shown with empty circles. Summary estimate of 
sensitivity (98%; 95% CI 93-99%) and specificity (53%; 95% CI 44–63%) obtained 
using bivariate model is shown with a filled square and its confidence intervals shown 
with a dotted ellipse around the square. Likelihood ratios can be derived from these 
estimates as LR+ = [Sn/(100–Sp)] and LR– = [(100–Sn0/Sp].
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Step 5: Interpreting the findings 
The prevalence of endometrial cancer varies according to age. So 
the likelihood or probability of cancer given a negative ultrasound 
test result will also vary. The changes in probability produced by 
the summary LR– can be mathematically computed or they can be 
estimated using a nomogram (see Box C4.7). A negative test result 
virtually eliminates the possibility of endometrial cancer among 
younger women; however, it may not substantially reduce the 
probability among older women (in our view). 
Resolution of scenario
The answer to your question ‘does a pelvic ultrasound scan 
exclude uterine cancer accurately in postmenopausal women 
with abnormal vaginal bleeding?’ has to be ‘yes, for many of 
your patients’. A negative result at less than 5 mm endometrial 
Pre-test 
probability is 
an estimate of 
probability of 
disease before tests 
are carried out. It 
is usually based on 
disease prevalence.
Post-test 
probability is 
an estimate of 
probability of 
disease in light of 
information obtained 
from testing. With 
accurate tests, the 
post-test estimates of 
probabilities change 
substantially from 
pre-test estimates.
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Box C4.7 The impact of a negative test result in endometrial 
ultrasound (at a 5-mm threshold) on the likelihood of 
endometrial cancer among postmenopausal women with 
vaginal bleeding
Generating post-test probabilities
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LR–
at 5 mm cut-off
Summary LR–
0.025
Pre-test probability
Nomogram adapted from N Engl J Med 1975; 293: 257.
See Box C4.6 for summary likelihood ratio for negative text result, LR–
Post-test probability
Likelihood Ratio
Pre-test probability of
endometrial cancer
without testing
13%
Post-test probability
with negative test
0.37%
Post-test probabilities of endometrial cancer according to risk 
groups based on age
Age group Pre-test probability* Post-test probability+
<50 years 0.5% 0.01%
51-60 years 1.0% 0.03%
>60 years 13.0% 0.37%
* Obtained from population based data
+ Computed using the following formula:
Post-test probability = Likelihood ratio ¥ Pre-test probability
[1 - Pre-test probability ¥ (1 - Likelihood ratio)]
thickness rules out endometrial cancer with good certainty among 
low risk patients (e.g. age < 60 years), so there should be no need 
for you to refer them to tertiary care. It is important to remember 
that there is always a chance of a false-negative test result, even 
among low risk patients. So, if patients remain symptomatic, they 
will need further evaluation. For high risk patients (e.g. age > 60 
years) you don’t have good certainty in ruling out disease from 
a negative ultrasound test, so you might even refer them on to 
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tertiary care without ultrasound testing. Needless to say, your low 
risk patients with ultrasound endometrial thickness greater than 
5 mm would need to be investigated further to ascertain presence 
or absence of pathology in a tertiary care setting. 
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●● Case study 5: 
Reviewing qualitative 
evidence to evaluate 
patient experience
Elaine Denny
The purpose of qualitative research is to explore experience and to 
seek understanding and explanation. Through quantitative research 
one may discover that an intervention is effective, but will patients 
find it acceptable? Will carers provide it? What will facilitate its 
implementation? What will hinder it? Answers to these and other 
related questions lie in exploration of subjective experiences 
of people. There has been an increasing recognition within 
health that many issues such as acceptability of interventions 
cannot fully be captured by quantitative means. Clinicians and 
practitioners need to allow people to relate their experience and 
the way in which they interpret their world in order to understand 
their concerns better. Researchers need to study these subjective 
phenomena to help improve the insight practitioners and policy 
makers have. Thus there has been an increasing amount of 
health-related qualitative research and an interest in summarizing 
findings of qualitative papers in a rigorous way using the tools of 
systematic review, aiding evidence-based practice.
Primary qualitative research deals with very individual responses 
of study participants. This approach does not generate statistical 
averages and it can sometimes be erroneously assumed that this 
leads to problems in conducting systematic reviews. The reality 
is not so bleak. Systematic reviews can be used to integrate 
research findings in a structured way regardless of whether 
the primary studies are quantitative or qualitative. The results 
generated by individual qualitative studies can be collated and 
synthesized to gain new insights. Qualitative reviewers do this 
through metasynthesis, a technique that seeks to gain further 
understanding and explanations of the phenomena researched in 
primary studies. 
This case study will demonstrate how to employ reviews of 
qualitative research to enrich evidence-based medicine. It will 
demonstrate how the key points about appraisal shown at the 
end of each Step in this book can be employed to evaluate such 
reviews for their trustworthiness and usefulness. 
Step 1 
Framing questions
Ø
Step 2 
Identifying relevant 
literature
Ø
Step 3 
Assessing quality of 
the literature
Ø
Step 4 
Summarizing the 
evidence
Ø
Step 5 
Interpreting the 
findings
Qualitative 
research seeks to 
understand the 
way people make 
sense of events and 
experience.
Quantitative 
research involves 
the collection of 
data in numerical 
form, or that which 
can be converted 
to numeric form for 
analysis.
Metasynthesis:
The synthesis of 
existing qualitative 
research findings on 
a specific research 
question. This does 
not involve meta-
analysis. 
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Scenario: The experience of 
endometriosis
You are a general practitioner in a busy practice, and you have 
just had a long consultation with a young woman. She presented 
with chronic pelvic pain and also found sexual intercourse very 
painful, which was affecting her relationship with her partner. She 
told you that the pain was constantly there, although it was worse 
around menstruation, and that she was at the end of her tether. 
You knew from her records that over the years she had consulted 
with some of your colleagues who had prescribed non-steroidal 
anti-inflammatory analgesia and oral contraception, but nothing 
so far had relieved the pain. Your colleagues had suspected 
that she was exaggerating the pain associated with normal 
menstruation. When you questioned how long this had been 
going on she replied that it had been ten years. Having browsed 
the Internet, she suspected that her symptoms may be caused by 
endometriosis. You referred her to a gynaecologist, who carried 
out a laparoscopy. This confirmed the diagnosis of endometriosis. 
You wondered whether referral could have been made earlier.
A MEDLINE search using the search term ‘endometriosis’ 
revealed a plethora of basic science and clinical papers, many of 
the latter commenting on the delay in diagnosing endometriosis 
and the poor experience of women within the health system. In 
order to feel better equipped to manage similar patients in the 
future, you decided to find out whether this woman’s experience 
was typical of endometriosis. Qualitative research findings will 
elaborate on the experience of women with endometriosis. 
This case study will utilize the paper: 
●● Systematic reviews of qualitative evidence: What are the 
experiences of women with endometriosis? J Obstet Gynaecol 
2006: 26: 501-6.
Step 1: Framing the question
Free form question 
How does the experience of endometriosis impact on women’s 
lives?
Structured question
The population Women with a confirmed diagnosis of 
endometriosis.
The interventions Either observation or treatment for 
endometriosis. 
The outcomes Effects on pain, work and social relationships, 
self-image, etc. 
The study design Interviews, focus groups, diary keeping.
Question 
components
The population: 
A clinically suitable 
sample of patients.
The interventions: 
Comparison 
of groups with 
and without the 
intervention.
The outcomes: 
Changes in health 
status, social 
relationships, self-
image, etc due to 
interventions.
The study design: 
Ways of conducting 
research to assess 
the effects of 
interventions.
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Note that the question does not pose a statistically testable 
hypothesis as the outcomes are described subjectively by study 
participants rather than quantified numerically.
Step 2: Identifying relevant studies
A search of MEDLINE using the search term endometriosis revealed 
12 546 citations. The majority were reports of quantitative studies. 
Using filters for qualitative research to narrow the search to 
qualitative studies produced 192 citations. However, the majority 
of these papers did not have a qualitative methodology and 
endometriosis was not the primary focus of the research. From this 
search, only four papers fulfilled the selection criteria based on the 
structured question above. The major social science search engines 
(ASSIA, QUALIDATA, REGARD and the Social Science Citation index) 
were searched using the following key terms: endometriosis, pain, 
self-image and terms for qualitative methodology (Box C5.1). From 
these searches and from reference lists, a further four qualitative 
studies on living with endometriosis emerged, giving eight peer 
reviewed studies for this review (Box C5.2).
As in all good reviews, the process concerning study selection 
and the decisions regarding selection should be transparent. In 
reviews of qualitative research, this is particularly important when 
different study designs are to be considered simultaneously (Box 
C5.3). There is a debate around whether studies using different 
methods should be combined in a review, although some argue 
Identifying 
relevant literature
●● Develop search 
term combinations 
●● Search relevant 
electronic 
databases
●● Search other 
relevant resources 
●● Obtain full papers 
of potentially 
relevant citations
●● Include/exclude 
studies using 
pre-set selection 
criteria
Study design filter 
employs a search 
term combination 
to capture citations 
of studies with a 
particular design.
Box C5.1 Some important databases of qualitative research 
in healthcare
ASSIA
Applied Social Sciences Index and Abstracts is an indexing and abstracting database 
that covers health, social services, psychology, sociology, economics and politics.
QUALIDATA
ESDS Qualidata is a specialist service of the Economic and Social Data Service 
(ESDS) that acquires digital data collections from qualitative and mixed methods 
contemporary research and from UK-based ‘classic studies’. Users are able to locate 
accessible sources of qualitative data across the UK.
ESRC Society Today (formerly REGARD)
This site contains all research funded by the Economic and Social Science Research 
Council, and summaries and final reports of research projects can be searched.
Social Science Citation Index
This is accessed via the Web of Science and provides citation information that enables 
researchers to source research data.
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that such restrictions detract from the richness of data obtained. 
In this review the selection was not restricted by qualitative 
research method.
Step 3: Assessing study quality 
There have been a number of methods developed by which 
to assess the quality of qualitative studies, although it is not 
appropriate to have a formulaic approach to determine the quality 
of this type of research. 
Box C5.2 Identification of relevant literature on experiences 
of women with endometriosis
Potentially relevant citations identified through
comprehensive electronic searching of MEDLINE database
n = 12546 citations with titles and abstracts
Citations evaluated after applying qualitative research
design filter
n = 192 papers
Studies included in the review used in this case
n = 8
Studies included from MEDLINE in the published review
n = 4
Studies included from comprehensive search of major
social sciences databases
n = 4
Citations filtered (see Box C5.3)
 n = 12354
Citations and studies excluded
 n = 188
Searching for qualitative studies
See Section 2.1.3 for searching for study designs. A qualitative research design filter 
can be used to restrict the citations of initial searches to those with a qualitative 
methodology. Due to its in-depth thesaurus terms, CINAHL is generally accepted as a 
good database to find qualitative research articles. In CINAHL exploding ‘qualitative 
research’ will include ‘action research’, ‘ethnographic research’, ‘grounded theory’, 
‘naturalistic inquiry’ and ‘phenomenological research’. Other terms that can be 
part of a qualitative research filter include: interviews.exp (includes structured 
interview, semi-structured interview, unstructured interview); observational methods.
exp (includes non-participant observation, participant observation); focus groups; 
narratives; diary keeping.
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In this review, the framework for the study of quality 
assessment paid particular attention to the validity with which 
studies captured the meaning that women put on their experience. 
From this an insight or understanding develops of the experience 
of endometriosis. A set of questions was formulated to be 
addressed when reading each of the articles in order to assess 
quality (Box C5.4). These need to be used with sensitivity in order 
to allow a qualitative critical appraisal. As this is a subjective 
process, it is crucial that quality assessment is initially undertaken 
by at least two reviewers acting independently, who then come 
together to formulate an agreed assessment. One important 
element of systematic review of qualitative research is the notion 
of generalization (Box C5.4). Within qualitative research the aim 
is not to extrapolate to wider populations, but to add to the 
understanding of a phenomenon. So in this case we would want 
to know how far the findings of the studies in the review concur 
with other studies that provide insight into the experience of 
endometriosis.
Step 4: Summarizing the evidence
The reporting of narrative is a common method of presentation 
of findings in primary qualitative studies. In a systematic review 
these can be collated and synthesized. This is usually accomplished 
by the generation of themes, which can initially be done by using 
the key areas identified within each selected study which is carried 
out by reviewing published findings, rather than re-analysing 
original data. Reading and re-reading the studies will result in the 
The quality of a 
qualitative research 
study depends 
on the degree to 
which its design, 
conduct and analysis 
is trustworthy. 
Trustworthiness 
consists of several 
concepts including 
credibility, 
dependability, 
transferability, 
confirmability.
Box C5.3 Some important study designs for qualitative 
research in healthcare
Interviewing Questioning people about their views or experience of a phenomenon 
or event. Can range from structured, where each participant is asked 
the same questions, to unstructured, which consists of a list of 
broad areas to be covered, the exact format of each interview being 
determined as it progresses.
Focus group The collection of qualitative data using a group interview on a topic 
chosen by the researcher. Usually 6-12 people are involved, and they 
can be used to gauge issues of importance to interested parties in 
order to develop an interview schedule, or as a research method in 
their own right.
Diary keeping A qualitative research method, usually an addition to questionnaire 
or interview data, where participants record experience and emotions 
contemporaneously. Can be free form, where people write what they 
want to, or structured where they have specific questions to answer 
or topics to write about.
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Box C5.4 Description of quality of studies on experiences of 
women with endometriosis
Key issues on which the quality of qualitative research studies is 
judged
●● Qualitative research gives a voice to participants, which allows them to talk about 
their experience; therefore research findings should reflect their perspective and not 
that of the researcher.
●● Qualitative research design should be flexible enough for adaptation as perspectives 
of participants are revealed, but without losing rigour.
●● The sample should be purposive, that is drawn from the population that has 
the experience. However, it should not be so narrowly drawn that only certain 
experiences get reported. For example, sampling from self-help groups will often 
attract participants with negative experiences.
●● Transparency in each stage of the research process is vital in a flexible and responsive 
research design.
●● Different sources of knowledge are usually consulted for the literature review, and the 
extent to which the study under review conforms to or refutes this can be gauged.
●● How the research moves through these stages should be explicit and justified. Often 
this will be an iterative process, in which case an explanation as to how each stage is 
influenced by the previous one should be given.
●● Qualitative research is context specific and so the aim is to increase understanding. 
There should be a discussion of the extent to which the findings are consistent with 
those from similar studies.
Description of study quality
Information on quality is presented as 100% stacked bars. Data in the stacks represent 
the number of studies.
17
53
6 2
2 6
71
75% 100%50%25%
Compliance with quality items
0%
2 6
NoYes
Are different sources of knowledge about the same
issue compared and contrasted?
Does the research as reported illuminate the subjective
meaning and context of those being researched?
Is there evidence of adaption and responsiveness of the
research design to the circumstances and issues of real
life social settings met during the study course?
Does the sample produce the type of knowledge
necessary to understand the structures and processes
within which the individuals or situations are located?
Is the description provided detailed enough to allow
the reader to interpret the context and meaning of
what is being researched?
Does the research move from description of the data,
through quotation or examples, to an analysis and
interpretation of the meaning and significance?
Are claims being made for the consistency of the
findings to either other bodies of knowledge or to
other populations or groups?
6 2
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development and possible merging of further themes. This process 
can be facilitated by the use of qualitative data handling software 
(Box C5.5). 
The themes formulated in this way allow synthesis of the 
qualitative findings. This integration of studies is analogous 
to the pooling of data in a quantitative review. It is important 
that during this process the original meaning of the work is not 
lost. Similarities in the studies can be identified and categorized 
using the identified or emergent themes. Aberrant findings 
can be explored to elicit an explanation. In this way a reviewer 
gets a picture of the phenomenon under study, in this case the 
experience of living with endometriosis. 
The reliability of summarizing qualitative evidence and 
interpretation of findings (Steps 4 and 5) can be improved in one of 
two ways. Where there is a research team, each member conducts 
steps 4 and 5 independently. They will then agree emerging themes 
and iron out inconsistencies, which need to be made transparent in 
subsequent reports or publications. Alternatively Steps 4 and 5 can 
be independently verified by someone outside of the team who has 
expertise in the research issue. 
In the endometriosis studies reviewed, detailed narrative was 
reported but analysis of the data was limited. Common themes 
were identified from the articles, but no article reported on all of 
these themes apart from pain. Nevertheless, similar results were 
reported by all studies. As pain was the one common theme, it 
provides a useful example of how findings can be synthesized. 
Various descriptions of pain were given in the articles. In three of 
these articles individual narrative from participants in the research 
was reported in the words of the author(s) as representative 
Phenomenon is an 
occurrence or a fact. 
It  is often used as a 
generic term for the 
object of a research 
study.
Theme is an idea 
that is developed 
by the coding of 
qualitative data. The 
large quantities of 
data produced by 
a qualitative study 
are managed by the 
generation of themes 
and the coding of 
parts of the data 
to each theme. The 
perspectives of each 
research participant 
on each theme can 
be compared and 
analysed.
Box C5.5 A simple overview of qualitative data synthesis
●● Data collected in qualitative research can include transcripts of interviews, group 
discussions, observation, reflective field notes, etc. 
●● The analysis of qualitative data involves interpretation of these transcripts to form 
impressions. Coding is an interpretive technique that requires the researcher to 
read the text and demarcate segments within it. Each segment is labelled with a 
word or short phrase that suggests how the associated data segments inform the 
research objectives. When coding is complete, the researcher can discuss similarities 
and differences in codes across transcripts. This forms the basis for organizing and 
reporting results.
●● The use of qualitative data handling software can assist in analysis of large quantities 
of data, by categorizing it according to codes generated by the researcher. This way 
data on a particular phenomenon can be retrieved quickly from every transcript.
●● Using the example of endometriosis pain, all references to pain in the interview 
transcripts may be entered into the software under the code of ‘pain’. Sub codes 
of ‘pelvic pain’, ‘dyspareunia’, etc may also be used to categorize the data. The 
researcher can later retrieve all references to pain from the entire participant group 
at the click of a mouse.
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of the group as a whole. The remaining papers gave examples 
of descriptions of pain from individual women, with terms 
such as ‘intense’, ‘a knife going into each ovary’, ‘stabbing’ and 
‘tremendous’ being frequently used. This is unlikely to be captured 
by the linear pain scales of quantitative research. 
In synthesizing this information we can conclude that pain was 
a constant theme in all qualitative research on endometriosis. In 
three studies this was described by the authors from unreported 
data, but five studies reported women’s own descriptions of the 
quality and severity of pain. Seven of the studies also reported 
how the experience of pain impacted on quality of life, e.g. on 
work and social relationships. In four of the studies women 
described how their social life had suffered, with friends and 
family losing patience when planned events were continually 
cancelled. Relationships with partners were also negatively 
affected, although one study did point to partners as offering the 
major support to women with endometriosis. Three studies found 
that women who took time off work due to pain felt guilty, and 
were often disbelieved by colleagues and employers, sometimes 
being made to feel they were malingering.
Step 5: Interpreting the findings
This case scenario focused on the experience of endometriosis 
reported in a systematic review of qualitative research. It revealed 
that the experience of endometriosis has a profound negative 
effect on the lives of women. Despite a comprehensive search 
of relevant databases, only a few studies of variable quality 
were found. They provided detailed narrative but analyses were 
limited. As one purpose of qualitative research is the generation 
of new theory to explain a phenomenon, this lack of analysis is a 
limitation of the reviewed research. 
Resolution of scenario
By conducting this systematic review and evaluating the studies 
you have gained a better understanding of your own patient’s 
experience, and have discovered that her history is a familiar one. 
You could not have gained this insight by reading clinical papers 
that focus on the effectiveness of different treatments rather 
than on the impact of living with endometriosis. The research that 
was retrieved tended to report and analyse women’s comments, 
but did not do so from any particular theoretical perspective (e.g. 
psychology). However, your understanding of women’s experience 
has improved and this may influence your management of similar 
patients in the future.
Since this review was undertaken more qualitative papers 
on endometriosis have been published, substantiating the main 
findings of this review. 
Theory is abstract 
knowledge or 
reasoning as a way 
of explaining social 
relations. Theory 
may influence 
research (deduction), 
or research may lead 
to the development 
of theory 
(induction).
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●● Case study 6: 
Reviewing evidence on 
the effects of educational 
interventions
Sharon Buckley
Medical educationalists increasingly use systematic reviews to 
evaluate the effects of educational interventions. Peculiarities 
of electronic databases and inherent complexities of primary 
educational research make systematic reviews in this field 
challenging. However, such reviews can provide valuable insights 
into the available evidence about particular effects of teaching 
methods on student learning, guiding resource allocation and 
supporting educational practice. 
This case study will explore the specific issues relating to 
systematic reviews of the effects of educational interventions. 
Based on a published review, it will consider the requirements for 
literature searching and quality assessment in the educational 
context. It will demonstrate an approach to synthesis of 
educational research evidence when meta-analysis is not 
appropriate.
Scenario: effects of portfolios on 
student learning in undergraduate 
medical education
You are an Education Development Specialist based in a large 
medical and nursing school. Your faculty is considering introducing 
a professional development portfolio for all its undergraduate 
medical students. Views on whether, how and when the portfolio 
should be introduced are mixed: some faculty view portfolios as an 
ideal preparation for postgraduate medical education and lifelong 
learning, others as a drain on scarce resources that emphasizes 
reflection at the expense of essential clinical knowledge and 
understanding. You are keen that any decisions about curriculum 
development should be based on the best available evidence as to 
the effects of using a portfolio on undergraduate student learning. 
You have identified the following Best Evidence Medical Education 
(BEME) review that is relevant to your search:
●● The educational effects of portfolios on undergraduate student 
learning: a Best Evidence Medical Education (BEME) systematic 
review. Med Teacher 2009; 31 :282–98.
Step 1 
Framing questions
Ø
Step 2 
Identifying relevant 
literature
Ø
Step 3 
Assessing quality of 
the literature
Ø
Step 4 
Summarizing the 
evidence
Ø
Step 5 
Interpreting the 
findings
BEME: Collaboration 
committed to 
the promotion 
of Best Evidence 
Medical Education 
(BEME) through 
the dissemination 
and production 
of systematic 
reviews of medical 
education. An 
additional objective 
is the creation of 
a culture of BEME 
amongst teachers, 
institutions and 
national bodies.
140 Systematic Reviews to Support Evidence-based Medicine
You appraise the review so that you can be confident in using 
its conclusions to inform your practice.  
Step 1: Framing the question
Free form question
How does the use of portfolios affect student learning in 
undergraduate (medical and nursing) education? 
Structured question
Population Undergraduates, defined as students following 
a course of initial training in a particular 
profession leading to a degree qualification.
Intervention A ‘portfolio’, defined as a collection of evidence 
of student learning, a learning journal or diary, or 
a combination of these two elements.
Outcomes Educational outcomes are classified into levels 
according to a hierarchy, called the modified 
Kirkpatrick hierarchy, frequently used in 
medical education. This attempts to capture the 
impact of educational interventions using the 
following levels: participation or completion, 
modification of attitudes or perceptions, 
modification of knowledge or skills, change in 
participants’ behaviour and change in delivery 
of care and health outcomes. This review 
collected information on any reported outcome 
demonstrating an effect on student learning as 
a result of using a portfolio. Changes in delivery 
of care or improvements in patient outcomes 
are not normally demonstrable outcomes for 
undergraduate education as students are not 
responsible for provision of patient care. 
Study designs Primary research studies of all types that assess 
the effects on learning of use of a portfolio.
The reviewers clearly defined their populations, interventions and 
outcomes but have not limited the review to studies looking at 
particular outcomes or study designs. They wish to ensure that no 
relevant studies are missed by prematurely excluding particular 
outcomes or study designs. Given the variety of educational 
research designs and the range of effects of portfolios reported 
anecdotally, you are satisfied that this approach is appropriate. 
While the published review includes studies from professions 
allied to medicine such as dentistry and physiotherapy, this case 
study will focus solely on medicine and nursing, which have the 
largest body of available evidence. 
Question 
components
The population: A 
suitable sample of 
learners
The interventions: 
An educational 
intervention
The outcomes: 
Changes in 
perceptions, 
attitudes, 
knowledge, skills, 
behaviour, etc due 
to interventions.
The study design: 
Ways of conducting 
research to assess 
the effect of 
intervention on 
outcomes
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Step 2: Identifying the literature
Searches of the educational literature for medicine and allied 
professions can be challenging. The relevant educational literature 
is dispersed across many different databases, subject headings vary 
considerably and classification of articles against subject headings 
is not always accurate. The use of only subject headings may not 
reliably find all relevant articles, and therefore free text words 
also were used. To ensure comprehensive coverage, reviewers 
searched 10 different databases from their inception and without 
language restriction, encompassing the literature from educational 
(ERIC, British and Australian Education Indices), clinical (MEDLINE, 
EMBASE, CINAHL, BNI) and social sciences (ASSIA, PsycInfo) 
(Box C6.1). Search terms and synonyms used reflect closely the 
population and intervention components of the research question 
and the reviewers used both subject headings and free text (Box 
C6.2). The reviewers supplemented the electronic searches with 
hand searches of the reference lists of selected studies.
The relevance of grey literature to educational systematic 
reviews depends very much on the topic being examined. For this 
review, the reviewers judged at an early stage that unpublished 
sources were unlikely to unearth significant papers not found by 
other methods and that searching of the grey literature would 
Box C6.1 Searching for medical education literature
Best Evidence Medical Education (BEME) (www.bemecollaboration.org)
A collaboration committed to the promotion of Best Evidence Medical Education 
through the dissemination and production of systematic reviews of medical education. 
An additional objective is the creation of a culture of best evidence medical education 
amongst teachers, institutions and national bodies.
Some important databases of medical education research
(see also Box 2.2)
BNI The British Nursing Index is a nursing and midwifery database, covering over 200 
UK journals and other English language titles.
ASSIA Applied Social Sciences Index and Abstracts is an indexing and abstracting 
database that covers health, social services, psychology, sociology, economics and 
politics.
ERIC The Education Resources Information Centre, an extensive database of education 
journals and grey literature relating to education.
BEI The British Education Index, covering Education Journals, on-line documents and 
conferences.
AUEI The Australian Education Index, a subscription database consisting of more than 
130 000 documents relating to educational research, policy and practice
TIMELIT Topics in Medical Education, a database covering professional education, 
health education and patient education.
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be a poor use of their valuable time and resources. Whilst this 
approach may be appropriate in this case, other reviews may 
require search of the grey literature.
Screening of the 2371 possible citations identified 580 as 
possibly relevant using predefined selection criteria based on 
the review question. Of these, full papers of 554 were obtained. 
Further screening of full manuscripts against selection criteria 
identified 69 studies for inclusion, 18 from medicine, 32 from 
nursing and 19 from other professions (Box C6.1). Selection 
Identification of relevant literature on educational effects of 
portfolios
Potentially relevant citations identified through
comprehensive electronic searching of 
10 electronic database
n = 2371 citations with titles and abstracts
Retrieval of hard copies of potentially relevant citations
n = 554 papers
Studies included in this case
Effects of portfolio in medicine and nursing
n = 50
Studies included in the published review
n = 69
Citations excluded
 n = 1817
Studies excluded after
assessment of full text
 n = 485
Box C6.2 How to develop a search term combination for 
searching electronic bibliographic databases
An example of a search term combination for MEDLINE database
Free form question: How does the use of portfolios affect student learning in 
undergraduate (medical and nursing) education?
Structured question (not all components may be needed for searching)
●● The population Undergraduate medical and nursing education
●● The interventions Portfolio 
●● The outcome Any (not used in search term combination)
●● The study design Any (not used in search term combination)
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Question components and relevant 
search terms
Type of terms Boolean operator
MeSH Free
The population: Undergraduates
1 students x
OR (captures population)
2 freshers x
3 freshman/men x
4 Sophomore x
5 Senior x
6 additional terms (see in original 
report of the review)
7 OR 1-6
The population: medical education
8 medical education, undergraduate x
OR (captures population)
9 clinical skills x
10 allied health x
11 nursing x
12 pharmacology x
13 medical x
14 clinical teaching x
15 additional terms (see in original 
report of the review)
16 OR 8-15
The intervention: Portfolio
17 portfolio x
OR (captures intervention)
18 learning record x
19 case folder x
20 case notes x
21 learning journal x
22 log book x
23 self reflection x
24 additional terms (see in original 
report of the review)
25 OR 17-24
26 AND /7,16,25 AND (combines all components)
See related section in Step 2
criteria were established a priori and applied by two independent 
reviewers. Reasons for exclusion were primarily that a particular 
intervention did not meet the definition of a portfolio or that the 
study did not contain primary research data. 
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Aware of the particular factors relating to educational literature, 
you agree that the reviewers’ approach to searching and selection 
is appropriate and, as far as possible, avoids the risk of missing 
studies due to publication bias.
Step 3: Assessing study quality
Among the 18 studies in medicine there were two with a 
comparative design, including one randomized trial, and 16 
observational studies without a comparison group. Among the 32 
nursing studies there were also two with a comparative design 
but without randomization, and 29 observational studies without 
a comparison group. Whilst many studies used a combination 
of methods, over half of all included studies administered 
questionnaires to learners; a third used focus group interviews 
of learners and another third performed direct assessment of 
portfolios. For educational studies, assessment of study quality is a 
controversial area, with conflicting views on the appropriateness of 
particular quality assessment tools. Here, the reviewers assembled 
a quality checklist and applied this to all studies, regardless of 
design. In many included studies, it was not possible to make a 
judgement about study quality due to lack of clarity in reporting. 
As an example, Box C6.3 illustrates data for four of the 11 quality 
items used. The reviewers call, as do other commentators on 
educational research, for authors to report their methods more 
thoroughly. However, the review also reported an encouraging 
trend: in each professional group (medicine and nursing) more 
recent studies had significantly higher quality scores than those 
Triangulation is 
the application 
and combination 
of several research 
methodologies in 
the study of the 
same phenomenon.
Box C6.3 Description of quality of studies on educational 
effects of portfolios
13019
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221018
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Compliance with quality items
0%
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Prospective
Adequate data collection methods
Control for confounding
Triangulation
Overall quality
Information on quality is presented as 100% stacked bars. Data in the stacks represent 
the number of studies.
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published earlier (data not shown). Overall, 18 of the 50 studies 
included in the review are classed as higher quality, meeting seven 
or more of the 11 quality items. The higher quality group included 
one randomized controlled trial, in which medical students taking 
a clinical oncology module were randomly allocated to either 
receive a portfolio or to a control group without a portfolio. The 
portfolio group recorded patient encounters and received tutorial 
support in portfolio development.
Step 4: Summarizing the evidence 
For this review, as for many other educational systematic reviews, 
the limitations of the available data meant that meta-analysis 
of data and statistical investigation of heterogeneity in effects 
between studies was inappropriate and that a descriptive approach 
to summarizing the evidence was needed. The reviewers adopted a 
two-fold approach to this.
First, the reviewers describe how portfolios are generally used in 
undergraduate education (Box C3.9). Portfolios were mainly used 
in the clinical setting and their completion was compulsory for 
students. They required the students to reflect on their learning 
and share their reflections with other students and staff. In 
general, students had only limited choice of content and were 
assessed on their work. Learning journals or diaries were common 
in nursing, with ‘hybrid’ portfolios that combined collections of 
evidence with a learning journal more common in medicine.  
Second, the reviewers identify the main messages emerging 
from the ‘higher quality’ studies, providing the reader with a rich 
description of the findings of these studies, grouped according 
to theme. Higher quality studies reported that using a portfolio 
can enhance students’ knowledge and understanding, particularly 
their ability to integrate theory with practice, but that these 
improvements do not always translate into improved assessments. 
Similarly, portfolios can encourage self-awareness and reflection, 
but do not guarantee the quality of those reflections. Completing 
a portfolio can help some students to cope with difficult or 
uncertain situations, such as a patient death and can prepare 
them for the rigours of postgraduate training. Engaging with 
students through a portfolio can help tutors become more aware 
of students’ learning needs, influencing their teaching approaches 
and allowing them to give more structured feedback. Higher 
quality studies identified the time required for completion as the 
main drawback to portfolios. In some cases, where this detracts 
from other clinical learning, this is not desirable.
The effect of an educational intervention can be assessed using the 
Kirkpatrick hierarchy as modified for use in educational settings (Box 
C6.4). The hierarchy classifies the impact studies can have according 
to the results they demonstrate for various outcomes. Participants’ 
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reactions to an intervention demonstrate impact at a lower level, 
whilst directly measurable changes in participants’ knowledge, skills 
or behaviours demonstrate impact at a higher level. At the highest 
level are changes in organizational practice or benefits to patients 
in terms of improved health outcomes. In this review, most studies 
demonstrated improvements at lower levels on the Kirkpatrick scale, 
with only one study (from nursing) reporting a change in participant 
behaviour. 
Box C6.4 Educational outcomes among studies of portfolios 
Key themes recorded in higher quality studies. Portfolios may:
●● Improve students’ knowledge and understanding, especially their ability to integrate 
theory with practice. However, these effects may not always translate into higher 
scores in formal assessments
●● Encourage students’ self-awareness and reflection. However, keeping a portfolio will 
not, in itself, guarantee the quality of those reflections
●● Assist tutors in providing structured feedback to their students and increase their 
awareness of students’ needs
●● Provide emotional support for students facing difficult situations such as a patient 
death
●● Prepare students for the demands of postgraduate training
●● Detract from other clinical learning, if implemented in such a way that the time 
required for completion is disproportionate.
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Step 5: Interpreting the findings
This review showed that the available evidence for the educational 
effects of portfolios on student learning is limited. Relatively few 
studies were of higher methodological quality and almost none 
reported results of outcomes at the higher levels of the modified 
Kirkpatrick hierarchy. However, limited evidence is not synonymous 
with lack of effectiveness. The summary of the evidence available 
does suggest that some important benefits in participants’ 
perceptions, knowledge and skills are possible if portfolios are 
implemented appropriately. The review makes clear that in order 
to realize the benefits of portfolios, the time demands on both 
students and tutors should be kept within reasonable limits. 
They also caution faculty against assuming that a portfolio will 
automatically develop students’ reflective abilities and suggest 
that additional guidance on how to reflect should accompany any 
portfolio intervention that aims to develop these skills. Clearly 
more research is needed, as is greater clarity and thoroughness of 
reporting, although the trend towards improvements in quality 
score in more recent publications is encouraging.
Resolution of scenario
You are disappointed, but not surprised that the evidence base 
for the effectiveness of portfolios is limited, and are encouraged 
by the clear directions for implementation offered by the higher 
quality studies. You share the findings with faculty in your 
department and develop a proposal for implementation that 
incorporates the recommendations of the reviewers. You decide to 
include in your proposal a research study that measures directly 
the educational effects of portfolios, in order to add to the 
evidence base on the subject.
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●● Case study 7: 
Gauging strength of 
evidence to guide 
decision making 
Katja Suter
Questions arising in patient care can differ from those addressed 
in research. The quality of studies included in a review can be 
poor. Their results can be heterogeneous with effects varying 
from study to study. The effect size summarized in a meta-
analysis can be small. Step 5 provided guidance on how to take 
all this information into account when gauging the strength of 
the evidence in a systematic review. When does evidence from 
randomized trials slump to a low strength level? When does 
evidence from observational studies rise to a moderate or even 
high strength level? This case study (and Case study 8) illustrates 
with a worked example how to assess the strength of the evidence 
collated in a review. 
Clinicians often puzzle over the relative benefits and harm of 
the different classes of drugs for treating the same diagnosis. 
In hypertension large trials have investigated the effects of 
angiotensin-receptor blockers (ARBs) versus placebo and those of 
angiotensin-converting-enzyme inhibitors (ACE-Is) versus placebo. 
Based on a published review, this case study explores how to 
determine the strength of the evidence about the relative benefits 
of these antihypertensive agents (and Case study 8 explores their 
adverse effects). It explains how healthcare providers and patients 
can take this into account when deciding on treatment. 
Scenario: The comparative 
effectiveness of angiotensin-
receptor blockers (ARBs) versus 
angiotensin-converting-enzyme 
inhibitors (ACE-Is) 
You are a general practitioner caring for a 50-year-old overweight 
patient with recently diagnosed hypertension (150/100 mmHg). 
His blood pressure did not improve under initial management 
encouraging him to lose weight. The patient and you decide to start 
an antihypertensive drug. Among the many drugs recommended as 
Step 1 
Framing questions
Ø
Step 2 
Identifying relevant 
literature
Ø
Step 3 
Assessing quality of 
the literature
Ø
Step 4 
Summarizing the 
evidence
Ø
Step 5 
Interpreting the 
findings
Effect is a measure 
of association 
between an 
intervention or 
exposure and an 
outcome. 
The quality of a 
study depends on the 
degree to which its 
design, conduct and 
analysis minimizes 
biases.
Heterogeneity 
is the variation of 
effects between 
studies. It may 
arise because of 
differences in key 
characteristics of 
their populations, 
interventions and 
outcomes (clinical 
heterogeneity), 
or their study 
designs and quality 
(methodological 
heterogeneity).
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first-line treatment in guidelines, you have a personal preference 
for renin-system inhibitors. Both drug classes, ARBs and ACE-Is, 
are effective in lowering blood pressure and preventing major 
events such as heart attacks and strokes in trials comparing them 
to placebo. However, you are less certain as to what extent the two 
drugs differ in their effectiveness when directly compared to each 
other. This problem has turned up repeatedly in daily practice. Is 
there a review summarizing the evidence to allow one to establish a 
preference for one or the other drug? 
In a search of MEDLINE using PubMed Clinical Queries at 
http://www.ncbi.nlm.nih.gov/corehtml/query/static/clinical.shtml 
(accessed May 2011) you enter “angiotensin-receptor blockers” 
AND “ACE Inhibitors” AND “Hypertension” in the search box of the 
Systematic Review feature and click the ‘Go’ button. The search 
revealed the following reference:
●● Systematic review: comparative effectiveness of angiotensin-
converting enzyme inhibitors and angiotensin II receptor 
blockers for treating essential hypertension. Ann Intern Med 
2008; 148: 16-29 
A comprehensive report of this review is published by the 
American Agency for Healthcare Research and Quality (AHRQ) at 
http://effectivehealthcare.ahrq.gov/repFiles/ACEI_ARBFullReport.
pdf (accessed May 2011). 
Step 1: Framing the question
Free form question 
Which renin-system inhibitor is better in treating hypertension – 
an ARB or an ACE-inhibitor?
Structured question
The populations Adult patients with essential hypertension, 
with or without additional co-morbidities 
such as diabetes mellitus or established 
cardiovascular disease.
The interventions All drugs from the class of ARBs (e.g. 
losartan, irbesartan, valsartan or telmisartan) 
compared directly to drugs from the class 
of ACE inhibitors (e.g. captopril, enalapril, 
ramipril, or fosinopril) and minimal study 
duration of 12 weeks. 
The outcomes Mortality, morbidity (stroke, myocardial 
infarction, heart failure, end-stage renal 
disease, severe peripheral vascular disease), 
quality of life and successful monotherapy 
(Box C7.1). 
The study designs All randomized controlled trials.
Guidelines are 
systematically 
developed 
statements to assist 
practitioners and 
patients in making 
decisions about 
specific clinical 
situations. Their 
recommendations 
should reflect 
the strength of 
the underpinning 
evidence.
Surrogate outcome 
measurements 
substitute for direct 
measures of how 
patients feel, what 
their function is, or 
if they survive. They 
include physiologic 
al variables or 
measures of 
subclinical disease. 
To be valid, the 
surrogate must 
be statistically 
correlated with the 
clinically relevant 
outcome.
Question 
components
The population: 
A clinically suitable 
sample of patients
The interventions: 
Comparison 
of groups 
with different 
interventions
The outcomes: 
Changes in health 
state due to 
interventions
The study design: 
Ways of conducting 
research to assess 
the effect of 
interventions (Box 
1.4)
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Box C7.1 Hierarchy of outcomes in antihypertensive therapy 
ranked by importance and directness of measurement
Importance* Direct measurement
(descending order of importance)
Surrogate 
measurement
 
Reduce mortality 
 ⦁ All-cause mortality
 ⦁ Cardiovascular mortality
 ⦁ Cerebrovascular mortality
Reduce major morbidity 
 ⦁ Disabling stroke 
 ⦁ Myocardial infarction
 ⦁ Moderate to severe heart failure 
 ⦁ Advanced or end-stage renal 
disease 
 ⦁ Leg ulceration and amputation 
due to peripheral vascular disease 
Reduce mild morbidity 
 ⦁ Mild angina pectoris 
 ⦁ Mild intermittent claudication
 ⦁ Mild renal impairment
 ⦁ Transient ischaemic attack
Improve quality of life (QoL)
 ⦁ General QoL
 ⦁ Specific dimensions of health-
related QoL (e.g. cognitive 
function, symptomatic well-being)
 ⦁ Disease-specific QoL
Successful monotherapy 
Physiological variables 
or disease markers 
which only indirectly 
capture the outcome 
 ⦁ Lipid levels 
 ⦁ Function of glucose 
metabolism as 
markers of diabetes 
and diabetes 
control: blood 
glucose, glycosylated 
haemoglobin HbA1c
 ⦁ Left ventricular 
function
 ⦁ Renal function 
as marker of 
renal disease: 
serum creatinine, 
glomerular filtration 
rate
Reduce cost 
 ⦁ Reduction in drug cost to the 
healthcare system (policy makers 
might call this an important or 
critical outcome)
This expands on the question posed in Boxes 1.2 and 1.3
Also see Box C8.1
*  Importance of outcome coded in different shades of grey for ease of display. Ranking of 
importance outcomes can be undertaken through formal survey of patients or practitioners 
asking them to provide responses on a scale anchored between critical at one extreme 
and not at all important at the other. An explicit approach enables users of a review to 
compare published judgements with the judgements relevant for their own environment.
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When thinking about outcomes, one needs to consider all 
outcomes that are important to patients. Most outcomes belong 
to one of three broad categories: mortality, morbidity and quality 
of life. Mortality can be separated into all-cause mortality or 
disease-specific (e.g. cardio- or cerebro-vascular) mortality. 
Morbidity addresses, for example, stroke, myocardial infarction, 
heart failure, end-stage renal disease or severe peripheral vascular 
disease. Quality of life can refer to general quality of life assessed 
with generic instruments or specific dimensions, like physical 
function, pain or sleep. Patients consider successful monotherapy 
as an important outcome as it prevents them being exposed to an 
additional drug, avoiding potential adverse effects. 
Some outcomes are more important to patients than others. 
Whether an outcome is critical, important or less important also 
depends on the perspective. Cost might be of little importance 
to patients when their drugs are fully covered by their health 
insurance. It might be important or even critical from the 
perspective of a policy maker. Reviewers should therefore 
indicate whose perspective they take. Often research focuses 
on intermediate or surrogate measures of outcomes such as 
control of blood pressure, lipids, glomerular filtration rate or 
blood glucose. Surrogate measurements do not capture outcomes 
directly. This indirectness should be taken into account when 
assigning a level of strength to the evidence. 
The reviewers had a well-founded concern that no studies 
might exist for some of the clinically relevant outcomes. They 
therefore included surrogate outcome measurements such as 
impaired glomerular filtration rate for end-stage renal disease. 
Clinicians and decision makers would need to extrapolate from 
such a surrogate marker. Uncertainty through indirectness lowers 
the strength of the evidence. The large licensing studies comparing 
ARBs and ACE-Is against placebo or other antihypertensive agents 
evaluated only surrogate outcomes. The review on which this case 
study is based deals with the issue of indirectness head on. For 
illustrative purposes, this chapter confines itself to assessing three 
outcomes: mortality and major cardiovascular morbidity, end-
stage renal disease and successful monotherapy for blood pressure 
control.
Step 2: Identifying the relevant 
literature
An electronic search was undertaken in two databases, in PubMed/
MEDLINE and in CENTRAL, the Cochrane Central Register of 
Controlled Trials (Box 2.2). Furthermore, the reviewers had access 
to the register of the Cochrane Hypertension Review Group.  
Their search terms included hypertension (population), drug 
interventions and study designs, but did not specify outcomes. The 
results were limited to studies published in the English language 
Clinically 
relevant outcome 
measurements 
directly measure 
how patients feel, 
what their function 
is, or if they survive. 
Strength of 
evidence describes 
the extent to which 
we can be confident 
that the estimate 
of an observed 
effect is correct for 
important questions. 
It takes into account 
directness of 
outcome measure, 
study design, 
study quality, 
heterogeneity, 
imprecision and 
publication bias (this 
is not an exhaustive 
list).
Identifying 
relevant literature
●● Develop search 
term combinations 
●● Search relevant 
electronic 
databases
●● Search other 
relevant resources 
●● Obtain full papers 
of potentially 
relevant citations
●● Include/exclude 
studies using 
pre-set selection 
criteria
●● Assess for risk of 
missing studies
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after the year 1988. The researchers used additional material 
that five pharmaceutical companies submitted to the AHRQ. They 
reviewed reference lists of relevant review articles, and citations 
identified by a peer reviewer of their protocol. Box C7.2 documents 
the selection process: The review finally included 45 randomized 
trials. A funnel plot explored the risk of missing studies (see Box 
C7.5).
Box C7.2 Identification of relevant literature on the 
comparative effectiveness of angiotensin-receptor blockers 
(ARBs) versus angiotensin-converting-enzyme inhibitors 
(ACE-Is)
Electronic databases searched
1. MEDLINE
2. Cochrane Central Register of Controlled Trials
3. Register of the Cochrane Hypertension Review Group
Study identification flow chart
Potentially relevant citations from an electronic search in
PubMed+Cochrane CENTRAL, from reference lists,
information from pharmaceutical industry
n = 1185 citations with titles and abstracts
Retrieval of hard copies of potentially relevant papers
n = 194 papers
Studies on outcomes considered in this case study
n = 45
Mortality and cardiovascular morbidity: n = 9
End-stage renal disease: n = 6
Successful monotherapy: n = 19
Studies finally included
n = 69
Reviews, studies with different
topic, comparisons against
placebo excluded
 n = 423
Studies excluded after
assessment of full text
 n = 125
*This case study only describes the evidence for three outcomes.
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Step 3: Assessing study quality 
Study design threshold for study 
selection
The reviewers, concerned that they might not find enough 
randomized trials, accepted a low threshold for study design by 
including observational studies with a comparison group. They 
considered randomized and non-randomized controlled trials, 
prospective and retrospective cohort and case-control studies. The 
decision ensured that they could fall back on observational data in 
case of insufficient data from randomized studies. This case study 
will only consider the results from the randomized trials included. 
Description of study quality assessment 
for the selected trials
The checklist for methodological quality of the studies addresses 
generic and specific quality items (Box C7.3). For key generic 
biases, it explored whether randomization (including allocation 
concealment) was appropriate, whether the studies blinded 
patients, healthcare providers and outcome assessors, and whether 
Bias either 
exaggerates or 
underestimates the 
‘true’ effect of an 
intervention.
The quality of a 
study depends on the 
degree to which its 
design, conduct and 
analysis minimizes 
biases.
The direction of 
effect indicates 
a beneficial or a 
harmful effect. 
The point estimate 
of effect tells us 
about direction and 
magnitude of effect. 
Box C7.3 Description of study quality on the comparative 
effectiveness of angiotensin-receptor blockers (ARBs) 
versus angiotensin-converting-enzyme inhibitors (ACE-Is) in 
essential hypertension.
 
91125
22 16 7
2013 12
378
2358
75% 100%50%25%
Compliance with quality items
0%
Unclearly reportedYes No
Generic quality items
Adequate randomization
Blinding of patients and physicians
Blinding of outcome assessors
Loss to follow-up < 10%
Intention-to-treat analysis
8314
9332
Specific quality items
Co-morbidities reported
Co-medications reported
Information on quality is presented as 100% stacked bars. Data in the stacks represent 
the numbers of the studies.
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the groups remained comparable throughout the observation 
period by assessing cross-over, losses to follow-up and potential 
differentials between the groups. It checked whether the analysis 
included all patients as randomized (intention-to-treat analysis). 
Specific quality items comprise equal distribution of co-morbidities 
such as diabetes or renal disease and co-interventions such as 
concomitant treatment with additional antihypertensive drugs or 
dose-escalating protocols among both treatment arms.
As shown in Box C7.3 most studies had at least some 
methodological weaknesses or lacked unambiguous reporting. This 
applied in particular to adequacy of randomization, completeness 
of follow-up and execution of an intention-to-treat analysis. Half 
the studies blinded patients, physicians and outcome assessors. 
The assessment of the specific quality items found insufficient 
reporting about co-morbid conditions of the patients and about 
concurrent medication. These limitations lower the methodological 
quality of the individual studies, introducing a risk of bias. 
Step 4: Summarizing the evidence
Heterogeneity of the results across studies, precision of the 
observed effects and the likelihood of publication bias play a role 
in gauging the strength of the evidence. 
Mortality and major cardiovascular 
morbidity 
Only nine of the 45 included randomized studies reported at least 
one of the outcomes (mortality, stroke, myocardial infarction or 
heart failure), and only five of those nine studies observed at least 
one event (Box C7.4). Most studies followed the patients up only 
short term (median 6 months; range 3.5–60 months). One study 
with the longest follow-up contributed 55 of the 61 events (90%) 
across all studies and all interventions. Despite the inclusion of 
more than 3000 patients there was imprecision because only very 
few events were captured. As an example, the four studies with 
1628 patients detected only 17 events of a myocardial infarction. 
The scarcity of events in outcomes led to wide confidence 
intervals. There was no particular heterogeneity of results. Overall, 
the findings were compatible with superiority or inferiority of 
either drug.
End-stage renal disease 
Six studies assessed renal function (i.e. the capacity of the kidney 
to remove metabolites from the body) using different measures 
such as serum creatinine, glomerular filtration rate or creatinine 
clearance (Box C7.4). To collate different measures into a single 
summary estimate of renal function requires conversion to 
standardized difference in means or SMD. On this measure, a 
minus value indicates that the ACE-Is were superior and a plus 
The precision 
of effect relates 
to the degree of 
uncertainty in the 
estimation of effect 
that is due to the 
play of chance. The 
confidence interval 
tells us about 
precision. 
Point estimate of 
effect is its observed 
value in a study. 
Confidence 
interval is the 
imprecision in the 
point estimate, i.e. 
the range around 
it within which 
the ‘true’ value of 
the effect can be 
expected to lie with 
a given degree of 
certainty (e.g. 95%).
Confidence interval
Point estimate
Relative risk (RR) 
is an effect measure 
for binary data. It 
is the ratio of risk 
in the experimental 
group to the risk in 
the control group.
Standardized 
difference in 
means or SMD is 
an effect measure 
for continuous 
data where studies 
have measured 
an outcome using 
different scales 
(e.g. pain may 
be measured in a 
variety of ways or 
depr ssion ass ssed 
on a variety of 
scales). In order 
to summarize 
such studies, it 
is necessary to 
standardize the 
results into a 
uniform scale.
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Box C7.4 Results for death, major cardiovascular and renal 
outcomes among randomized trials comparing angiotensin-
receptor blockers (ARBs) versus angiotensin-converting-
enzyme inhibitors (ACE-Is)
Outcome: Mortality and major cardiovascular morbidity
Outcome Number of studies, 
patients, events
Relative risk+
(ACE/ACE-I)
95% CI Heterogeneity
Chi2/I2-test
Mortality 8 studies, 4264 
patients, 15 events
1.05 0.40 to 2.75 p = 0.79/0%
Stroke 3 studies, 1779 
patients, 13 events
0.84 0.30 to 2.35 p = 0.56/0%
Myocardial 
infarction
4 studies, 1628 
patients, 17 events
1.32 0.54 to 3.57 p = 0.61/0%
Heart failure 1 study, 168 patients, 
16 events
1.20 0.68 to 1.78 Not relevant
Outcome: End-stage renal disease
Study Surrogate 
measurement of 
renal function* 
Patients 
(total)
Follow-up
(months) 
SMD$ 95% CI
1 GFR (ml/min)  96 36 0.27 –0.29 to 0.83
2 CCl (ml/min)  29     4.25 0.55 –0.19 to 1.29
3 CCl (ml/min)  33  6 –0.57 –1.34 to 0.21
4 S-creatinine (mg/dl)  57 12 0.38 –0.23 to 0.99
5 S-creatinine (mg/dl)  89  3 0.00 –0.43 to 0.43
6 GFR (ml/min) 250 60 −0.12 –0.38 to 0.15
Pooled 
estimate
Random 
effects 
model
0.05 –0.20 to 0.30
+ A relative risk > 1 indicated that the ACE-Is were superior, a relative risk < 1 indicated 
that the ARBs were superior.
$ SMD = Standardized difference in means
* Surrogate measurements: CCl = creatinine clearance; GFR = glomerular filtration 
rate; S-creatinine = serum creatinine 
Also see Box C7.1 for importance of outcomes.
value indicates that the ARBs were superior; zero indicated the line 
of no effect. There was no particular heterogeneity of results from 
study to study. Pooling the results of the individual studies using 
a random effects model shows a negligible effect, the SMD of 
0.05 favouring ARBs. The 95% confidence interval of -0.20–0.30 
confirmed that there was no difference in effect between the 
two drugs, and that the data would be compatible with both 
superiority and inferiority of either drug.
Relative risk (RR) 
is an effect measure 
for binary data. It 
is the ratio of risk 
in the experimental 
group to the risk in 
the control group.
Case study 7: Gauging strength of evidence to guide decision making  157
Successful monotherapy 
Nineteen trials evaluated the potency of either drug in controlling 
blood pressure to allow monotherapy for treating hypertension, 
and potentially improving compliance. The forest plot in Box C7.5 
displays the results of the individual studies. There was no particular 
heterogeneity of results from study to study. The summary estimate 
expressed as risk difference did not detect any difference between 
ARBs and ACE-Is, and the narrow 95% confidence interval of -0.02–
0.02 confirmed that a difference did not exist. 
Publication bias could only be reliably assessed for this outcome. 
A funnel plot explored the risk for missing studies. The search for 
primary studies had only covered two electronic databases. One 
of these, CENTRAL, contained citations of trials from a range of 
bibliographic databases, notably MEDLINE (around 60% of the 
records) and EMBASE, from other published and unpublished 
sources, as well as from hand-searching journals in non-English 
languages. Screening the reference lists of existing reviews 
contributed additional references, as did the public reviewing 
the draft review protocol and materials from pharmaceutical 
companies. Visual inspection of the large number of studies for 
the outcome successful monotherapy in a funnel plot did not raise 
suspicion about truncation, reducing concern about the risk of 
publication bias (Box C7.5). 
Risk difference 
(RD) is an effect 
measure for 
binary data. In a 
comparative study, 
it is the difference in 
event rates between 
two groups.
Box C7.5 Forest and funnel plots for successful 
monotherapy among trials comparing angiotensin-receptor 
blockers (ARBs) versus angiotensin-converting-enzyme 
inhibitors (ACE-Is) in essential hypertension
Forest plot
ARB ACE-I Risk Difference Risk Difference
Study or Subgroup Events Total Events Total Weight Random, 95%Cl Random, 95%Cl
Argenziano 1999 182 264 182 264  8.7% 0.00 [–0.08, 0.08]
–0.5
Cuspidi 2002  53 115  57 124  3.4% 0.00 [–0.13, 0.13]
Eguchi 2003  29  37  29  36  1.6% –0.02 [–0.21, 0.16]
Forgari 2004  45  75  39  75  2.2% 0.08 [–0.08, 0.24]
Ghiadoni 2003  23  29  21  28  1.1% 0.04 [–0.17, 0.26]
Karlberg 1999  89 139  88 139  4.2% 0.01 [–0.11, 0.12]
Kavgaci 2002  13  20   7  10  0.4% –0.05 [–0.40, 0.30]
Lacourciere 2000  20  52  30  51  1.5% –0.20 [–0.39, –0.01]
LaRochelle 1997  11 121   4  61  8.4% 0.03 [–0.06, 0.11]
Malacco 2004 479 604 479 609 25.8% 0.01 [–0.04, 0.05]
Mogensen 2000  54  66  46  64  2.6% 0.10 [–0.04, 0.24]
Neutel 1999 169 385  93 193  7.3% –0.04 [–0.13, 0.04]
Robles 2004  10  15  11  15  0.5% –0.07 [–0.39, 0.26]
Rosei 2005  39  66  40  63  1.9% –0.04 [–0.21, 0.12]
Ruff 1996   3  50   4  25  2.2% –0.10 [–0.26, 0.06]
Ruilope 2001 153 168 152 163 16.2% –0.02 [–0.08, 0.04]
Saito 2004  66 200  51 214  7.2% 0.09 [0.01, 0.10]
Townsend 1995  62 132  72 136  3.8% –0.06 [–0.18, 0.06]
Uchiyama–Tanaka 2005  14  18  19  25  0.8% –0.02 [–0.24, 0.27]
Total (95% Cl) 2556 2295 100% –0.00 [–0.02, 0.02]
Heterogeneity: Tau2 = 0.00; Chi2 = 16.76, df= 18 (P = 0.54); I2 = 0%
Test for overall effect: Z = 0.02 (P = 0.99)
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Funnel plot
0.250–0.25–0.5
0.2
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0
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SE(RD)
Review manager software was used to compute effects and produce graphics
Step 5: Interpreting the findings 
Before moving on to gauging the strength of the evidence, the 
key findings concerning importance of outcomes and precision of 
results are tabulated (Box C7.6). These are put together with study 
design, methodological limitations in study quality, inconsistency 
of results and risk of publication bias to assign a level of strength 
to the evidence (Box C7.7). 
The strength level first assigned to the evidence on the 
outcome mortality and major cardiovascular morbidity is high as 
it emanates from randomized design. This initial assignment is 
re-adjusted as the strength is limited by the risk of bias due to 
methodological limitations and imprecision related to the scarcity 
of events. Each shortcoming justifies reduction in the strength 
level initially assigned. Consistency in results reassures that effects 
do not vary between high and lower quality studies. This indicates 
that methodological limitations did not exert an impact on the 
effect sizes. It may be judged that the overall strength of the 
evidence is relegated finally to a low level, which means that our 
confidence in the observed effect of the two drugs on mortality 
and cardiovascular morbidity is limited and the ‘true’ effect may be 
substantially different.
The second critical outcome, end-stage renal disease due to 
hypertension, is measured using surrogates. Limitations through 
indirectness, risk of bias and imprecision of the effect are serious. 
Thus the initially assigned high level, due to randomized dosing, 
The Grading of 
Recommendations 
Assessment, 
Development and 
Evaluation (GRADE) 
working group 
is an informal 
collaboration that 
aims to develop 
a comprehensive 
methodology 
for assessing the 
strength of the 
evidence collated in 
systematic reviews 
and for generating 
recommendations 
from evidence 
in guidelines. 
See www.
gradeworkinggroup.
org. Interpretation 
of findings in this 
case study draws on 
this methodology.
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may be relegated to very low strength of evidence. This indicates 
that the ‘true’ effect on end-stage renal disease is likely to be 
substantially different from the observed effect renal function. 
The third outcome, successful monotherapy, is important to 
patients. These studies also have methodological limitations. The 
large numbers of events produce a narrow confidence interval 
around the point estimate of effect. There is no evidence of risk of 
publication bias. Thus, on balance, the high level of the strength 
initially assigned on account of randomized design is lowered to 
moderate strength of evidence. Hence, this evidence is likely to 
represent the ‘true’ effect.
Resolution of the scenario
The verdict, taking into account the overall strength of the 
evidence is transparent: Head-to-head comparison of the two 
drugs did not show a convincing difference in effect across a 
range of critical and important outcomes. While one cannot be 
absolutely certain that differences in effect do not exist for some 
outcome measures, the appraised evidence does not provide 
strong clues for the existence of a difference. Stronger evidence 
on critical and important outcomes would be desirable, though in 
practice the appraised evidence is reassuring. One could consider 
prescribing one or another agent on account of benefits being 
similar. A key element impinging on this decision is consideration 
of the risk of potential adverse effects. Case study 8 will explore 
this issue.
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Box C7.6 Summary of findings of a review comparing angiotensin-receptor blockers (ARBs) versus 
angiotensin-converting-enzyme inhibitors (ACE-Is) in essential hypertension
Importance Outcome Measurement Number of patients Summary effect 
Effect [95% CI]
Relative risk (ARB/ACE-I)ARB ACE-I
C
r
i
t
i
c
a
l
Mortality and major 
cardiovascular morbidity 
9 trials
Total events: 61
Mortality 1659 1663 1.05 [0.40 to 2.75] 
Stroke 0.84 [0.30 to 2.35]
Myocardial infarction 1.32 [0.54 to 3.57]
Heart failure 1.20 [0.68 to 1.78]
End stage renal disease 
6 trials
Renal function 
(surrogate)
 253  246 Effect size (SMD*) 
0.051 [–0.19 to 0.29]
I
m
p
o
r
t
a
n
t
Successful monotherapy
19 trials 
Total events: 2938
Successful monotherapy 2556 2295
Risk difference (ARB – ACE-I)
−0.00 [−0.03 to 0.02]
* SMD = standardized mean difference
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Box C7.7 Assessing strength of the evidence collated in a review comparing angiotensin-receptor 
blockers (ARBs) versus angiotensin-converting-enzyme inhibitors (ACE-Is) in essential hypertension
Outcome and its 
Importance
Study design 
Directness 
of outcome 
measure
Study quality
(risk of bias)
Inconsistency 
of results
(heterogeneity)
Imprecision of 
effects
Publication 
bias 
Strength 
of 
evidence
 Mortality 
and major 
cardiovascular 
morbidity 
Randomized trial Direct
Some 
limitations 
Consistent Imprecise Not assessed Low
(Critical)
Initially assigned a 
high strength level Æ No change Æ Relegation Æ No change Æ Relegation Æ No change ∟ 
End-stage renal 
disease  
Randomized trial  Indirect 
Some 
limitations
Consistent Imprecise Not assessed Very low 
(Critical)
Initially assigned a 
high strength level Æ Relegation Æ Relegation Æ No change Æ Relegation Æ No change ∟
 Successful 
monotherapy 
Randomized trial Direct
Some 
limitations 
Consistent Precise Not detected Moderate
(Important)
Initially assigned a 
high strength level Æ No change Æ Relegation ÆNo change Æ No change Æ No change ∟
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●● Case study 8: To use 
or not to use a therapy? 
Incorporating evidence on 
adverse effects 
Katja Suter
For making informed decisions, healthcare professionals and 
patients need to balance the benefits against the adverse effects of 
interventions. Systematic reviews of effectiveness should include 
information on adverse effects and other harms, but the primary 
studies they include often do not capture data on these outcomes, 
or only do this secondarily. To allow collation of information on rare 
harmful outcomes, particularly those that develop over a long time 
period, systematic reviews need to include a range of study designs 
(see Case study 2). Another issue reviews need to consider is how 
comprehensive they need to be in the coverage of the potential 
adverse effects. Package leaflets of drugs or information for the 
user that accompanies medicinal products often report 50 or more 
adverse effects of varying frequency and severity. Reviews covering 
evidence on all possible adverse effects are not always necessary or 
feasible. To narrow the focus on a few severe adverse effects that 
particularly impact on the clinical decision would be reasonable. This 
will allow weighing up of benefits against potential harms. 
This case study demonstrates how to seek and assess evidence 
on adverse effects of a drug. It will evaluate potential harms 
associated with a drug assessed for its effectiveness in Case study 
7. Based on a published review, it will apply the review theory 
related to framing questions, identifying literature, assessing study 
quality, summarizing the results on adverse effects, and gauging 
the strength of the evidence on two treatment options, showing 
how to come up with a decision.
Scenario: Considering adverse 
effects when choosing an 
antihypertensive treatment 
You are a general practitioner who currently has an overweight 
50-year-old patient with recently diagnosed hypertension 
(150/100 mmHg). The blood pressure did not improve under the 
initial management strategy of encouraging him to lose weight. 
Both the patient and you decide to start an antihypertensive 
medication. Among the many drugs recommended as first-line 
treatment in guidelines, you favour a renin-system blocking 
Step 1 
Framing questions
Ø
Step 2 
Identifying relevant 
literature
Ø
Step 3 
Assessing quality of 
the literature
Ø
Step 4 
Summarizing the 
evidence
Ø
Step 5 
Interpreting the 
findings
Adverse effect 
is an undesirable 
and unintended 
harmful or 
unpleasant reaction 
resulting from an 
intervention.
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drug, either angiotensin-converting-enzyme inhibitors (ACE-Is) or 
angiotensin-receptor blockers (ARBs). Which one to choose? 
Recently, you critically appraised a systematic review (Case 
study 7) comparing ARBs with ACE-Is head-to-head, which 
showed similar effects for ARBs and ACE-Is in reducing blood 
pressure. The review did not show differences between the ARBs 
and ACE-Is for outcomes such as death, major cardiovascular 
morbidity and end-stage renal disease. You want to explore 
adverse effects, and you consult the following review: 
●● Systematic review: comparative effectiveness of angiotensin-
converting-enzyme inhibitors and angiotensin-II-receptor 
blockers for treating essential hypertension. Ann Intern Med 
2008; 148: 16–29.
A comprehensive report of this review is published by the 
American Agency for Healthcare Research and Quality (AHRQ) at 
http://effectivehealthcare.ahrq.gov/repFiles/ACEI_ARBFullReport.
pdf (accessed July 2009). The review of adverse effects in this 
report collates results from randomized trials and observational 
studies. The assessment of adverse effects captured in randomized 
trials follows the same principles demonstrated in Case study 7. 
Frequently, however, observational studies are the only source of 
information for adverse effects, and this case study demonstrates 
how to appraise this information. Mind you, if available, one 
would always consider the evidence on common side-effects from 
experimental studies, because of the lower risk of bias associated 
with this design (Box 1.4). 
Step 1: Framing the question
Free form question
Is there a difference in adverse effects between ARBs and ACE-Is?
Structured question
The populations Adults with essential hypertension.
The interventions All drugs from the class of ARBs (e.g. 
losartan, irbesartan, valsartan or telmisartan) 
compared to drugs from the class of ACE-Is 
(e.g. captopril, enalapril, ramipril or fosinopril) 
and minimal study duration of 12 weeks. 
The outcomes Key adverse effects including cough, 
headache, dizziness and ‘withdrawal due to 
adverse events’ (this case study focuses on 
cough and withdrawals only).
The study designs Experimental and observational studies with 
a control group (this case study focuses on 
evidence collated from cohort and case-
control studies).
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Not all adverse effects have the same impact on decision 
making. More common and more serious ones that affect the 
patient’s wellbeing weigh heavier than physiological changes 
without particular consequences or rare adverse effects. Box 
C8.1 ranks harmful outcomes from ARBs and ACE-Is according 
to their importance, alongside the beneficial outcomes from Case 
study 7. One might notice that in Box C8.1 common adverse 
effects such as increase in serum creatinine, increase in liver 
enzymes or reduction in haemoglobin are missing. Such changes 
in physiological variables are surrogate measurements and supply 
only indirect evidence for drug-related renal failure, hepatitis or 
symptomatic anaemia respectively. Surrogates lower the strength 
of the evidence. 
How should one select a few key adverse effects from the 
many potential harms? More common ones tend to play a 
more significant role in patient care than rare or very rare ones, 
even if the latter are more serious. (Very) rare effects are less 
likely to prevent us from recommending a drug. For example, 
Stevens–Johnson syndrome, a potentially life-threatening drug 
reaction, occurs in less than 1 in 10 000 cases. Considering patient 
preferences, clinicians would usually not take this low level of 
risk into account when deciding to prescribe or not to prescribe a 
drug. For illustrative purposes, this case study is restricted to two 
adverse outcomes: cough and ‘withdrawals due to adverse effects’. 
Step 2: Identifying relevant literature
Capturing studies on adverse effects is a challenge. This is because 
the terminology for adverse effect lacks standardization and 
adverse effects are usually not listed in the title or abstract. 
Furthermore, databases like MEDLINE (PubMed) do not have a 
separate MeSH term for adverse effects, which may exist as a 
subheading to certain MeSH terms. This improves precision but 
lowers the sensitivity of a search (Step 2, Sections 2.1.2 and 2.1.3). 
The reviewers searched MEDLINE and CENTRAL (Cochrane 
Central Register of Controlled Trials) for randomized trials and 
observational studies in the English language and accessed a 
register of the Cochrane Hypertension Review Group. Box C8.2 
shows the search term combinations used for the MEDLINE 
database. The researchers refrained from defining adverse effects 
as outcomes in their search strategy, acknowledging their poor 
coding in electronic databases. The assessment for adverse effects 
took place during full-text screening. 
The search provided 1185 citations, the screening of titles/
abstracts narrowed the results down to 194 citations for full-
text assessments, the final study pool for the systematic review 
included 69 reports. Of those, 26 RCTs and three observational 
studies reported on cough, and 22 RTCs and two observational 
studies on ‘withdrawals due to adverse effects’ (Box C8.3). 
Withdrawal of 
participants or 
patients can be for 
many reasons, e.g. 
non-compliance with 
the intervention, 
cross-over to 
an alternative 
intervention, drop 
out of the study and 
loss to follow-up. 
When the reason 
for withdrawal is the 
appearance of an 
adverse effect, this 
information can be 
used as an outcome 
measure for drug 
safety.
Precision of a 
search is the 
proportion of 
relevant studies 
identified by a 
search strategy. 
This is expressed as 
a percentage of all 
studies (relevant and 
irrelevant) identified 
by that strategy. 
It is a measure 
of the ability of a 
search to exclude 
irrelevant studies. 
Do not confuse with 
precision of effect.
Sensitivity of 
a search is the 
proportion of 
relevant studies 
identified by a search 
strategy expressed 
as a percentage of 
all relevant studies 
on a given topic. It 
is a measure of the 
comprehensiveness 
of a search method. 
Do not confuse with 
sensitivity of a test.
Study design filter 
employs a search 
term combination to 
capture citations of 
studies of a particular 
design.
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Box C8.1 Comparison of beneficial outcomes and adverse 
effects of antihypertensive treatment with angiotensin-
receptor blockers (ARBs) versus angiotensin-converting-
enzyme inhibitors (ACE-Is)
Importance* Beneficial outcomes
(descending order of importance)
Adverse effects
C
ri
ti
ca
l
  
Reduce mortality 
• All-cause mortality
• Cardiovascular mortality
• Cerebrovascular mortality
Reduce major morbidity 
• Disabling stroke 
• Myocardial infarction
• Moderate to severe heart failure 
• Advanced or end-stage renal 
disease 
• Leg ulceration and amputation due 
to peripheral vascular disease 
Frequent and non-reversible 
effects
Im
p
o
rt
an
t
Reduce mild morbidity 
• Mild angina pectoris 
• Mild intermittent claudication
• Mild renal impairment
• Transient ischaemic attack
Improve quality of life (QoL)
• General QoL
• Specific dimensions of health 
related QoL (e.g. cognitive 
function, symptomatic well-being)
• Disease-specific QoL
Successful monotherapy 
Low incidence and fully reversible 
effects 
Morbidity 
• Cough (frequent)
• Headache (frequent)
• Dizziness (frequent)
• Angio-oedema (rare)
• Acute renal failure (rare)
Le
ss
 im
p
o
rt
an
t
Reduce cost 
• Reduction in drug cost to the 
healthcare system (policy makers 
might call this an important or 
critical outcome)
Very low incidence and fully 
reversible effects 
• Dose-dependent change in 
taste (occasional)
• Mild moods swings (occasional)
• Hepatitis (very rare)
• Symptomatic anaemia (very 
rare)
• Steven-Johnson syndrome (very 
rare)
* The beneficial outcomes are taken from Case study 7; also see Box C7.1
Adverse effects can occur very frequently (> 1 in 10); frequently (between 1 in 10 and 
1 in 100); occasionally (between 1 in 100 and in /1000); rarely (between 1 in 1000 and 
1 in 10 000); very rarely (<1 in 10 000, including singular reports). This scale is only a 
suggestion.
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Box C8.2 Search term combination for Ovid MEDLINE to 
identify citations of literature on the adverse effects of 
angiotensin-receptor blockers (ARBs) versus angiotensin-
converting-enzyme inhibitors (ACE-Is)
The original search term combination consisted of 56 sets of terms, where of the 
following table shows a selection to give an example how to combine search terms.
Question components and a 
selection of relevant terms
Type of 
terms
Boolean operator
(see glossary)
Free MeSH
The population: Patients with hypertension
1. exp hypertension/ x
OR (captures population)2. additional terms (see in original 
report of the review)
 
3. or/1–2
The interventions:  ARBs and ACE-Is
4. (losartan OR valsartan).tw x
OR (captures intervention)
5. angiotensin II type 1 receptor 
blockers/
x
6. (quinapril OR captopril OR 
enalapril).tw
x
7. angiotensin-converting-enzyme 
inhibitors/
x
8. additional terms (see in original 
report of the review)
9. or/4–8
The Outcomes 
No search is performed to capture 
outcomes
10. and/3,9 AND (combines population 
and intervention)
The study designs: Observational studies
11. Comparative Study/ x
OR (captures study designs)
12. exp Evaluation Studies/ x 
13. Follow-up Studies/ x
14. (control$ OR prospective$ OR 
volunteers$).tw. 
x
15. additional terms (see in original 
report of the review)
16. or/11–15
17. and/10, 16 AND (combines population 
and intervention and study 
designs)
18. limit 16 to human
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Box C8.3 Identification of relevant literature on adverse 
effects of angiotensin-receptor blockers (ARBs) versus 
angiotensin-converting-enzyme inhibitors (ACE-Is)
Electronic databases searched
1. MEDLINE
2. Cochrane Central Register of Controlled Trials
3. Register of the Cochrane Hypertension Review Group
Study identification flow chart
Potentially relevant citations identified through
electronic searching of databases, bibliographies
submitted by pharmaceutical companies, reference
lists, and expert contacts
n = 1185
Retrieval of hard copies of potentially relevant citations
n = 194
Studies on cough and/or withdrawal due to
adverse effects
n = 36
Cough: n = 9 (26 RCT, 3 observational studies)
Withdrawals due to adverse effects: n = 24
(22 RCT, 2 observational studies)
Studies included in systematic review
n = 69
Citations excluded
 n = 991
Studies excluded after
assessment of full text
 n = 125
* This case study only describes the observational studies in detail.
Commands and symbols for Ovid MEDLINE
$ Truncation 
exp  Explodes the MeSH and searches for term and all its conceptually narrower 
terms
.tw  Textword search
/  Medical subject heading (MeSH) search will search for MeSH in indexing terms
The original search is part of the full report of the review available at http://
effectivehealthcare.ahrq.gov/repFiles/ACE-I_ARBFullReport.pdf.
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Step 3: Assessing study quality 
Study design threshold for study 
selection
Different study designs need to be considered for information 
about adverse effects. Randomized trials are well suited for 
common, anticipated adverse effects, whereas observational 
studies may be more useful for delayed or rare adverse effects. 
In the latter situation, it will be reasonable to consider more 
than one observational design, taking into account the strengths 
and weaknesses of each (Box 1.4). The review underlying this 
case study included randomized trials and observational (cohort 
and case-control) studies. This case study demonstrates how to 
appraise observational evidence. 
Quality assessment of observational 
studies on safety 
Quality assessment of observational studies is concerned with 
methodological issues similar to those relevant for randomized 
studies (Step 3, Box 3.2). Establishing comparable groups 
to prevent selection bias, ensuring appropriate use of the 
interventions, minimizing bias in the measurement of outcomes, 
and an appropriate statistical analysis are key to study quality. The 
key quality items used in this case study are described below:
Prospective design: A prospective design with forward planning, 
comprehensive assessment of the patients and collection of all 
relevant data may facilitate efforts outlined above to minimize 
bias (Box C2.2). One might have access to a database which has 
already meticulously documented the enrolment of patients, 
carefully measured a wide variety of prognostic factors, follow-up 
all patients and rigorously recorded their outcomes. In this situation 
a retrospective design will not be a particular disadvantage. A 
prospective study, badly done, may fail to document how patients 
were selected, measure prognostic factors in an incomplete and 
sloppy way, and lose a large proportion of their patients to follow-
up. Therefore, prospective or retrospective should not be treated as 
quality criteria in themselves. In addition, one should look to see 
whether studies adhered to the criteria listed above. 
Assembling comparable groups at the outset: Groups that 
are unequal in important prognostic factors pose a major threat 
to the validity of observational studies. This is because those 
differences – rather than the differences in the interventions 
– may be linked to the outcomes. (Large) experimental studies 
balance out potential confounding factors by randomly allocating 
patients with varying risks factors equally between groups. 
Assembling groups that are similar at baseline is more challenging 
in observational studies, and most of the time they rely on the 
analysis to perform statistical adjustment for group differences. 
Bias either 
exaggerates or 
underestimates the 
‘true’ effect of an 
intervention.
The quality of a 
study depends on the 
degree to which its 
design, conduct and 
analysis minimizes 
biases.
Confounding 
is a situation in 
comparative studies 
where the effect 
of an exposure 
or intervention 
on an outcome is 
distorted due to 
the association 
of the outcome 
with another 
factor, which can 
prevent or cause 
the outcome 
independent of 
the exposure 
or intervention. 
Data analysis 
may be adjusted 
for confounding 
in observational 
studies.
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To do so, the researchers have to identify at baseline all relevant 
prognostic factors and co-morbidities that can bring about 
‘adverse effects’ regardless of the exposure; avoiding ACE-Is in 
patients with chronic bronchitis as cough may be an adverse 
effect of ACE-I. This selective prescribing behaviour could bias the 
assessment of frequency of cough.
Ascertaining exposure: In observational studies it is essential 
to correctly identify those exposed and those not exposed to an 
intervention. Consider a study that included new and current users 
of antihypertensive drugs. More ‘new users’ of antihypertensive 
drugs were in the ACE-I group, while more ‘previous users’ of 
antihypertensive drugs entered the ARB group. A considerable 
proportion of those ‘previous users’ had experienced cough using 
ACE-Is and had switched to ARBs before entering the study. This 
could reduce the frequency of cough associated with ACE-Is. 
Thus it is important to minimize misclassification in exposure, by 
collecting information on all co-medications and any cross-over of 
medications.
Outcome ascertainment: Outcome assessment in observational 
studies is vulnerable to the same biases as in experimental studies. 
Measurement bias has to be dealt with using similar precautions. 
Subjective outcomes such as a bothersome cough or the 
experience of adverse effects that warranted withdrawal demand 
the person ascertaining the outcome be kept blind to the exposure 
status. Only few observational studies manage to implement 
appropriate measures to achieve blinding. Adverse effects with less 
frequent or delayed occurrence need a (sufficiently) long follow-up 
for detection. 
Appropriate analysis: Once key relevant prognostic factors 
have been identified, appropriate adjustment in the analysis for 
differences of those factors between the groups increases the 
chance that any observed association between exposure and 
outcome reflects the ‘truth’. It is often difficult to identify and 
adjust for all confounding factors. Loss to follow-up and missing 
values interfere with performing an appropriate analysis.
Description of quality of the selected 
observational studies
A separate description of quality assessment of the two outcomes 
cough and ‘withdrawal’ is provided (Box C8.4). This is because 
quality can vary between outcomes even if they are measured in 
the same studies. While cough is a subjective outcome susceptible 
to bias in the absence of blinding, the outcome withdrawal is 
objective and absence of blinding is unlikely to influence the count 
of people who withdraw. Lack of blinded outcome assessment 
would be a limitation of the study quality for cough but it would 
not be for counting the number of ‘withdrawals’. 
Prognosis is a 
probable course 
or outcome of a 
disease. Prognostic 
factors are 
patient or disease 
characteristics that 
influence the course. 
Good prognosis 
is associated 
with a low rate 
of undesirable 
outcomes. Poor 
prognosis is 
associated with 
a high rate of 
undesirable 
outcomes.
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Box C8.4 Description of quality of comparative 
observational studies on adverse effects of angiotensin-
receptor blockers (ARBs) versus angiotensin-converting-
enzyme inhibitors (ACE-Is) in essential hypertension
12
3
3
3
3
11 1
12
75% 100%50%25%
Compliance with quality items
0%
Unclearly reportedYes No
Cough
Prospective design
Assembling comparable groups
Important confounders
Ascertaining exposure
Attrition and cross-overs
Ascertaining outcome
Appropriate analysis
2
2
2
11
11
11
11
Withdrawals for adverse effects
Prospective design
Assembling comparable groups
Important confounders
Ascertaining exposure
Attrition and cross-overs
Ascertaining outcome
Appropriate analysis
*  This case study only describes the observational studies. Data in stacks represents the 
number of studies
Studies reporting on cough
The three cohort studies reporting on cough had considerable 
methodological weaknesses: Due to the observational design, 
all studies were open label; patients, healthcare providers and 
outcome assessors were aware of the treatment allocations 
except in one study where the telephone interviewer who did the 
outcome assessment was blinded. All studies lacked conclusive 
information about co-morbidities and co-medication. Most studies 
did not report on loss to follow-up.
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Studies reporting on ‘withdrawals due 
to adverse effects’
Two observational studies (one cohort study and one case-control 
study) reporting on ‘withdrawals due to adverse effects’, too, had 
profound weaknesses. While some quality issues, e.g. blinding, 
were difficult or impossible to address, others would have been 
amenable to methodological safeguards, such as the case-control 
study could have described its selection of cases and controls. 
Both studies lacked information about patient characteristics, 
co-morbidities, co-medication and adjustment for differences in 
prognostic factors. Furthermore, they reported that significant 
amounts of data were missing and there was considerable loss to 
follow-up.
Step 4: Summarizing the evidence
Cough 
Three cohort studies reported on cough: one large post-marketing 
cohort study with more than 50 000 patients and two smaller 
studies with 449 patients and 49 patients, respectively. Among a 
total of 51 908 patients there were 691 cough events. The pooled 
summary estimate for ARBs to reduce cough compared to ACE-Is 
was an odds ratio or OR of 0.40 with 95% CI of 0.34-0.48. There 
was no heterogeneity in the effects across the studies (I2 = 0%; 
ChI2 = 0.80; p = 0.67). 
‘Withdrawal due to adverse effects’ 
One cohort and one case-control study reported on ‘withdrawals 
due to adverse effects’. Both studies were small with 39 and 88 
patients, respectively. The two studies with this outcome found 
18 withdrawals in 127 patients. After pooling, the point estimate 
described a large effect and an OR of 0.36, but the 95% CI ranged 
from 0.12 to 1.08. Such a large spread in the confidence interval 
indicated imprecision arising from a small number of participants 
and a low number of events. 
Careful readers might have noticed in Box C8.5 that results 
from the cohort and the case-control study designs are combined. 
Study designs have different weaknesses and potentials for 
bias and should not normally be mixed up in meta-analysis. 
There is agreement that the results from randomized trials and 
observational studies should not be pooled. How best to synthesize 
non-randomized studies of different designs (e.g. case-control 
and cohort studies) is an issue of ongoing debate. It is clear that 
pooling does not compensate for methodological weaknesses. 
One point of view is that if these weaknesses lead to differences 
in effects, which will be captured by an increase in heterogeneity. 
This should encourage the exploration of reasons for heterogeneity 
(Boxes 4.6 and 4.7). 
Odds ratio (OR) is 
an effect measure 
for binary data. It 
is the ratio of odds 
in the experimental 
group to the odds in 
the control group.
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What are the circumstances in which the results from 
observational studies are sufficiently compelling to warrant trust 
in their findings. Strong or very strong associations between 
exposure and outcome will be prerequisite. Some authorities 
recommend using an OR value smaller than 0.5 or larger than 2 to 
define a strong association or large effect. Although observational 
studies are susceptible to bias and confounding that lead often 
to overestimation of the effects, it is unlikely that imbalance 
of prognostic factors between comparison groups will be solely 
responsible for large or very large effects. Thus, intervention or 
exposure is likely to be contributing to the observed effect. 
Step 5: Interpreting the findings
How can we bring together what we have learnt in the previous 
Steps to come up with a decision? Step 1 has ranked the 
outcomes of interest according to their importance for patients 
and introduced the distinction between patient-important and 
surrogate outcomes (the latter are regarded as indirect evidence 
for patient-important outcomes). In Step 2 studies have been 
selected taking study design into consideration. Step 3 has 
reviewed the methodological quality of the selected studies. Step 
4 has explored heterogeneity of results and produced summary 
effects. 
The gauging of strength of the evidence is shown separately 
for each outcome (Box C8.6). For the outcome cough the point 
estimate of OR showed an association. The 95% confidence 
interval around this estimate was very precise. In the absence of 
features that impair the strength of the overall evidence, such a 
large effect could increase our confidence that ARBs ‘truly’ lower 
the risk of cough compared to ACE-Is. Concerning ‘withdrawals 
due to adverse effects’, both studies reported fewer withdrawals 
for patients treated with ARBs compared to ACE-Is, but the 
estimation of association was imprecise. None of the five studies 
explored the effect of drug doses on the rate of adverse effect.
When assigning a level of strength to the evidence the starting 
point is the study design. The lack of randomized treatment 
allocation makes observational studies start at a low strength 
level. Methodological limitations of included studies relegate the 
strength to very low level. In this situation even large effects 
cannot justifiably raise the strength level. 
The data available in the review on cough and ‘withdrawals’ 
from randomized trials was substantial. From 26 trials, the pooled 
relative risk, RR, for cough was 0.23 with 95% CI 0.16–0.33, 
indicating a strong effect resulting in less cough for patients 
treated with ARBs. From 21 trials, the pooled RR for ‘withdrawals 
due to adverse effects’ was 0.58 (95% CI 0.46–0.74), again 
indicating a strong effect with fewer withdrawals for patients 
treated with ARBs. Considering this information, the strength 
The Grading of 
Recommendations 
Assessment, 
Development and 
Evaluation (GRADE) 
working group 
is an informal 
collaboration that 
aims to develop 
a comprehensive 
methodology 
for assessing the 
strength of the 
evidence collated in 
systematic reviews 
and for generating 
recommendations 
from evidence 
in guidelines. 
See www.
gradeworkinggroup.
org. Interpretation 
of findings in this 
case study draws on 
this methodology.
The strength of 
the evidence lies 
in the relevance of 
the outcomes, the 
methodological 
quality of the 
included studies, 
the heterogeneity of 
results, the precision 
and size of effects, 
etc, features that 
underpin the trust 
in the inferences 
generated from a 
review.
Relative Risk (RR) 
is an effect measure 
for binary data. It 
is the ratio of risk 
in the experimental 
group to the risk in 
the control group.
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Box C8.5 Forest plot for outcomes cough and ‘withdrawal due to adverse effects’ comparing 
angiotensin-receptor blockers (ARBs) versus angiotensin-converting-enzyme inhibitors (ACE-Is)
Outcome: Cough
 
Study or Subgroup  
Gregoire 2001 
Mackay 1999 
Sato 2003 
Total (95% CI) 
Total events 
Heterogeneity: Chi² = 0.80, df = 2 (P = 0.67); I² = 0% 
Test for overall effect: Z = 10.49 (P < 0.00001) 
Events  
4 
64 
0 
68 
Total 
80 
14522 
26 
14628 
Events  
55 
566 
2 
623 
Total 
369 
36888 
23 
37280 
Weight 
5.6% 
94.0% 
0.4% 
100.0% 
Fixed, 95% CI 
0.42 [0.21, 0.86] 
0.41 [0.34, 0.48] 
0.11 [0.01, 1.88] 
0.40 [0.34, 0.48] 
ARB  ACE -I Peto Odds Ratio  Peto Odds Ratio  
Fixed, 95% CI 
0.01 0.1 1 10 100 
less cough ARB  less cough ACE -I 
Outcome: ‘Withdrawal due to adverse effects’
 
Study or Subgroup  
Avanza 2000, cohort study 
Verdeggia 2000, case -control 
Total (95% CI) 
Total events 
Heterogeneity: Chi² = 1.01, df = 1 (P = 0.31); I² = 1% 
Test for overall effect: Z = 1.83 (P = 0.07) 
Events  
0 
2 
2 
Total 
17 
22 
39 
Events  
4 
12 
16 
Total 
22 
66 
88 
Weight 
28.9% 
71.1% 
100.0% 
Fixed, 95% CI 
0.15 [0.02, 1.14] 
0.51 [0.14, 1.90] 
0.36 [0.12, 1.08] 
ARB  ACE -I Peto Odds Ratio  Peto Odds Ratio  
Fixed, 95% CI 
0.01 0.1 1 10 100 
less withdrawals ARB less withdrawals ACE-I 
Review manager software used to compute effects and produce graphics.
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Box C8.6 Assessment of the strength of overall evidence 
for the outcomes cough and ‘withdrawal due to adverse 
effects’ in observational studies comparing angiotensin-
receptor blockers (ARBs) versus angiotensin-converting-
enzyme inhibitors (ACE-Is)
Summary of findings
Importance 
of outcome 
Outcome 
Number of 
patients 
Odds ratio (ARB/ACE-I) 
[95% CI] 
ARB ACE-I
Im
p
o
rt
an
t
Cough 
3 cohort studies
Total events: 691 
14 628 37 280 0.40 [0.34–0.48]
Im
p
o
rt
an
t
Withdrawals 
2 observational studies
Total events: 18
39 88 0.36 [0.12–1.08]
Gauging the strength of evidence
Strength is initially assessed as low due to the observational study design. 
Methodological limitations relegate the level of strength of evidence to very low.
Outcome Study design
Study 
quality (risk 
of bias)*
Size of 
effect+
Dose–
response 
gradient
Strength 
of 
evidence$
Cough
2 prospective 
cohorts, 
1 cross-sectional 
cohort
Serious 
limitations
Large 
and 
precise
Not 
available
Very low
Initially assigned 
a low strength 
level
Æ Relegation Æ No 
change
Æ No 
change ∟
Withdrawals 
due to 
adverse 
effects
1 prospective 
cohort
1 case-control
Serious 
limitations
Imprecise
Not 
available
Very low
Initially assigned 
a low strength 
level
Æ Relegation Æ No 
change
Æ No 
change ∟
* See Box C8.4
+ The methodological weaknesses of the studies were so serious that raising the 
strength level of evidence on grounds of large effect was not justifiable
$ Raised to moderate if not high level after consideration of randomized evidence. See 
Box C8.7
OR = odds ratio
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level assigned based on observational studies can be raised to at 
least moderate if not high level. This increases the confidence that 
the rate of cough and of ‘withdrawals’ is ‘truly’ higher in patients 
treated with ACE-Is compared to ARBs. 
Resolution of scenario
The overall summary of findings (Box C8.7) provides the basis 
for simultaneous considerations of both benefits and adverse 
effects of ARBs and ACE-Is in hypertension. This overview helps 
clinicians, policy makers and patients to balance their pros and 
cons in decision making. This review, including evidence from both 
observational and randomized studies, found moderately strong 
evidence that ACE-Is cause higher frequency of cough than do 
ARBs in patients with hypertension. In addition, more patients 
on ACE-Is withdrew from the clinical trials due to adverse effects 
than ARBs. From Case study 7 both drugs were shown to have  
similar effectiveness in controlling blood pressure. Armed with 
this information and the knowledge that ARBs are more expensive 
than ACE-Is, how would one decide? If the patient’s healthcare 
insurance includes a co-payment, they would have to pay the 
cost of using ARBs out of their own pocket. Since cough is fully 
reversible after stopping the ACE-Is, the patient, in order to reduce 
cost, may decide to take the risk of adverse effects on ACE-Is 
first. Using the same evidence, another patient with different 
circumstances may make a different, but informed, decision.
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Box C8.7 Summary of findings from a review on the comparative effectiveness of angiotensin-receptor 
blockers (ARBs) versus angiotensin-converting-enzyme inhibitors (ACE-Is)
Outcomes, study designs and results Assessment of strength of evidence
Importance Outcome Directness
No. of 
patients 
(studies)
Effect* 
(95% CI)
Study 
quality (risk 
of bias)
Inconsistency 
I2
Imprecision
Publication 
Bias
Strength 
of 
evidence
Beneficial outcomes
C
r
i
t
i
c
a
l
Mortality Direct
4264
(8 RCTs)
RR: 1.05
(0.40 to 2.75)
Some 
limitations
Consistent 
I2 = 0%
Imprecise 
Not 
assessed
Moderate 
Stroke Direct
1779
(3 RCTs)
RR: 0.84
(0.30–2.35)
Some 
limitations
Consistent 
I2 = 0%
Imprecise
Not 
assessed
Moderate 
Myocardial  
infarction
Direct
1628
(4 RCTs)
RR: 1.32
(0.54–3.57)
Some 
limitations
Consistent 
I2 = 0
Imprecise
Not 
assessed
Moderate 
Heart failure Direct
168
(1 RCT)
RR: 1.20
(0.68–1.78)
Some 
limitations
Not relevant Imprecise
Not 
assessed
Moderate 
Renal 
function
Indirect
Surrogates
499
(6 RCTs)
Effect Size
0.051
(–0.19–0.29)
Some 
limitations
Consistent Imprecise
Not 
assessed
Low 
I
m
p
o
r
t
a
n
t
Successful 
monotherapy
Direct
4851
(19 RCTs)
RD (ARB-
ACE-I)
0.00
(–0.02–0.02)
Some 
limitations
Consistent 
I2 = 0%
Precise
Not 
detected
High 
Adverse effects
Cough Direct
51 908
(3 cohorts)
OR: 0.4
(0.34–0.48)
Serious 
limitations
Not assessed Not assessed
Not 
assessed
Very low 
Withdrawals Direct
127
(2 cohorts/
case-control)
0.36 
(0.12–1.08)
Serious 
limitations
Not assessed Not assessed
Not 
assessed
Very low 
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●● Glossary
This glossary uses information from the publications listed in the 
Suggested Reading.
Absolute risk reduction (ARR) see Risk difference (RD).
Accuracy measure A statistic for summarizing the accuracy 
with which a test predicts a diagnosis. There are three 
commonly used sets of accuracy measures for binary tests: 
sensitivity and specificity; positive and negative predictive 
values; and likelihood ratios. All these measures are paired. 
Single measures of accuracy are seldom used with the exception 
of the diagnostic odds ratio.
Adverse effect It is an undesirable and unintended harmful 
or unpleasant reaction resulting from an intervention. It often 
predicts hazard from its future administration and warrants 
prevention or specific treatment or alteration or withdrawal of 
the intervention.
Attrition bias (exclusion bias) Systematic differences between 
study groups caused by exclusion or dropout of subjects 
(e.g. because of side-effects of intervention) from the study. 
Intention-to-treat analysis in combination with appropriate 
sensitivity analyses including all subjects can protect against 
this bias. Also see Intention-to-treat (ITT) analysis and 
Withdrawals.
Baseline risk The frequency of outcome in a population without 
intervention. It is related to the severity of underlying disease 
and prognostic features. Good prognosis is associated with 
low baseline risk while poor prognosis is associated with high 
baseline risk of undesirable outcomes. Baseline risk is important 
for determining who will benefit most from interventions. Also 
see Number needed to treat (NNT).
Bias (systematic error) A tendency for results to depart 
systematically, either lower or higher, from the ‘true’ results. 
Bias either exaggerates or underestimates the ‘true’ effect 
of an intervention or exposure. It may arise due to several 
reasons, e.g. errors in design and conduct of a study. This may 
lead to systematic differences in comparison groups (selection 
bias), differences in care or exposure to factors other than 
the intervention of interest (performance bias), differences in 
assessment of outcomes (measurement bias), withdrawals or 
exclusions of people entered into the study (attrition bias), etc. 
Studies with unbiased results are said to be internally valid.
Binary data Measurement where the data have one of two 
alternatives, e.g. the patient is either alive or dead, the test 
result is either positive or negative, etc.
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Bivariate model A statistical method for generating summary 
estimates of test accuracy. It adjusts for the correlation that 
might exist between test sensitivity and specificity.
Blinding (masking) Blinding keeps the study participants, 
caregivers, researchers and outcome assessors ignorant about 
the interventions to which the subjects have been allocated in 
a study. In single-blind studies only the subjects are ignorant 
about interventions, whilst in double-blind studies both the 
participants and caregivers or researchers are blind. Outcome 
assessors can often be blinded even when participants and 
caregivers can’t be. Blinding protects against performance bias 
and detection bias, and it may contribute to adequate allocation 
concealment during randomization. Also see Randomization.
Boolean logic Boolean logic (named after George Boole) 
refers to the logical relationship among search terms. Boolean 
operators AND, OR and NOT are used during literature searches 
to include or exclude certain citations from electronic databases. 
They are also used in Internet search engines.
Case-control study A comparative observational study where 
participants/patients with the outcome (cases) and those 
without the outcome (controls) are compared for their prior 
intervention or exposure rates.
Clinical trial A loosely defined term generally meaning to 
describe a study to evaluate efficacy and effectiveness of 
interventions. This term encompasses study designs ranging 
from randomized controlled trials to uncontrolled observations 
of a few cases.  
Cochrane Collaboration An international not-for-profit 
organization that aims to help with informed decision making 
about healthcare by preparing, maintaining and improving 
accessibility of systematic reviews of interventions (http://www.
cochrane.org). The major product of the Collaboration is the 
Cochrane Database of Systematic Reviews which is part of the 
Cochrane Library (http://www.update-software.com/cochrane/). 
Those who prepare Cochrane Reviews are mostly healthcare 
professionals who volunteer to work in one of more than 
40 Collaborative Review Groups (CRGs). Each CRG has a co-
ordinator, and an editorial team to oversee the quality of their 
reviews. The activities of the Collaboration are directed by an 
elected Steering Group and are supported by staff in Cochrane 
Centres worldwide.
Cohort study A comparative observational study where 
participants with an intervention or exposure (not allocated by 
the researcher) are followed up to examine the difference in 
outcomes compared to a control group, e.g. those receiving no 
care.
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Comparative study A study where the effect of an intervention 
or exposure is assessed using comparison groups. This can be 
a randomized controlled trial, a cohort study, a case-control 
study, etc. 
Confidence interval (CI) The range within which the ‘true’ 
value of a measurement (e.g. effect of an intervention) 
is expected to lie in a population with a given degree of 
certainty. Confidence intervals represent the distribution 
probability of random errors, but not of systematic errors (bias). 
Conventionally, 95% confidence intervals are used.
Confounding A situation in studies where the effect of an 
intervention on an outcome is distorted due to the association 
of the outcome with another factor, the confounding variable, 
which can prevent or cause the outcome independent of 
the intervention. It occurs when groups being compared are 
different with respect to important factors other than the 
interventions or exposures under investigation. Adjustment for 
confounding requires stratified or multivariable analysis. Also 
see Randomization.
Continuous data Measurement on a continuous scale such as 
height, weight, blood pressure, etc. For continuous data, effect 
is often expressed in terms of mean difference. Also see Effect 
size (ES). 
Control event rate (CER) The proportion of subjects in the 
control group in whom an event or outcome is observed, in a 
defined time period.
Controlled clinical trial A loosely defined term to describe a 
prospective comparative study for assessing effectiveness of 
interventions (regardless of whether randomization is used or 
not). Watch out for indiscriminate use of this ambiguous term in 
reviews. It is also a MeSH in the MEDLINE database.
Cost-effectiveness analysis see Economic evaluation and 
Efficiency. 
Diagnostic odds ratio The ratio of the likelihood ratio for 
a positive test result to the likelihood ratio for a negative 
test result. It provides a single measure of accuracy. Also see 
Accuracy measure.
Diary keeping A qualitative research method, usually an 
addition to questionnaire or interview data, where participants 
record experience and emotions contemporaneously. It can be 
free form, where people write what they want to, or structured 
where they have specific questions to answer or topics to write 
about.
Dose-response A dose-response relationship demonstrates 
that at higher doses the strength of association between 
exposure and outcome is increased.
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Economic evaluation (e.g. cost-effectiveness analysis) A 
study that takes into account both the clinical effectiveness and 
the costs of alternative interventions to address the question 
of how to achieve an optimal clinical outcome at least cost. The 
term cost-effectiveness analysis is often used synonymously but 
this is a misnomer. A full economic evaluation considers both 
clinical and cost outcomes whereas a partial evaluation may 
only consider costs without regard to clinical outcomes. 
Effect (effect measure, treatment effect, estimate of effect, 
effect size) Effect is the observed association between 
interventions and outcomes or a statistic to summarize the 
strength of the observed association. The statistic could be a 
relative risk, odds ratio, risk difference, or number needed to 
treat for binary data; a mean difference, or standardized mean 
difference for continuous data; or a hazard ratio for survival 
data. The effect has a point estimate and a confidence interval. 
The term individual effect is often used to describe effects 
observed in individual studies included in a review. The term 
summary effect is used to describe the effect generated by 
pooling individual effects in a meta-analysis.
Effect modification It occurs when a factor influences the 
effect of the intervention under study, e.g. age may modify 
responsiveness to treatment.
Effect size (ES) This term is sometimes used for an effect 
measure for continuous data. Also see Effect measure.
Effectiveness The extent to which an intervention (therapy, 
prevention, diagnosis, screening, education, social care, etc) 
produces a beneficial outcome in the routine setting. Unlike 
efficacy, it seeks to address the question: Does an intervention 
work under ordinary day-to-day circumstances?
Efficacy The extent to which an intervention can produce a 
beneficial outcome under ideal circumstances. 
Efficiency The extent to which the balance between input 
(costs) and outputs (outcomes) of interventions represents 
value for money. It addresses the question of whether clinical 
outcomes are maximized for the given input costs. Also see 
Economic evaluation.
Evidence-based medicine (EBM) The conscientious, explicit 
and judicious use of current best evidence in making decisions 
about the care of individual patients. It involves the process of 
systematically finding, appraising and using contemporaneous 
research findings as the basis for clinical decisions. Evidence-
based practice (EBP) is a related term. Both EBM and EBP follow 
four steps: formulate a clear clinical question from a patient’s 
problem; search the literature for relevant clinical articles; 
evaluate (critically appraise) the evidence for its validity and 
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usefulness; implement useful findings in clinical practice, taking 
account of patients’ preferences and caregivers’ experience. 
Another related term is evidence-based healthcare, which is an 
extension of the principles of EBM to all professions associated 
with healthcare, including purchasing and management. 
Systematic reviews provide powerful evidence to support all 
forms of EBM.
Experimental event rate (EER) The proportion of participants 
in the experimental group in whom an event or outcome is 
observed, in a specified time period.
Experimental study A comparative study in which decisions 
concerning the allocation of participants or patients to different 
interventions are under the control of the researcher, e.g. 
randomized controlled trial.
Exposure A factor (including interventions) which is thought 
to be associated with the development or prevention of an 
outcome.
External validity (generalizability, applicability) The extent to 
which the effects observed in a study can be expected to apply 
in routine clinical practice, i.e. to people who did not participate 
in the study. Also see Validity.
Fixed effect model A statistical model for combining results 
of individual studies, which assumes that the effect is truly 
constant in all the populations studied. Thus, only within-study 
variation is taken to influence the uncertainty of the summary 
effect and it produces narrower confidence intervals than the 
random effects model. Also see Random effects model.
Focus group A qualitative research method. The collection of 
qualitative data using a group interview on a topic. Usually 6-12 
participants are involved, and they can be used to gauge issues 
of importance. Also see Interview.
Forest plot A graphical display of individual effects observed in 
studies included in a systematic review along with the summary 
effect, if meta-analysis is used.
Funnel plot A scatter plot of effects observed in individual 
studies included in a systematic review against some measure 
of study information, e.g. study size, inverse of variance, etc. 
It is used in exploration for the risk of publication and related 
biases.
Generalization The extent to which findings of a qualitative 
research study are consistent with findings of similar studies, 
adding to the understanding of a phenomenon. Within 
qualitative research the aim is not to extrapolate to wider 
populations, so this term should not be confused with the terms 
External validity and Generalizability. 
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Generalizability See External validity. Also see Generalization.
GRADE The Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) working group is an 
informal collaboration that aims to develop a comprehensive 
methodology for assessing the strength of the evidence collated 
in systematic reviews and for generating recommendations from 
evidence in guidelines. See www.gradeworkinggroup.org.
Guidelines Statements that aim to assist practitioners and 
patients in making decisions about specific clinical situations. 
They often, but not always, use evidence from systematic 
reviews.
Hazard ratio An effect measure for survival data, which 
compares the survival experience of two groups.
Health technology assessment (HTA) Health technology 
includes any method used by those working in health services 
to promote health, to screen, diagnose, prevent and treat 
disease, and to improve rehabilitation and long-term care. HTA 
considers the effectiveness, appropriateness, costs and broader 
impact of interventions using both primary research and 
systematic reviews.
Heterogeneity/homogeneity The degree to which the effects 
among individual studies being systematically reviewed are 
similar (homogeneity) or different (heterogeneity). This may be 
observed graphically by examining the variation in individual 
effects (both point estimates and confidence intervals) in a 
Forest plot. Quantitatively, statistical tests of heterogeneity/
homogeneity may be used to determine if the observed 
variation in effects is greater than that expected due to the 
play of chance alone. For making a clinical judgement about 
heterogeneity, one might look at the differences between 
populations, interventions and outcomes of studies. 
Homogeneity see Heterogeneity.
I2 statistic It is a statistic for assessment of heterogeneity 
during study synthesis. Ranging from 0% to 100%, it gives 
the percentage of total variation across studies due to 
heterogeneity.
Intention-to-treat (ITT) analysis An analysis where subjects 
are analysed according to their initial group allocation, 
independent of whether they dropped out or not, fully complied 
with the intervention or not, or crossed over and received 
alternative interventions. A true ITT analysis includes an 
outcome (whether observed or estimated) for all patients. Also 
see Attrition bias and Sensitivity analysis. 
Internal validity see Validity.
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Intervention A therapeutic or preventative regimen, e.g. a drug, 
an operative procedure, a dietary supplement, an educational 
leaflet, a test (followed by a treatment), etc undertaken with 
the aim of improving health outcomes. In a randomized trial, 
the effect of an intervention is the comparison of outcomes 
between two groups, one with the intervention and the other 
without (e.g. a placebo or another control intervention).
Interview A qualitative research method. It involves questioning 
people about their views or experience of a phenomenon or 
event. Can range from structured, where each participant is asked 
the same questions,  to unstructured, which consists of a list of 
broad areas to be covered, the exact format of each interview 
being determined as it progresses. Also see Focus group.
Inverse of variance see Variance.
Kirkpatrick hierarchy A classification of medical educational 
outcomes to capture the impact of educational interventions. 
It has various levels: 1a: Participation or completion captures 
attendance at and views on the learning experience, e.g. 
course evaluation; 1b: Modification of attitudes captures 
change in attitudes or perceptions, e.g. subjective reaction or 
satisfaction of participants with course, difference between 
pre- and post-course attitude questionnaire; 2: Modification 
of knowledge or skills captures change knowledge or skills, 
e.g. difference in scores from pre- to post-course; 3: Health 
professional’s behaviour captures the transfer of learning to the 
workplace or integration of new knowledge and skills leading 
to modification of behaviour or performance, e.g. difference in 
performance after the teaching evidenced by more evidence-
based prescribing and more frequent attendance at journal club; 
and 4: Change in delivery of care and health outcomes captures 
changes in the delivery of care attributable to the educational 
programme with or without assessments of improvement in the 
health outcomes and wellbeing of patients as a direct result of 
teaching, e.g. audit of practice showing greater compliance with 
evidence-based criteria.
Likelihood ratio (LR) It is the ratio of the probability of a 
positive (or negative) test result in subjects with disease to the 
probability of the same test result in subjects without disease. 
The LR indicates by how much a given test result raises or 
lowers the probability of having the disease. With a positive 
test result, a LR+ > 1 increases the probability that disease 
will be present. The greater the LR+, the larger the increase 
in probability of the disease and the more clinically useful the 
test result. With a negative test result, a LR- < 1 decreases the 
probability that the disease is present: the smaller the LR-, the 
larger the decrease in the probability of disease and the more 
clinically useful the test result.
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Mean difference The difference between the means (i.e. 
the average values) of two groups of measurements on a 
continuous scale. Also see Effect and Standardized mean 
difference (SMD).
Measurement bias (detection bias, ascertainment 
bias) Systematic differences between groups in how 
outcomes are assessed in a study. Blinding of study subjects and 
outcome assessors protects against this bias.
MeSH Medical Subject Heading. Controlled term used in 
the MEDLINE database to index citations. Other electronic 
bibliographic databases frequently use MeSH-like terms.
Meta-analysis A statistical technique for combining (pooling) 
the results of a number of studies addressing the same question 
to produce a summary result. 
Meta-regression A multivariable model with effect estimates 
of individual studies (usually weighted according to their size) 
as dependent variable and various study characteristics as 
independent variables. It searches for the influence of study 
characteristics on the size of effects observed in a systematic 
review. Also see Multivariable analysis.
Metasynthesis The amalgamation of the results of a group 
of qualitative studies on the same or a related issue. Included 
studies can be evaluated and the findings combined. This is 
achieved from reviewing the published data and not from meta-
analysing data.
Multivariable analysis (multivariable model) An analysis 
that relates some independent or explanatory or predictor 
variables (X1, X2, .....) to an dependent or outcome variable 
(Y) through a mathematical model such as Y = b0 + b1X1 
+ b2X2 + ..... , where Y is the outcome variable Y; b0 is the 
intercept term; and b1, b2, ..... are the regression coefficients 
indicating the impact of the independent variables X1, X2, ..... 
on the dependent variable Y. The coefficient is interpreted as 
the change in the outcome variable associated with a one-unit 
change in the independent variable and provides a measure of 
association or effect. Multivariable analysis is used to adjust for 
confounding, e.g. by including confounding factors along with 
the intervention (or exposure) as the independent variables in 
the model. This way the effect of intervention (or exposure) on 
outcome can be estimated while adjusting for the confounding 
effect of other factors. Also see Confounding.
Negative predictive value The proportion of subjects who test 
negative who truly do not have the disease.
Normal distribution A frequency distribution that is 
symmetrical around the mean and bell shaped (also called 
Gaussian distribution).
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Null hypothesis The hypothesis put forward when carrying out 
significance tests that states that there is no difference between 
groups in a study. For example, statistically we discover that 
an intervention is effective by rejecting the null hypothesis 
that outcomes do not differ between the experimental and the 
control group. Also see p-value.
Number needed to harm (NNH) It is the number of patients 
who need to be treated for one additional patient to experience 
an episode of harm (adverse effect, complication, etc). It is 
computed in the same manner as NNT.
Number needed to treat (NNT) An effect measure for binary 
data. It is the number of patients who need to be treated to 
prevent one undesirable outcome. In an individual study it is 
the inverse of risk difference (RD). In a systematic review it is 
computed using baseline risk and a measure of relative effect 
(relative risk, odds ratio). It is a clinically intuitive measure of 
the impact of a treatment. 
Observational study Research studies in which interventions, 
exposures and outcomes are merely observed with or without 
control groups. These could be cohort studies, case-control 
studies, cross-sectional studies, etc.
Odds The ratio of the number of participants with an outcome 
to the number without the outcome in a group. Thus, if out of 
100 subjects, 30 had the outcome (and 70 did not), the odds 
would be 30/70 or 0.42. Also see Risk.
Odds ratio (OR) An effect measure for binary data. It is the 
ratio of odds of an event or outcome in the experimental 
group to the odds of an outcome in the control group. An 
OR of 1 indicates no difference between comparison groups. 
For undesirable outcomes an OR that is < 1 indicates that the 
intervention is effective in reducing the odds of that outcome. 
Also see Relative risk.
Outcome The changes in health status that arise from 
interventions or exposure. The results of such changes are used 
to estimate the effect.
p-value (statistical significance) The probability, given a null 
hypothesis, that the observed effects or more extreme effects 
in a study could have occurred due to play of chance (random 
error). In an effectiveness study, it is the probability of finding 
an effect by chance as unusual as, or more unusual than, 
the one calculated, given that the null hypothesis is correct. 
Conventionally, a p-value of < 5% (i.e. p < 0.05) has been 
regarded as statistically significant. This threshold, however, 
should never be allowed to become a straight jacket. When 
statistical tests have low power, e.g. tests for heterogeneity, 
a less stringent threshold (e.g. p < 0.1 or < 0.2) may be used. 
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Conversely, when there is a risk of spurious significance, e.g. 
multiple testing in subgroup analysis, a more stringent threshold 
(e.g. p < 0.01) may be used. When interpreting the significance 
of effects, p-values should always be used in conjunction with 
confidence intervals (CI). Also see Confidence interval (CI).
Performance bias Systematic differences in the care provided 
to the study subjects other than the interventions being 
evaluated. Blinding of carers and subjects and standardization of 
the care plan can protect against this bias.
Phenomenon An occurrence or a fact. Phenomenon is often 
used as a generic term for the object of a qualitative research 
study.
Point estimate of effect The observed value of the effect of 
an intervention among the subjects in a study sample. Also see 
Confidence interval (CI).
Positive predictive value The proportion of subjects who test 
positive who truly have the disease.
Post-test probability of disease An estimate of the probability 
of disease in light of the information obtained from testing. 
With accurate tests, the post-test estimates of probabilities 
change substantially from pre-test estimates. In this way a 
positive test result may help to rule in disease and a negative 
test result may help to rule out disease. 
Power The ability to demonstrate an association when one 
exists. The ability to reject the null hypothesis when it is indeed 
false. Power is related to sample size. The larger the sample size, 
the more the power, and the lower is the risk that a possible 
association could be missed.
Precision (specificity) of a search The proportion of relevant 
studies identified by a search strategy expressed as a percentage 
of all studies (relevant and irrelevant) identified by that method. 
It describes the ability of a search to exclude irrelevant studies. 
Also see Sensitivity of a search.
Precision of effect see Random error.
Pre-test probability of disease An estimate of probability of 
disease before tests are carried out. It is usually estimated as 
the prevalence of disease in a given setting (e.g. community, 
primary care, secondary care, hospital, etc.) Sometimes, when 
such information is not available, it may have to be estimated.
Publication bias Arises when the likelihood of publication of a 
study is related to the significance of its results. For example, 
a study is less likely to be published if it finds an intervention 
ineffective. Reviewers should make all efforts to identify such 
negative studies; otherwise their inferences about the value of 
Glossary 191
intervention will be biased. Funnel plots may be used to explore 
for the risk of publication and related biases.
Qualitative research Research concerned with the subjective 
world that offers insight into social, emotional and experiential 
phenomena in health and social care. Including findings from 
qualitative research may enhance the quality and salience of 
reviews.
Quality of a qualitative research study The quality of a 
qualitative research study depends on the degree to which its 
design, conduct and analysis is trustworthy. Trustworthiness 
consists of several concepts including credibility, dependability, 
transferability, confirmability. 
Quality of a study (methodological quality) The degree to 
which a study minimizes biases. Features related to the design, 
the conduct and the statistical analysis of the study can be used 
to measure quality. This determines the validity of results.
Quasi-experimental (quasi-randomized) study A term 
sometimes used to describe a study where allocation of subjects 
to different groups is controlled by the researcher, like in an 
experimental study, but the method falls short of genuine 
randomization (and allocation concealment), e.g. by using date 
of birth or even-odd days. 
Random effects model A statistical model for combining the 
results of studies that allows for variation in the effect among 
the populations studied. Thus, both within-study variation and 
between-study variation are included in the assessment of the 
uncertainty of results. Also see Fixed effect model.
Random error (imprecision or sampling error) Error due 
to the play of chance that leads to wide confidence intervals 
around point estimates of effect. The width of the confidence 
interval reflects the magnitude of random error or imprecision. 
Also see p-value.
Randomization (with allocation concealment) Randomization 
is the allocation of study subjects to two or more alternative 
groups using a chance procedure, such as computer-generated 
random numbers, to generate a sequence for allocation. It 
ensures that subjects have a prespecified (very often an equal) 
chance of being allocated one of two or more interventions. 
In this way the groups are likely to be balanced for known 
as well as unknown and unmeasured confounding variables. 
Concealment of the allocation sequence until the time of 
allocation to groups is essential for protection against selection 
bias. Foreknowledge of group allocation leaves the decision to 
recruit the subject open to manipulation by researchers and 
study subjects themselves. Allocation concealment is almost 
192 Systematic Reviews to Support Evidence-based Medicine
always possible even when blinding is not. Randomization alone 
without concealment does not protect against selection bias. 
Randomized controlled trial (RCT) A comparative study with 
random allocation (with allocation concealment) of subjects 
to interventions, and follow-up to examine differences in 
outcomes between the various groups.
Relative risk (RR) (risk ratio, rate ratio) An effect measure for 
binary data. It is the ratio of risk in the experimental group to 
the risk in the control group. An RR of 1 indicates no difference 
between comparison groups. For undesirable outcomes an 
RR that is < 1 indicates that the intervention is effective in 
reducing the risk of that outcome. Also see Odds ratio.
Review An article that summarizes the evidence contained in a 
number of different individual studies and draws conclusions 
about their findings. It may or may not be systematic. Also see 
Systematic review and Meta-analysis.
RevMan The Cochrane Collaboration’s software for review 
management and meta-analysis, available at http://www.
cochrane.org/cochrane/revman.htm. 
Risk (proportion or rate) The proportion of subjects in a group 
who are observed to have an outcome. Thus, if out of 100 
subjects, 30 had the outcome, the risk (rate of outcome) would 
be 30/100 or 0.30. Also see Odds.
Risk difference (RD) (absolute risk reduction, rate 
difference) An effect measure for binary data. In a 
comparative study, it is the difference in event rates between 
two groups. The inverse of RD produces number needed to treat 
(NNT). Also see Number needed to treat.
Sample Subjects selected for a study from a much larger group 
or population.
Selection bias (allocation bias) Systematic differences in 
prognosis and/or therapeutic sensitivity at baseline between 
study groups. Randomization (with concealed allocation) of a 
large number of patients protects against this bias.  
Sensitivity (recall) of a search The proportion of relevant 
studies identified by a search strategy expressed as a 
percentage of all relevant studies on a given topic. It describes 
the comprehensiveness of a search method, i.e. its ability to 
identify all relevant studies on a given topic. Highly sensitive 
strategies tend to have low levels of specificity (precision) and 
vice versa. Also see Precision of a search.
Sensitivity (true positive rate) of a test The proportion of 
those people who really have the disease who are correctly 
identified as such.
Glossary 193
Sensitivity analysis Repetition of an analysis under different 
assumptions to examine the impact of these assumptions on 
the results. In systematic reviews, when there is poor reporting 
in individual studies, authors of primary studies should be 
asked to provide missing and unclear information. However, 
this is not always possible and reviewers often have to make 
assumptions about methods and data, and they may impute 
missing information. In this situation, sensitivity analysis should 
be carried out by involving a re-analysis of the review’s findings, 
taking into account the uncertainty in the methods and the 
data. This helps to determine if the inferences of a systematic 
review change due to these uncertainties. In a primary study 
there may be withdrawals, so sensitivity analysis may involve 
repeating the analysis imputing the best or worst outcome 
for the missing observations or carrying forward the last 
outcome assessment. Also see Intention-to-treat analysis and 
Withdrawals.
Specificity (true negative rate) of a test The proportion of 
those subjects who really do not have disease who are correctly 
identified as such.
Standardized mean difference (SMD) Standardized difference 
in means is an effect measure for continuous data where 
studies have measured an outcome using different scales (e.g. 
pain may be measured in a variety of ways or assessment of 
depression on a variety of scales). In order to summarize such 
studies, it is necessary to standardize the results into a uniform 
scale. The mean difference is divided by an estimate of the 
within-group variance to produce a standardized value without 
any units. Also see Effect (erroneously called standardized 
mean difference).
Strength of evidence The strength of evidence describes the 
extent to which we can be confident that the estimate of 
an observed effect, i.e. the measure of association between 
interventions and outcomes obtained in the review, is correct 
for important questions. 
Subgroup analysis Meta-analyses may be carried out in pre-
specified subgroups of studies stratified according to differences 
in populations, interventions, outcomes and study designs. This 
allows reviewers to determine if the effects of an intervention 
vary between subgroups. 
Summary receiver operating characteristics curve (SROC) A 
method of summarizing the performance of a dichotomous test, 
pooling 2 x 2 tables from multiple studies or multiple cut-off 
points. It takes into account the relation between sensitivity 
and specificity among the individual studies by plotting the 
true positive rate (sensitivity) against the false positive rate 
(1-specificity).
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Surrogate outcomes A substitute for direct measures of how 
patients feel, what their function is, or if they survive. They 
include physiological variables (e.g. blood pressure for stroke 
or HbA1c for diabetic complications) or measures of subclinical 
disease (e.g. degree of atherosclerosis on coronary angiography 
for future heart attack). To be valid, the surrogate must be 
statistically correlated with the clinically relevant outcome but 
also capture the net effect of the intervention on outcomes. 
Many surrogates lack good evidence of validity.
Systematic error see Bias.
Systematic review (systematic overview) Research that 
summarizes the evidence on a clearly formulated question using 
systematic and explicit methods to identify, select and appraise 
relevant primary studies, and to extract, collate and report their 
findings. By following this process it becomes a proper piece of 
research. It may or may not use statistical meta-analysis.
Theme An idea that is developed by the categorization of 
qualitative research data under its heading. The large quantities 
of data produced by qualitative study are managed by the 
generation of themes and the coding of parts of the data to 
each theme. The perspectives of each research participant on 
each theme can then be compared and analysed.
Theory Abstract knowledge or reasoning as a way of explaining 
social relations. Theory may influence research (deduction), or 
research may lead to the development of theory (induction).
Trial see Clinical trial.
Triangulation Triangulation is the application and combination 
of several research methodologies in the study of the same 
phenomenon.
Validity (internal validity) The degree to which the results of 
a study are likely to approximate the ‘truth’ for the subjects 
recruited in a study, i.e. are the results free of bias? It refers to 
the integrity of the design and is a prerequisite for applicability 
(external validity) of a study’s findings. Also see External validity.
Variance A statistical measure of variation measured in terms 
of the deviations of individual observations from the mean 
value. The inverse of variance of the observed individual effects 
is often used to weight studies in statistical analyses used in 
systematic reviews, e.g. meta-analysis, meta-regression and 
funnel plot analysis.
Withdrawals Participants or patients who do not fully comply 
with the intervention, cross over and receive an alternative 
intervention, choose to drop out, or are lost to follow-up. If an 
adverse effect is the reason for withdrawal, this information 
can be used as an outcome measure. Also see Attrition bias, 
Intention-to-treat analysis and Sensitivity analysis.
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